



EDWIN L. STEELE LABORATORIES

DEPARTMENT OF RADIATION ONCOLOGY
MASSACHUSETTS GENERAL HOSPITAL
HARVARD MEDICAL SCHOOL



RESEARCH REPORT 2019



TABLE OF CONTENTS

	PAGE
PREFACE	4
MISSION, STRATEGIES AND ACCOMPLISHMENTS	7
RESEARCH GRANTS AND AWARDS	9
RESEARCH GOALS	13
RESEARCH HIGHLIGHTS	15
FACULTY RESEARCH SUMMARIES	23
PUBLICATIONS	32
RESEARCH TEAM	67
ALUMNI TABLE	69
RESOURCES AND ENVIRONMENT	71

PREFACE

A solid tumor is an organ composed of cancer cells and host stromal cells—nourished by blood vessels and drained by lymphatic vessels—all embedded in an extracellular matrix. The interaction among these cells, the surrounding matrix, and the local cellular microenvironment influences the expression of various genes, whose protein products control the pathophysiological characteristics of the tumor, govern tumor progression and affect the tumor's response to various therapies. The overarching goal of our research is to dissect the role of tumor microenvironment in tumor progression and treatment resistance, and to translate this knowledge into improved cancer detection, prevention and treatment in humans. A tight integration between bench and bedside and application of engineering principles to oncology is a hallmark of our research.

To unravel the complex biology of tumors, the Steele Laboratories have developed an array of optical technologies, mathematical models and sophisticated animal preparations. These include multiphoton microscopy and genetically engineered mice with surgically implanted transparent windows, which together permit the real-time visualization of gene expression and function in tumors and their surrounding host stroma. This undertaking has provided unprecedented molecular, cellular, anatomical and functional insights into the vascular, interstitial and cellular barriers to cancer treatment. Specifically, we demonstrated that the blood and lymphatic vasculature, fibroblasts, immune cells and the extracellular matrix associated with tumors are abnormal, which collaborate together to create a hostile tumor microenvironment characterized by hypoxia, low pH and high interstitial fluid pressure.

We next hypothesized that agents that induce “normalization” of the microenvironment should improve the treatment outcome. Our work in this area has come to fruition and led to two novel strategies: vascular normalization and matrix normalization. The Steele Laboratories are now recognized worldwide for the discovery that direct and indirect antiangiogenic therapies can “normalize” tumor vessels, thus improving blood perfusion, oxygenation and treatment efficacy in cancer patients. This revolutionary concept explained how

bevacizumab (Avastin®)—the first antiangiogenic drug to receive FDA approval—works in patients and has spawned a number of basic and clinical studies. The vascular normalization hypothesis also explained how bevacizumab and other anti-VEGF drugs improve vision in patients with wet age-related macular degeneration and opened doors to treating other non-malignant diseases harboring abnormal vasculature that afflict more than 500 million people worldwide. These include neurofibromatosis-2 (NF2), tuberculosis and cardiovascular atherosclerotic plaque rupture. In 2014, our clinical findings showing the reversal of hearing loss in NF2 patients by normalizing their blood vessels led to the approval of bevacizumab for these patients in UK.

In parallel, by imaging collagen and measuring perfusion in tumors in vivo, we discovered that the extracellular matrix compresses blood vessels and impedes drug delivery in desmoplastic tumors (e.g., pancreatic cancer, hepatocellular carcinoma, certain breast cancers). We subsequently discovered that widely prescribed angiotensin blockers to control hypertension are capable of “normalizing” the extracellular matrix, opening compressed tumor vessels and improving the delivery and efficacy of therapy. This finding offers new hope for improving treatment of highly fibrotic tumors, and led to a phase II clinical trial in 2013 at MGH on testing the benefit of adding losartan to the standard of care (chemotherapy and radiation followed by surgery) in patients with locally advanced pancreatic ductal adenocarcinoma (NCT01821729). This trial provided compelling evidence in support of this emerging concept and has spawned a multi-institutional randomized clinical trial (NCT03563248) in pancreatic ductal adenocarcinoma. If successful, this will represent a major paradigm shift in the treatment of this uniformly fatal disease and open doors for improving treatment of other malignant and non-malignant diseases.

The Edwin L. Steele Laboratories for Tumor Biology were founded in 1975 by a generous gift by Mrs. Jane Bancroft Cook in memory of her late husband Edwin L. Steele. In addition, she endowed the Andrew Werk Cook Professorship of Radiation Oncology at Harvard University/MGH in honor of her second husband, Andrew Werk Cook. These donations to cancer research at MGH

have been critical in the growth of tumor biology research at MGH, which over the years has led to improved understanding and treatment of cancer. The continued support of Ms. Elizabeth Steele (daughter of Mrs. Cook) and Jane's Trust Foundation has allowed to translated our discoveries from bench to bedside. In September 1991, Dr. Rakesh Jain was recruited to be the director of the Steele Laboratories, starting with a small team of six people. We have since grown to approximately 65 members. The Steele Labs have fostered the careers of the 9 current faculty members, who collectively have trained over 220 graduate students and post-doctoral fellows from more than 25 countries. We have developed a leading, multidisciplinary research and education program in the integrative biology of cancer.

In addition to the research within our laboratory, we have a number of collaborative projects with clinicians and scientists at the MGH and other medical research centers worldwide. Results from the Steele Laboratories, as well as those from these collaborations, have been reported in more than 750 publications, and have been presented at national and international meetings. In recognition of our past research accomplishments and future research plans, members of the research group have received more than 100 awards, including membership in all three branches of the US National Academies – Medicine, Engineering and Sciences, US National Academy of Inventors, US Medal of Science and more than 100 grants from various private and government agencies including



the Advanced Medical Research Foundation, the Alex's Lemonade Stand Foundation, the American Association for Cancer Research, Brain Tumor Society, American Cancer Society, Burroughs Wellcome Fund, Cancer Research Institute, the Charles A. King Trust, Children's Tumor Foundation, Cholangiocarcinoma Foundation, Damon Runyon Foundation, Ellison Foundation, Fat Disorders Research Society, Fund for Medical Discovery, the Bill and Melinda Gates Foundation, German Cancer Foundation, Goldhirsch Foundation, Humboldt Foundation, Jane's Trust Foundation, Lymphatic Education and Research Network, Ludwig Center at Harvard, Lustgarten Foundation, the National Institutes of Health, the National Foundation for Cancer Research, the National Science Foundation, Neuroendocrine Tumor Research Foundation, Susan Komen Foundation, United Negro College Fund, U.S. Army Breast Cancer Program, Yvonne Silverman Bequest and the Whitaker Foundation.

The Steele Laboratories are also dedicated to education, offering a bi-annual course in tumor pathophysiology to Harvard-MIT students. Annually, we also offer a continuing medical education course at Harvard Medical School on tumor microenvironment (immunology, angiogenesis and metastasis) for national and international students, with the 35th offering scheduled for September 21 – 24, 2020.

Rakesh K. Jain

Rakesh K. Jain, Ph.D.
Andrew Werk Cook Professor of Radiation Oncology (Tumor
Biology)
Director, E.L. Steele Laboratories





MISSION

Research

Understand how the tumor microenvironment fuels tumor progression and metastasis, and confers resistance to chemo-, radio- and immunotherapy

Develop and test new strategies in animal models to overcome the barriers posed by the tumor microenvironment for improved detection and treatment of primary and metastatic tumors.

Translation

Translate these strategies from bench to bedside.

Education

Educate basic scientists, bioengineers, and oncologists in the integrative biology of cancer.


STRATEGIES

Research

- Unravel causal relationships between genetic and physiological function in various micro-environments using in vitro and in vivo microscopy and image analysis.
- Analyze experimentally and mathematically the physical and physiological barriers and pharmacokinetics, and integrate the resulting information.
- Overcome barriers by creative manipulation of the tumor microenvironment.
- Emphasize multidisciplinary approaches, integration of engineering with tumor biology, and bench-to-bedside translation.

Education

- Develop and implement integrative tumor biology and bioengineering courses.
- Provide close mentorship by the faculty on individual research projects.



ACCOMPLISHMENTS

- Recruited and sustained a “critical” number of outstanding faculty, post-doctoral fellows, graduate students and technical staff to support core research.
- Initiated and continued collaborations with members of Massachusetts General Hospital, Harvard, MIT and other institutions.
- Established state-of-the-art intravital microscopy facilities.
- Developed unique in vivo tumor models.
- Published over 750 original and review articles in peer-reviewed journals and books in seven core research areas: Angiogenesis and blood flow, Tumor microenvironment, Transvascular transport, Interstitial and lymphatic transport, Cell mechanics and transport, Mathematical modeling, and Bench-to-bedside translation.
- Obtained research support from the National Cancer Institute and other government and private sources.
- Received more than 100 awards from various scientific societies and academic institutions.
- Developed innovative courses in the integrative biology of cancer.
- Translated laboratory findings to cancer patients: e.g., the first treatment of schwannomas by bevacizumab and completion of more than three two dozen multidisciplinary clinical trials of anti-angiogenic therapy on cancer patients with brain, colorectal, liver, ovarian and connective tissue.
- Proposed the vascular normalization hypothesis that has changed the thinking in the field of oncology about how targeted therapies work.
- Proposed the matrix normalization hypothesis and showed the benefit of normalizing the tumor microenvironment using angiotensin system inhibitors in pancreatic cancer in mice and in a phase II trial.

RESEARCH GRANTS AND AWARDS

1976-1999	National Science Foundation
1980-	National Institute of Health – Jain; Munn (2000 -); Fukumura (2002-); Boucher (2003-); Padera (2009-); Duda (2009-); Garkavtsev (2013-)
1980-	American Cancer Society – Jain; Burton (2000 - 2001); di Tomaso (2001-2003); Brown (2003-2004); Xu (2012-2016)
1991-	Humboldt Fellowships - Leunig, Dellian, Sckell
1992-	National Research Service Awards - Berk, Munn, Litchtenbeld, Kadambi, Ramanujan, Koenig, Brown, Luong
1992	Kurt Wohl Lecturer (U. Delaware) - Jain
1992-1996	Howard Hughes Fellowship - Gazit, Ang
1992-1993	Hybritech-Lilly
1993-2000	Outstanding Investigator Grant, National Cancer Institute – Jain
1993, 1994	Instrumentation Awards, American Microcirculation Society - Berk, Leunig, Yuan, Jain
1994-1996	DuPont-Merck
1994-1996	Enzon
1994-2012	Deutsche Forschungsgemeinschaft - Patan, Hansen-Algenstaedt, Gralla, Kunert
1994	Outstanding Alumnus Award, Indian Institute of Technology – Jain
1995	Whitaker Award, Biomedical Engineering Society – Jain
1996-2002	US Army Breast Cancer Program
1996-2000	Whitaker Foundation (Munn)
1996-1999	Whitaker Junior Faculty Award - Berk, Munn
1996	Landis Award, Microcirculatory Society - Jain
1996-1998	Whitaker BERE Fellowship - Fukumura
1997-	National Science Foundation Fellowship – Padera, Lin, Pathak, Tong
1998-	National Foundation for Cancer Research
1999-2000	Stewart Trust Award – Fukumura
1999	Kaplan Lecture (HMS), Berkeley Lecture (UCB) – Jain
2000	Pharmaceutical and Bioengineering Award, American Institute of Chemical Engineers – Jain
2000-2001	Human Science Foundation Fellowship – Izumi
2000-	Japanese Ministry of Health and Welfare Fellowship – Izumi, Kohno
2000-2001	Japanese Science and Technology Agency Fellowship – Ushiyama
2000-2002	Mildred-Scheel-Stiftung Deutsche Krebshilfe Fellowship – Bockhorn
2000-2001	Genentech
2000-2001	Miravant
2000-2001	ImClone
2000-2001	Whitaker Health Sciences Fund Fellowship – Padera

2000-2003	Biotechnology Training Program Fellow – McKee
2001-2002	Susan Komen Foundation Fellowship – Dolmans
2001-2003	University of Copenhagen Fellowship – Junker
2001-2003	Whitaker Foundation Graduate Fellowship – Cochran
2001	Honorary Fellow, Indian Institute of Chemical Engineers – Jain
2001-	Whitaker Foundation Graduate Fellowship – Tam
2001	Netherlands America Commission for Educational Exchange Fulbright Fellowship – Hagendoorn
2001-2003	Clafin Distinguished Scholar – Xu
2001-2003	University of Tsukuba, Ministry of Education Science and Culture of Japan - Koike
2001-2003	Foundation for Science and Technology of Portugal – Sousa
2002	Bioengineering Division Award of the American Institute for Chemical Engineers – Jain
2002-2006	The Goldhirsh Foundation
2002	Gerritsen Award, Microcirculatory Society – Jain
2002- 2005	Cancer Research Institute – Duda
2002-	Whitaker Foundation Graduate Fellowship – Mok
2003	Alumni Wall of Fame, University of Delaware - Jain
2003-2005	Emmy-Noether grant of the German Research Foundation – Winkler
2003-2005	Susan Komen Foundation Fellowship – Tong
2003-2008	NIH Research Career Development Award – Munn
2003	Institute of Medicine, the National Academy of Sciences – Jain
2003-2005	American Association for Cancer Research Career Development Award – Duda
2003-2005	Japan Society for the Promotion of Science – Nagano
2004	National Academy of Engineering, the National Academy of Sciences – Jain
2004	Robert Bras Lecturer, Princess Margaret Hospital and National Cancer Institute of Canada – Jain
2004-2005	National Defense Medical College Fellowship – Miyazaki
2005-2008	Damon Runyon Foundation Fellowship – Lahdenranta
2005	John S. Laughlin Lecturer, Memorial Sloan-Kettering Cancer Center, New York – Jain
2005	AstraZeneca
2005	French Medical Research Foundation Fellowship- LaCorre
2005	Academic Scientist of the Year, 2005 Pharmaceutical Achievement Awards – Jain
2006-2008	Brain Tumor Society
2006-2008	Clafin Distinguished Award – di Tomaso
2006	Ford Foundation Diversity Fellowship – Dawson
2006-2009	Susan Komen Fellowship – Lacorre

2006-2009	Department of Defense Pre-doctoral Award – Lanning
2005-2008	Department of Defense Pre-doctoral Award – Pieters
2006	Distinguished Service Award, Nature Biotechnology - Miami Symposium on Angiogenesis – Jain
2006	Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research – Jain
2006	Robert L. Krigel Lecture, Fox Chase Cancer Center, Philadelphia – Jain
2006	Alpha Chi Sigma Research Award, American Institute of Chemical Engineers – Jain
2006	Benjamin Zweifach Distinguished Lecture, The City College, New York – Jain
2007	Research Team Award, Clinical Research Day, MGH – Jain, di Tomaso, Duda, Kozak
2007	Uehara Memorial Foundation Fellowship – Yamashita
2007	Sam Gerson Leadership Chair of Research, Brain Tumor Society – Jain
2007	Drug Discovery Initiative Award, Children’s Tumor Foundation – di Tomaso
2008	Sir Godfrey Hounsfield Lecture, Imperial College, London – Jain
2008	Richard D. Frisbee III Oncology Lecture, Yale University–Jain
2008	Sir Godfrey Hounsfield Lecture, Imperial College, London – Jain
2008	Peter C. Reilly Lecture, University of Notre Dame, Indiana–Jain
2008	Charles G. Moertel Lecture, Mayo Clinic, Rochester, Minnesota – Jain
2008	Ashland Distinguished Lecture, University of Kentucky, Lexington, Kentucky–Jain
2008	William E. Schiesser Lecture, Lehigh University, Bethlehem, Pennsylvania – Jain
2008	American Academy of Arts and Sciences–Jain
2008	Spiro Translational Research Award - Duda
2008	Susan Komen Fellowship - Kamoun
2008	Federal Share (Boucher)
2008	Tosteson Postdoctoral Fellowship Award from the Massachusetts Biomedical Research Corporation- Liao
2008	NIH Pathway to Independence Award-Padera
2009	National Academy of Sciences–Jain
2009	Dyax
2009	Zweifach Lecture, UCSD - Jain
2009	Susan Komen Fellowship - Stylianopoulos
2009	Merck Fellowship (Sodunke)
2009	Ruckenstein Lecture, University at Buffalo NY- Jain
2010	DoD Innovator Award (Jain)
2010	Pirkey Lecture, University of Texas at Austin - Jain
2010	Kelley Lectures, Purdue University - Jain

2010	William B. Lowrie Lecture, Ohio State Univ. - Jain
2010	Wagner Lecture, University of Michigan - Jain
2010	Spiro Translational Research Award - Duda
2010	Martin Research Prize for Excellence in Clinical Research-Padera, Tyrrell, Jain, di Tomaso
2011-	Federal Share (Boucher, Fukumura, Duda, Jain, Garkavtsev, Huang, Munn, Xu,)
2011	Gates Foundation
2011	MedImmune (SRA)
2011	Roche (SRA)
2011	NIH Director’s New Innovator Award-Padera
2011	Charles A. King Trust Fellowship Award-Liao
2011	Roland T. Lakey Award, Wayne State University - Jain
2011	American Cancer Society Basic Science Lecture, Society of Surgical Oncology - Jain
2011	Rous-Whipple Award, American Society of Investigative Pathology - Jain
2011	Irving O. Shoichet Lecture, University of Toronto, Canada – Jain
2011	Distinguished Research Lecturer, Carnegie Mellon- Jain
2012	NIH Pathway to Independence Award-Liao
2012	One of the 18 Indians Doing Cutting-Edge Research, Forbes (India) -Jain
2012	Herman Schwan Lecture, University of Pennsylvania- Jain
2012	ASCO Science of Oncology Award and Lecture, American Society of Clinical Oncology-Jain
2012	2012 Children’s Tumor Foundation – Clinical Research Award - Xu
2013	M. Gerritsen Award, Microcirculation Society - Fukumura, Duda, Munn, Jain
2013	Max Kade Foundation-Reiberger
2013	Children’s Tumor Foundation- Drug Discovery Initiative - Xu
2013	AACR-Boucher
2014	M. Gerritsen Award, Microcirculation Society - Fukumura, Duda, Munn, Jain
2014	Earl Bakken Distinguished Lecture, Amer. Institute for Medical and Biological Engineering -Jain
2014	AACR-Princess Takamatsu Lecture/Award, American Association for Cancer Research -Jain
2014	One of 50 Oncology Luminaries, American Society of Clinical Oncology (ASCO) -Jain
2014	Most cited paper (2013), Annals of Biomedical Engineering –Jain
2014	Fellow, American Association for the Advancement of Science (AAAS) -Jain
2015	NIH R01 - Munn, Padera, Jain
2015	Rice University Distinguished Alumnus Award – Munn
2015	Secretary General, IASGO –Duda

2015	“Eugene M. Landis Award” The Microcirculatory Society - Fukumura
2015	Honorary Doctorate, Katholieke Universiteit Leuven, Belgium –Jain
2015	Honorary Doctorate, Indian Institute of Technology (IIT), Kanpur, India -Jain
2015	Honorary Doctorate, Duke University -Jain
2015	Capussotti Award (International Association of Surgeons, Gastroenterologists, and Oncologists) –Duda
2015	Honoree of the One Hundred, Mass General Cancer Center –Duda
2015	Foreign Fellow, Indian National Science Academy (INSA) –Jain
2015	LE&RN/FDRS Lipedema Postdoctoral Fellowship -Bouta
2015	Schrodinger Fellowship by the Austrian Science Funds –Pinter
2015	Herman-Holtheusen Award of the German Society for Radiation Oncology -Askoxylakis
2015	Humboldt Foundation Feodor Lynen Research Fellowship –Schanne
2015	Susan G. Komen Foundation Postdoctoral Grant; FSQ Fellowship; FMD ECOR -Ferraro
2015	Tufts Graduate School of Arts and Sciences Travel Award, School of Engineering Travel Award, AACR Scholar in Training Award -Datta
2015	Poster of Distinction Award at MGH ECOR SAC Meeting -Ferraro, Datta
2015	De Beaumont Bonelli Foundation Travel Award, Lorini Foundation Award -Seano
2015	ABTA Fellowship -Chatterjee
2015	AACR-Aflac, Incorporated Scholar in Training Award, Keystone Global Helath Award -Jung
2015	Award of the State Scholarship Fund by the China Scholarship Council (CSC) -Y. Zhao
2015	Spiro Award -Padera, Xu
2015	Merrimack Pharma SRA -Duda
2015	Warshaw Award -Fukumura, Duda
2015	Nikon Small World Competition, 5th place-Seano
2015	SPARC SRA - Garkavstev
2015	North America Vascular Biology Organization Outstanding Poster Award- Bazou
2015	Pierre Gilles de Gennes Fondation pour la Recherche Fellowship, Consejo Superior de Investigaciones Cientificas Award-Bazou
2015	Children's Tumor Foundation Drug Discovery Award -Xu
2015	NIH Outstanding Investigator Award -Jain
2015	Bill and Melinda Gates Foundation Grand Challenges: New Interventions in Global Health Award -Jain
2015	Ludwig Institute Grant - Jain
2015	Bayer, BMS SRAs - Duda

2015	Rice University Distinguished Alumnus Award – Munn
2016	Inductee, American Institute of Medical and Biological Engineering - Munn
2016	Heroes of Hope Award Granara-Skerry Trust for Pancreatic Cancer Research - Duda
2016	Won Partners in Excellence Award - Roberge
2016	DoD New Investigator Award – Xu
2016	2016 AACR-GYRIG Scholar-in-Training Award – Jung
2014, 14, 16	One of the top 1% cited researchers in Clinical Medicine, Thomson Reuters -Jain
2016	Princess Takamatsu Cancer Research Fund International Lecturer, Japan - Jain
2016	SRA-Xu
2016	One of the Most Influential/Cited Authors on the 75 th Anniversary of <i>Cancer Research</i> – Jain
2016	R. B. Trull Lecture, University of Texas, Austin – Jain
2016	United States National Medal of Science (for 2013) – Jain
2016	NIH F3I Fellowship – Datta
2016	AACR Postdoctoral Fellowship – Wong
2016	Tosteson Postdoctoral Fellowship – Nia
2016	Uehara Foundation Postdoctoral Fellowship – Shigeta
2016	NIH R01 – Padera, Munn
2016	Feodor-Lynen Postdoctoral Research Fellow – Ghosh
2016	The Kyoto Univ. Foundation – Kawaguchi
2016	Resource Center for Health Science (RECHS) – Kawaguchi
2017	2017 NIH R01 BRG – Fukumura/Jain
2017	NIH U01 – Jain/Pittet
2017	NIH R41 – Duda
2017	NCI/NIAID R01 BRG, Supplement – w/ Pittet
2017	Exelixis, Leap SRAs – Duda
2017	ECOR ISF Grants – Fukumura, Duda
2017	Lifetime Achievement Award, American Assoc. of Indian Scientists in Cancer Research – Jain
2017	Ramzi Cotran Lecture, Harvard Medical School – Jain
2017	New England Choice Award – Jain
2017	One of the top 1% cited researchers in Clinical Medicine – Jain
2017	Elected to the National Academy of Inventors - Jain
2017	Swedish Research Council Fellowship -Patrik Andersson
2018	Maud Menten Lecture, University of Pittsburgh - Jain
2018	NIH Training Grant -Jessica Posada
2018	Cancer Research Institute Postdoctoral Fellowship - Nilesh Talele

2018	One of the top 1% cited researchers in Clinical Medicine -Jain
2018	NETF Pilot Grant – Duda
2018	Earl Benditt Award, North American Vascular Biology Organization -Jain
2018	One of the top 1% cited researchers in Clinical Medicine -Jain
2018	Cholangiocarcinoma Foundation – Aoki
2018	R21-Padera
2018	Children’s Tumor Fundation Drug Discovery Award - Xu
2019	Election to College of Fellows of American Institute of Medical and Biological Engeineering-Padera
2019	One of the top 1% cited researchers in Clinical Medicine – Jain

2019	Judah Folkman Lecture, Harvard Medical School/Boston Children’s Hospital -Jain
2019	Jeffrey M. Isner Memorial Lecture, Tufts University School of Medicine –Jain
2019	ECOR ISF Grants - Xu
2019	ACR-Loxo Oncology Pediatric Cancer Research Fellowship -Meenal Datta
2019	Cancer Research Institute Postdoctoral Fellowship-Jun Ren
2019	MGH Cancer center excellence award -Zohreh Amoozgar
2019	DOD Horizon award -Shan Krishnan
2019	Tosteson Fellowship – Jun Ren

RESEARCH GOALS

The long-term goal of our research is to reveal the role of host-tumor interactions in the biology and therapeutic response of tumors and to translate this insight into improved cancer detection, prevention and treatment. A quantitative understanding of pathophysiology of solid tumors is developed using five unique yet complementary approaches in our research

1 a microscopic approach to directly visualize gene expression, physiological function and delivery of therapeutics *in vivo*.

2 a macroscopic approach using tissue-isolated tumors to access and monitor arterial and venous blood in rodent and human tumors.

3 *in vitro* characterization of deformability, permeability, migration, adhesion and force generation in cells

4 molecular biology techniques as well as the development of transgenic cell lines and animals

5 mathematical modeling to integrate existing data and to guide new clinical and experimental studies.

These five approaches are intertwined in seven multi-disciplinary projects

1. tumor angiogenesis and blood flow
2. metabolic microenvironment
3. transvascular transport
4. interstitial and lymphatic transport
5. cell mechanics and transport;
6. mathematical modeling
7. translation of laboratory findings to the clinic

The goals of the first project are to understand the molecular and physical mechanisms underlying the temporal and spatial heterogeneities in tumor vasculature; and to develop strategies for manipulating these parameters to “normalize” the tumor vasculature. The goals of the second project are to determine molecular and cellular mechanisms that lead to the abnormal tumor microenvironment and to develop strategies to “normalize” the microenvironment.

The goals of the third project are to characterize transvascular transport pathways in tumors, to identify molecular mechanisms that govern transport of molecules across the vessel wall, and to develop molecular and physiological strategies for improved transport.

The goals of the fourth project are to characterize transport in the interstitium and relate it to the interstitial structure, to determine the causes of interstitial hypertension, to develop strategies to alter pressure in solid tumors, and to examine the diagnostic and prognostic value of tumor interstitial pressure in the management of cancer. Since lack of functioning lymphatics is a major cause of interstitial hypertension, a related goal is to further our understanding of lymph transport, and to identify inhibitors of lymphangiogenesis and lymphatic function in tumors.

The goals of the fifth project are to quantify the structural rigidity, force generation, and motility of cancer cells and of various lymphocyte subpopulations, to measure the adhesive interactions among lymphocytes, endothelial cells and tumor cells, to define the mechanisms which control these structural and functional properties, to relate these biophysical parameters with the in vivo movement of lymphocytes and cancer cells and to develop novel technologies for separating rare cells from blood based on this understanding.




Vascular cast of human colon tumor vessels used to study vascular abnormalities. The plastic material was injected and polymerized after the surgical resection of a tumor from the colon of a patient.

The goal of the sixth project is to bring together the knowledge generated in the first five projects by developing appropriate mathematical models. Current efforts are focused on improving the delivery of therapeutic agents to tumors using various approaches, scale-up of rodent data to humans, fractal analysis of vascular networks, mathematical modeling of angiogenesis and leukocyte-endothelial interactions and development of new transport and growth equations for solid tumors based.


The goal of the seventh project is to translate our laboratory findings in the clinic with the goal of improving current therapies and to develop new molecular and cellular biomarkers for individualizing cancer treatment.

We believe that our work will continue to provide valuable insight into tumor pathophysiology and suggest novel strategies for improved detection, prevention and treatment of solid tumors.

Normalization hypothesis: Anti-angiogenesis drugs cause abnormal tumor vessels (B) to become more normal with better function (C), allowing uniform drug delivery and more effective radiation therapy.



RESEARCH HIGHLIGHTS



RESEARCH HIGHLIGHTS

Project 1 Angiogenesis and Blood Flow

- Developed sophisticated animal models for studies of tumor angiogenesis, microcirculation, progression, metastases and treatments including dorsal window (Leunig et al., 1992b, Leunig et al., 1995, Leunig et al., 1997), cranial window (Yuan et al., 1994b), liver ((Fukumura et al., 1997b), gallbladder (Gohongi et al., 1999), pancreas (Tsuzuki et al., 2001), mammary fat pad (Monsky et al., 2002), tissue-isolated tumor (Kristjansen et al., 1994, Kristjansen et al., 1996).
- Developed state of the art imaging techniques for in vivo studies including multiphoton laser-scanning microscopy (Brown et al., 2001; Padera et al., 2002), Quantum dots (Stroh et al., 2005; Allen et al., 2010; Liu et al., 2010; Chen et al., 2013), Life time imaging (Kumar et al., 2009), OFDI (Vakoc et al., 2009), (Kim et al., 2010), (Kamoun et al., 2010), video-rate MPLSM (Kirkpatrick et al., 2012),
- Developed a noninvasive model to visualize angiogenesis and adipogenesis and found provocative reciprocal regulation between them, suggesting a novel therapy for obesity related diseases including cancer (Fukumura et al., 2003; Tam et al., 2009b). Established a physiologically based mathematical model to study body weight balance (Tam et al., 2009a).
- Provided the first quantitative measurements of geometric resistance to blood flow and of branching patterns in the rat and human tumor vasculature (Less et al., 1991).
- Established and tested a network model to explain the effect of vasoactive agents on tumor blood flow and interstitial fluid pressure (Zlotecki et al., 1995).
- Developed a novel scheme to quantify the vascular architecture in a tumor (Gazit et al., 1995, Gazit et al., 1997). This analysis has allowed us to calculate the role of vascular heterogeneity in nutrient and drug delivery of tumors (Baish et al., 1997, 2011, Baish and Jain, 2000, 2001).
- Utilized tissue-isolated tumors for residence time distribution studies to examine the accuracy of models used to estimate blood flow (Eskey et al., 1994) and for drug uptake studies to investigate barriers to drug delivery (Kristjansen et al., 1996, Heijn et al., 1999).
- Discovered new mechanisms of tumor angiogenesis (Patan et al., 1996) and vascular anastomosis (Cheng et al., 2011).
- Discovered a new mechanism of intermittent blood flow in tumors (Netti et al., 1996, 2001).
- Demonstrated roles of nitric oxide (Fukumura and Jain, 1998; Fukumura et al., 2006) on the regulation of tumor blood flow (Kristensen et al., 1997; Fukumura et al., 1997a), angiogenesis (Fukumura et al., 2001) and pericyte recruitment (Kashiwagi et al., 2005), and that perivascular nitric oxide gradients normalize tumor vasculature (Kashiwagi et al., 2008) and Tie-2 activation potentiate it (Goel et al., 2013).
- Measured the stress generated by tumor growth to explain vascular collapse (Helmlinger et al., 1997b; Koike et al., 2002) and showed that relieving stress by inducing tumor cell apoptosis could open vessels (Griffon-Etienne et al., 1999; Padera et al., 2004).
- Demonstrated the importance of host organ in tumor angiogenesis, microcirculation (Fukumura et al., 1997b; Tsuzuki et al., 2001; Monsky et al., 2002) and VEGF/bFGF induced vessels (Dellian et al., 1996a), suppression of secondary angiogenesis (Sckell et al., 1998, Gohongi et al., 1999; Hartford et al., 2000) and response to anti-VEGF and HER2 therapies (Bockhorn et al., 2003; Kodack et al., 2012).
- Discovered that tumor induces VEGF-promoter activity in the host fibroblasts (Fukumura et al., 1998), these activated fibroblasts play an active role in angiogenesis (Brown et al., 2001) and the host cells contribute significantly to VEGF production (Tsuzuki et al., 2000) and compensate tumor cells' production (Izumi et al., 2002)
- Discovered indirect pro-/anti-angiogenic effects such as hormone therapy/withdrawal (Jain et al., 1998a; Kristensen et al., 1999b) on blood flow and microcirculation in tumors angiogenesis. Anti-HER2 therapies (Izumi et al., 2002; Kodack et al., 2012)
- Demonstrated that VEGF produced by endothelial cells in oxygen gradients can lead to vascular network formation in vitro (Helmlinger et al., 2000).
- Quantified the frequency of mosaic vessels in tumors (Chang et al., 2000).
- Demonstrated that anti-VEGF and anti -VEGF-R2 antibodies potentiate radiation-induced short term and long term tumor control (Lee et al., 2000; Kozin et al., 2001).
- Demonstrated that decorin inhibits angiogenesis in vitro (Davies et al., 2001).
- Proposed that judiciously applied anti-angiogenic therapy can normalize tumor vasculature (Jain, 2001).
- Discovered the mechanism of blood flow shutdown by PDT (Dolmans et al., 2002a,b).
- Demonstrated that VEGF blockade can retard the growth of spontaneous autochthonous tumors (Izumi et al., 2003).
- Created long-lasting blood vessels in vivo using endothelial cells and mesenchymal precursor cells (Koike et al., 2004), hES cells (Wang et al., 2007), EPCs (Au et al., 2008a), MSCs (Au et al., 2008b), human iPS cells (Samuel et al., 2013).
- Discovered the differential transplantability of tumor stromal cells and stromal cell metastasis (Duda et al., 2004, 2010).
- Demonstrated normalization of tumor vasculature by an anti-angiogenic therapy (Tong et al., 2004; Winkler et al., 2004; Kashiwagi et al., 2008; Kamoun et al., 2009; Huang et al., 2012)
- Characterized nanoparticle transport (Stroh et al., 2005) and the effect of size (Popović et al., 2010; Chauhan et al., 2012), charge (Campbell et al., 2002; Stylianopoulos et al., 2010 & 2013; Han et al., 2013), shape (Chauhan et al., 2011), multistage system (Wong et al., 2011), and vascular normalization (Chauhan et al., 2012)
- Discovered Ang-2 as a potential target for anti-VEGF therapy resistance (Chae et al., 2010; Peterson et al., 2016; Kloepper et al., 2016).
- Demonstrated that CXCR4 promotes metastasis via Gr-1+ BMDC recruitment (Hiratsuka et al., 2011a).
- Discovered that tumors prime metastatic "soil" by inducing focal hyperpermeability in the lungs (Hiratsuka et al., 2011b).
- Determined how fluid forces and VEGF cooperate to control angiogenic sprouting (Song & Munn, 2011)
- Discovered PIGF/NRPI as a novel therapeutic target in pediatric medulloblastoma (Snuderl et al., 2013)
- Discovered obesity induces anti-VEGF therapy resistance via IL-6 and bFGF (Incio et al., 2018).

Project 2 Tumor Microenvironment

- Adapted and developed fluorescence ratio imaging microscopy (FRIM) to measure pH in vivo in normal and tumor microcirculation in the rabbit ear chamber and mouse dorsal chamber (Martin and Jain, 1993, Martin and Jain, 1994, Dellian et al., 1996b).
- Provided the first combined measurement of pH and pO₂ profiles in human tumor xenografts (Helmlinger et al., 1997a).
- Demonstrated that VEGF produced by endothelial cells in oxygen gradients can lead to vascular network formation in vitro via an autocrine mechanism (Helmlinger et al., 2000).
- Measured oxygen consumption of endothelial cells in vitro (Helmlinger et al., 2000) and of tumors during various treatments (Hansen-Algenstaedt et al., 2000).
- Delineated the mechanisms of low pH in tumors (Helmlinger et al., 2002).
- Measured glucose metabolism and vascular parameters in lung cancer patients using PET and MRI (Hunter et al., 1998).
- Measured the effect of creatine and cyclocreatine on energy levels in tumors (Kristensen et al., 1999a).
- Determined increase in tumor pO₂ by modified hemoglobins (Nozue et al., 1996).
- Examined the feasibility of the Eppendorf histograph for pO₂ measurements (Nozue et al., 1997a, Nozue et al., 1997b).
- Demonstrated a lack of universal correlation between pO₂ and IFP (Boucher et al., 1995).
- Discovered that HIF1 α deletion leads to lower VEGF expression, angiogenesis and oxygenation, yet the tumors grow more rapidly (Carmeliet et al., 1998), and HIF1 α (-/-) cells localize in hypoxic regions (Brown et al, 2001).
- Discovered that low pH and pO₂ independently regulate VEGF (Fukumura et al, 2001), and delineated the signaling pathways for low pH induced VEGF upregulation (Xu et al., 2002).
- Demonstrated signaling pathways in hypoxia-induced IL-8 expression (Xu et al., 2004).
- Demonstrated that HIF-2 α acts as a tumor suppressor (Acker et al., 2005).
- Discovered that the judicious application of anti-angiogenic therapy alleviates hypoxia in tumors (Winkler et al, 2004).
- Developed "smart" nano-particles that become smaller in size once they enter the tumor microenvironment and penetrate deeper into tumors (Wong et al, 2011)
- Discovered that medulloblastoma cells stimulate stromal granule cells via Shh to produce PIGF, which promotes medulloblastoma cell growth and spread (Snuderl et al., 2013)
- Discovered that reprogramming liver tumor microenvironment using CXCR4 inhibition can facilitate immunotherapy (Chen et al, 2015)
- Discovered that obesity induces inflammation, desmoplasia and resistance to anti-angiogenic therapy in breast cancer via IL-6 and bFGF (Incio et al., 2018) and chemotherapy in pancreatic cancer via IL-1 (Incio et al., 2016).

Project 3 Transvascular Transport


- Found that decompressing vessels with angiotensin inhibition can enhance oxygen delivery to tumors (Chauhan et al., 2013)
- Provided the first measurement of microvascular permeability in a human tumor xenograft using intravital fluorescence microscopy (Yuan et al., 1993).
- Demonstrated that the local microenvironment of tumors can control permeability (Yuan et al., 1994b; Fukumura et al., 1997b).
- Showed that anti-VEGF antibody or hormone withdrawal can lower tumor permeability and lead to vascular regression (Yuan et al., 1996, Jain et al., 1998a, Lichtenbeld et al., 1999, Jain et al., 1998), yet VEGF showed no correlation with vascular permeability in different sites (Fukumura et al., 1997b).
- Measured the molecular weight and charge dependencies of vascular permeability (Yuan et al., 1994a, 1995; Dellian et al., 2000; Campbell et al., 2002) and discovered that the pore size cut-off for transvascular pathways depends on tumor-host interaction and changes in response to therapy (Hobbs et al., 1998).
- Discovered that hyperpermeability of tumor vessels coupled with high interstitial pressure can lead to vascular stasis (Netti et al., 1996, Baish et al., 1997).
- Measured the hydraulic conductivity (Sevick and Jain, 1991a) and distribution of water channel protein (AQP1) in tumors (Endo et al., 1999).
- Discovered that increase in vascular permeability by VEGF depends on the host-origin of endothelium (Chang et al., 2000) and host-tumor interaction (Monsky et al., 1999).
- Demonstrated that the gaps between endothelial cells cause hyperpermeability in tumors (Hashizume et al., 2000).
- Measured the effect of PIGF and VEGF on the hydraulic conductivity of endothelium in vitro (Dull et al, 2001).
- Demonstrated induction of vascular permeability by nitric oxide in tumors and VEGF-induced angiogenic vessels (Fukumura et al., 1997a and 2001).
- Demonstrated that anti-VEGFR2 antibody reduces vascular permeability and normalizes tumor vasculature (Tong et al., 2004; Winkler et al., 2004).
- Examined how focal vessel hyperpermeability can influence network flow patterns (Sun et al., 2008).
- Found that modulating nanoparticle shape can enhance the penetration of tumors (Chauhan et al., 2011)
- Determined that vascular normalization can enhance the penetration of small but not large nanomedicines in tumors (Chauhan et al., 2012)
- Discovered that inhibiting VE-PTP, which itself inhibits the vessel maturation activities of Tie-2, matures vessels in primary and metastatic lesions to prevent disease progression and enhance radiation sensitivity (Goel et al., 2013)
- Demonstrated focused ultrasound-induced BTB disruption and enhanced drug delivery in brain metastasis (Arvanitisa et al., 2018)

- Provided evidence that microvascular pressure is the principal driving force for interstitial hypertension in tumors (Boucher et al., 1992, Zlotecki et al., 1993, 1995), and that interstitial pressure goes up with the onset of angiogenesis (Boucher et al., 1996).
- Theoretically predicted and experimentally confirmed the time constants of transvascular and interstitial fluid exchange in tumors (Netti et al., 1995) and developed a novel strategy for improving drug delivery based on these findings (Netti et al., 1999).
- Demonstrated that it is possible to lower tumor pressure using nicotinamide (Lee et al., 1992), dexamethasone (Kristjansen et al., 1993), pentoxifylline (Lee et al., 1994a), hemodilution (Lee et al., 1994b), TNF α (Kristensen et al., 1996, Kristensen et al., 1997), taxanes (Griffon-Etienne et al., 1999), radiation (Znati et al., 1996) and various vasoactive agents (Zlotecki et al., 1995).
- Suggested the possibility that pressure could be used as a prognostic marker (Leunig et al., 1992a, Leunig et al., 1994a).
- Demonstrated a lack of universal correlation between pO₂ and IFP (Boucher et al., 1995).
- Adapted fluorescence recovery after photobleaching (FRAP) to thick samples (Beck et al., 1993) and used it to measure the effect of charge, molecular weight and configuration on diffusion in gels (Johnson et al., 1995, Johnson et al., 1996a, Johnson et al., 1996b, Pluen et al., 1999).
- Measured the hydraulic conductivity of the tumor interstitial matrix (Boucher et al., 1998).
- Discovered that collagen network contributes to resistance (Netti et al., 2000; Davies et al., 2002; Ramanujan et al., 2002), and to host-organ dependence of interstitial transport in tumors (Pluen, et al, 2001).
- Adapted FRAP to measure binding kinetics between antibody and tumor associated antigens in vitro (Kaufman et al., 1991, Kaufman et al., 1992a, Kaufman et al., 1992b) and in vivo (Berk et al., 1997).
- Demonstrated that VEGF-C, the first lymphangiogenic molecule, leads to lymphatic hyperplasia in skin (Jeltsch et al., 1997), in the tumor margin (Padera et al, 2002), and angiogenesis in tumors (Kadambi et al, 2001).
- Developed a new model for lymphatic transport (Leu et al., 1994) and measured flow velocities in lymph capillaries of the tail skin of mice using RTD and FRAP (Swartz et al., 1996, Berk et al., 1996).
- Provided the first measurements of oncotic pressure in tumors (Stohrer et al, 2000).
- Demonstrated the absence of functional lymphatics in tumors despite the presence of VEGF-C and its receptors (Leu et al., 2000; Padera et al., 2002).
- Demonstrated that LYVE-1 is not specific to lymphatics, and LYVE-1 Prox1 structures, presumably lymphatics are absent in primary and secondary tumors in livers of patients (Mouta-Carreira, et al, 2001)
- Developed a new model for acute lymphedema in the tail and alleviated edema using a flap transfer (Slavin et al., 1999, Losken et al, 2001).
- Developed a technique for optically imaging collagen in tumors in vivo using second harmonic generation (Brown et al., 2003).
- Quantified the dynamics of collagen modification after pharmacologic intervention and provided mechanistic insight into improved diffusive transport induced by the hormone relaxin (Brown et al., 2003).
- Demonstrated that radiation enhances the production of collagen I and reduces fluid flow in tumors (Znati et al., 2003).
- Developed a two-photon correlation microscopy technique and found two-phase nature of interstitial transport in tumors (Alexandrakis et al., 2004).
- Demonstrated that compressive mechanical forces generated by proliferating cancer cells can cause the collapse of intratumor blood and lymphatic vessels (Padera et al., 2004).
- Demonstrated that VEGF-C overexpression leads to the formation of lymphatic vessels that demonstrate retrograde flow and implies that the VEGF-C alone can not produce mature, functional lymphatic vessels (Isaka et al., 2004).
- Demonstrated that nitric oxide and eNOS act on the collecting lymphatic vessels, but not the initial lymphatic vessels, of the mouse tail and alters the rate of lymph flow in these vessels (Hagendoorn et al., 2004).
- Demonstrated that VEGF signaling blockade reduces the tumor interstitial fluid pressure in experimental tumors (Lee et al., 2000; Tong et al., 2004).
- Evaluated tadpole model as a novel system to study lymphangiogenesis (Ny et al., 2005)
- Discovered elevated IFP and abnormal lymphatics in premalignant lesions (Hagendoorn et al., 2006).
- Imaged each step in the process of lymphatic metastasis and found that VEGF-C increases cancer cell arrival in the lymph node and thereby increases metastasis formation (Hoshida et al., 2006).
- Demonstrated a lack of efficacy of VEGFR TKIs against lymphatic metastasis in the adjuvant setting (Padera et al., 2008)
- Demonstrated the critical function of NO in the autonomous contraction of collecting lymphatic vessels (Liao et al., 2011).
- Discovered that the widely-prescribed anti-hypertensive drugs can "normalize" the collagen matrix and improve the delivery and efficacy of drugs in desmoplastic tumors (Diop-Frimpong et al, 2011).
- Found that TGF-beta inhibition can enhance the penetration and efficacy of nanomedicines in tumors (Liu et al., 2012)
- Discovered that VEGF-C sensitizes lymphatic endothelial cells to radiation (Kesler et al., 2014)
- Found that lymph node metastasis do not require sprouting angiogenesis in order to grow (Jeong, Jones et al., 2015).
- Developed mathematical model to characterize the role of mechanobiological inputs in driving lymphatic pumping (Kunert et al., 2015).
- Demonstrated the first dynamic lymph flow measurement without injected contrast in vivo (Blatter et al., 2016).
- Showed that MRSA infections permanently impair lymphatic pumping by killing lymphatic muscle cells (Jones et al., 2018).
- Showed that lymph node metastasis can invade lymph node blood vessels, escape the lymph node and colonize distant metastatic sites (Pereira et al 2018).
- Showed that tumor draining lymphatic vessels have impaired pumping (Liao et al 2019)

RESEARCH HIGHLIGHTS

Project 5 Cell Mechanics and Transport

- Adapted and further developed rectangular and cylindrical systems to quantify deformation, rolling and adhesion of lymphocytes (Munn et al., 1994, Yuan et al., 2000).
- Developed a new technology to measure membrane-associated antigen in intact cell monolayers (Munn et al., 1995).
- Demonstrated that interleukin-2 (IL-2) increases the rigidity of NK cells (Melder and Jain, 1992) and that thioglycollate can reduce the rigidity of IL-2 activated NK cells without affecting their cytotoxicity or adhesiveness (Melder and Jain, 1994), and thus avoid entrapment in the lungs (Melder et al, 2001)
- Discovered that RBCs augment selectin and integrin mediated rolling and adhesion of lymphocytes to the vascular endothelium both in vitro and in vivo (Melder et al., 1995b, Munn et al., 1996, Melder et al., 2000; Yuan et al., 2001).
- Demonstrated that rolling in the dorsal skin is reduced but not eliminated in P-selectin deficient mice (Yamada et al., 1995a), and that rolling increases with age (Yamada et al., 1995b).
- Discovered that rolling is normal but adhesion is reduced in E-selectin Mice (Milstone et al., 1998).
- Demonstrated using three different in vivo tumor models that IL-2 activated NK cells preferentially adhere to the tumor vasculature (Ohkubo et al., 1991, Sasaki et al., 1991, Melder et al., 1993, Melder et al., 1994, Melder et al., 1995a), even though the leukocyte-endothelial interaction in tumors is heterogeneous (Fukumura et al., 1995) and differs among subpopulations of lymphocytes (Melder et al., 1997, Koenig et al., 2000).
- Discovered the connection between angiogenesis and leukocyte adhesion (Melder et al., 1996, Detmar et al., 1998, Moulton et al., 1999).
- Discovered that VEGF upregulates while bFGF downregulates adhesion molecules in vascular endothelium in vitro and in vivo (Melder et al., 1996, Detmar et al., 1998, Jain et al., 1998) and PKC γ , PLD and PKC signaling is involved in inhibition by bFGF (Koenig et al., 2000).
- Developed a physiologically based model of cell biodistribution in mice and humans (Zhu et al., 1996).
- Developed a new method for labeling cells for in vivo biodistribution studies using PET and MRI (Melder et al., 1993, Melder et al., 1994, Schoeph et al., 1998).
- Using a chorioallantoic membrane model and in vivo microscopy, characterized the early events in metastasis and examined the induction of metastasis-related genes (Shioda et al., 1997).
- Showed increased rate of lymphocyte turnover in SIV-injected macaques (Rosenzweig et al., 1998), and differential proliferation in lymphocytes in acute SIV infection (Kaur et al., 2000).
- Demonstrated tumor targeting by salmonella and showed that salmonella accumulation in tumors is due to selective growth in necrotic regions rather than active migration (Forbes et al., 2003).
- Demonstrated that bone marrow stem cells can be labeled with quantum dots for improved in vivo detection (Stroh et al., 2005).
- Quantified bone-marrow cell-derived neovascularization in transplanted and spontaneous tumors and demonstrated its dependence on mouse strain and tumor site (Duda et al., 2005)
- Demonstration that telopeptide-free collagen I enhances RhoA activity and the invasion of a metastatic breast tumor cell line (Demou et al., 2005).
- Demonstrated that platelets play a role in angiogenesis (Kisucka et al., 2006).
- Evaluated circulating endothelial cells (CECs) as a biomarker for antiangiogenic therapy in cancer patients, and characterized the phenotype of CECs (Willett et al., 2004; Willett et al., 2005; Duda et al., 2006).
- Discovered that mechanical compressive stresses can make cancer cells more invasive (Tse et al, 2011).
- Identified the components of tumors that contribute to compressive mechanical stresses in tumors (Stylianopoulos et al., 2012) and anti-VEGF therapy and obesity induces ECM deposition and mechanical stress that compress blood vessels (Rahbari et al, 2016; Incio et al, 2015 & 2016)
- Desmonstrated that targeting cancer-associated fibroblast activity can reduce compressive mechanical stresses in tumors to decompress vessels, increase perfusion, and enhance chemotherapy efficacy (Chauhan et al., 2013) and targeting fibroblasts by angiotensin receptor blocker (ARB) significantly improved pancreatic cancer surgery (Liu et al, 2017; Murphy et al, 2018)




RESEARCH HIGHLIGHTS

Project 6 Mathematical Modeling


- Developed macro- and microscopic distributed models for antibody distribution in tumors to demonstrate the role of binding (Baxter and Jain, 1991a, Baxter and Jain, 1991b).
- Developed lumped and distributed models for bifunctional antibodies and haptens, and described the data available in the literature (Yuan et al., 1991; Baxter et al., 1992).
- Developed a physiologically-based pharmacokinetic model for antibody using one- and two-step approaches. The model described the data in mice (Baxter et al., 1994) and predicted the human data (Baxter et al., 1995), and allowed dose estimations (Zhu et al., 1997, Zhu et al., 1998).
- Developed a physiologically based model of cell biodistribution in mice and humans (Zhu et al., 1996; Melder et al., 2002; Friedrich et al., 2002).
- Response to anti-VEGF treatment in rectal cancer. Top: before treatment; bottom: after treatment. Arrow shows location of shrinking, more pale tumor.
- Developed a distributed parameter model for microscopic distribution of drugs in ADEPT approach (Baxter and Jain, 1996).
- Developed a poro-elastic model of tumors and suggested a novel strategy to improve the drug delivery to solid tumors (Netti et al., 1995, 1997, 1999).
- Developed the theoretical framework to calculate residual stress in tumors (Skalak et al., 1996).
- Calculated solid stress generated by tumor spheroids (Helmlinger et al., 1997b) and proposed the hypothesis that the tumors lack functional lymphatics due to their collapse by solid stress.
- Developed a novel scheme to quantify the vascular architecture in a tumor (Gazit et al., 1995, 1997). This analysis has allowed us to calculate the role of vascular heterogeneity in nutrient and drug delivery to tumors (Baish et al., 1997, Baish and Jain, 1998, 2000).
- Developed a poro-elastic model for interstitial lymphatic transport (Swartz et al., 1999a).
- Developed a mathematical model for necrosis and dormancy in primary tumors and suppression of angiogenesis in distal tumors based on the transport and generation of angiogenic and anti-angiogenic molecules (Ramanujan et al., 2000).
- Developed a lattice Boltzmann model of leukocyte-RBC-endothelial interaction (Migliorini et al., 2002)
- Developed a linear poroelasticity model for the solid stress generated by spheroid growth as a model of tumor expansion (Roose et al., 2003).
- Developed a mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors (Stoll et al., 2003).
- Developed a model for temporal heterogeneities of tumor blood flow (Mollica et al., 2003).
- Used microfluidics to separate blood components (Shevkoplyas et al., 2005).
- Analyzed blood rheology based on the particulate nature of blood using lattice Boltzmann analysis (Sun et al. Biophys. J., 2005).
- Analyzed the effect of erythrocytes in the margination of leukocytes in vessel expansions (Sun et al., Physica A, 2005).
- Provided the first measurements of interstitial hypertension in various human tumors (Boucher et al., 1991, Roh et al., 1991, Gutmann et al., 1992, Less et al., 1992, Jain, 1994c, Boucher et al., 1997, Padera et al., 2002, Willett et al., 2004).
- Analyzed the effects of fiber geometry and charge on drug transport (Stylianopoulos et al Biophys J 2010a, 2010b).
- Developed a 2 parameter model to describe network efficiency (Baish et al., PNAS 2011).
- Predicted that combining 'vascular normalization' and 'stress normalization' can greatly enhance chemotherapy delivery in tumors (Stylianopoulos et al., 2013)

Mathematical modeling of blood flow. Erythrocytes flow from left to right (time sequence--A-D). E-H give the corresponding pressure profiles in the plasma.




Project 7 Bench-to-bedside translation

- Provided the first quantitative measurements of geometric resistance to blood flow and of branching patterns in the rat and human tumor vasculature (Less et al., 1997).
- Provided the first glimpse of how anti-angiogenic drug Avastin works in cancer patients (Willett et al., 2004, 2005, 2007).
- Provided the first evidence for vascular normalization by an antiangiogenic agent in rectal carcinoma patients (Willett et al., 2004).
- Demonstrated that VEGF signaling blockade reduces the tumor interstitial fluid pressure in human rectal cancer (Willett et al., 2004; 2005).
- Provided the first evidence that Avastin increases the level of VEGF and PlGF in patients' circulation (Willett et al., 2005).
- Found the presence of PDGFR- β on the lymphatic vessels of Gorham's lymphangiomatosis (Hagendoorn et al., 2006)
- Provided the first evidence that an oral antiangiogenic agent creates a window of normalization in recurrent gliomas and alleviates edema in the brain of these patients (Batchelor et al., 2007). This has led to the recently completed pivotal trial of cediranib in glioblastoma patients.
- Discovered that glioblastoma re-growth after antiangiogenic treatment is associated with increases in plasma levels of bFGF, stromal-derived factor 1 alpha (SDF1 α), and blood circulating endothelial cells (CECs) (Batchelor et al., 2007).
- Discovered that liver cancer response may be predicted by MRI and plasma measurements of interleukin 6, and that re-growth after antiangiogenic treatment is associated with increases in plasma levels of interleukin 6, stromal-derived factor 1 alpha (SDF1 α), and blood circulating progenitor cells (CPCs) (Zhu et al., 2009).
- Discovered that antiangiogenic therapy with bevacizumab benefits patients with benign tumors (schwannomas)(Plotkin et al., 2009)
- Established a "vascular normalization index" in glioblastoma patients that might predict response to anti-VEGF therapy as early as 1 day after treatment (Sorensen et al., 2009).
- Discovered that blocking VEGF increases SDF1 α , CXCR4, NRP-1 and CXCL6 in rectal cancer by laser-capture microdissection in serial patient biopsies (Xu et al., 2009).
- Demonstrated that the brain tumor patients whose tumor blood perfusion improved due to vascular normalization by anti-angiogenic therapy survive longer (Sorensen et al, 2011; Emblem et al, 2013; Batchelor et al, 2013).
- Demonstrated that vascular normalization and not pruning after antiangiogenic therapy with chemotherapy is the mechanism of benefit in breast and lung cancer patients (Heist et al., 2015; Tolaney et al., 2015)
- Discovered that the anti-VEGFR2 agent cabozantinib has immunomodulatory effects in breast cancer patients (Tolaney et al., 2017)
- Demonstrated that adding losartan – to normalize the tumor matrix – to chemoradiotherapy was associated with high complete resection rates in locally advanced pancreatic ductal adenocarcinoma patients (Murphy et al., 2018)



Response to anti-VEGF treatment in rectal cancer. Top: before treatment; bottom: after treatment. Arrow shows location of shrinking, more pale tumor.



We are pleased with our progress, which is a result of the hard work, dedication, innovation, organization, and cooperation of the members of the Steele Laboratories, as well as the collaborative support of various members of the MGH/Harvard/MIT community.

Faculty Research Summaries

Reengineering the Tumor Microenvironment to Improve Cancer Treatment: "Bench to Bedside" & Back



Rakesh K. Jain, PhD, A.W.
Cook Professor of Tumor
Biology

A solid tumor is an organ composed of cancer cells and host stromal cells, which are nourished by the vasculature and embedded in an extracellular matrix. The interactions among these cells, the surrounding matrix, and the local cellular microenvironment fuel tumor progression, and affect the tumor's response to various therapies. Blood and lymphatic vessels

also serve as conduits for metastatic spread. The overarching goal of our research is to dissect the pathophysiology of the vascular and extra-vascular components of tumors, to determine the role of tumor-host interactions in tumor growth, metastasis and treatment, and to translate this knowledge into improved cancer detection, prevention, and treatment in humans.

To unravel the complex biology of tumors, we have developed an array of imaging technologies, mathematical models, and sophisticated animal preparations. These include multiphoton microscopy and genetically engineered mice with surgically implanted transparent windows, which permit the *in vivo* visualization of gene expression and function in tumors and their surrounding host stroma. This undertaking has provided unprecedented molecular, cellular, anatomical, and functional insights into the vascular, interstitial and cellular barriers to cancer treatment.

Our laboratory found that high interstitial pressure is a universal characteristic of solid tumors, and that it can impair the delivery of molecular medicine within tumors, induce peri-tumor edema and contribute to lymphatic metastasis. We have identified the mechanisms underlying this elevated pressure: high vascular permeability, lack of functional lymphatics, and mechanical stress generated by tumor growth. Overexpression of the lymphangiogenic factor VEGF-C increases lymph node metastasis, but does not increase lymphatic function or decrease the interstitial pressure. However, judicious application of antiangiogenic agents can lower the pressure and improve the delivery and efficacy of various cancer treatments. To gain a deeper insight of tumor microenvironment, we measured interstitial convection, diffusion, and binding using photobleaching, and pO₂ and pH profiles around individual tumor vessels using phosphorescence quenching and ratio imaging. We proposed the novel hypothesis that the anomalous assembly of the collagen network can prevent the penetration of therapeutic agents in tumors, and showed that the hormone relaxin, bacterial

collagenase, MMP1/8 and anti-hypertensive drugs can improve drug distribution by modifying this network.

Our finding that angiogenic molecules regulate adhesion molecules on the vasculature provided the first link between the disparate fields of angiogenesis and adhesion, and revealed a novel mechanism by which tumors evade immune recognition. We also discovered that cancer cells co-opt the host stromal cells and entice them to produce pro- and anti-growth factors.

Our work has revealed that the abnormal vascular and extravascular compartments in solid tumors often thwarts the effectiveness of both conventional and novel therapies, including immunotherapy. Our laboratory is most celebrated for a new hypothesis that "normalizing" the abnormal tumor vasculature and matrix can improve both the delivery and efficacy of therapeutics. We have validated these concepts in multiple clinical trials and identified candidate biomarkers for improving treatment.

By integrating principles from physiology, pharmacology, immunology, and molecular biology, our laboratory has developed mathematical models of drug delivery and pathophysiological processes in solid tumors. These modeling tools have allowed us to extract simple, important principles that have guided the development of novel diagnostic and therapeutic strategies.

Selected Publications

- J Incio, et al. Obesity promotes resistance to anti-VEGF therapy in breast cancer by upregulating IL-6 and potentially FGF-2. *Science Translational Medicine*, 10: eaag0945.
- Naxerova K, et al. Origins of lymphatic and distant metastases in human colorectal cancer. *Science* 357: 55-60 (2017).
- M Pinter and RK Jain. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. *Science Translational Medicine* 9: eaan5616 (2017).
- Kodack D, et al. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. *Science Translational Medicine* 9: eaal4682 (2017).
- Incio J, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. *Cancer Discovery* 6: 852-869 (2016).
- Jain RK. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. *Cancer Cell* 26: 605-622 (2014).
- Jain RK. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. *J Clinical Oncology* 2013; 31:2205-18.
- Snuderl M et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. *Cell* 2013; 152: 1065-1076.
- Batchelor TT, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell* 2007; 11: 83-95.
- Jain RK. Normalization of the tumor vasculature: An emerging concept in anti-angiogenic therapy. *Science* 2005; 307:58-62
- Willett C, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. *Nature Medicine* 2004; 10:145-147.
- Padera TP, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. *Science* 2002; 296:1883-1886.
- Izumi Y, et al. Herceptin acts as an anti-angiogenic cocktail. *Nature* 2002; 416: 279-280.
- Fukumura D, et al. Tumor induction of VEGF promoter activity in stromal cells. *Cell* 1998; 94:715-725.]

The Modulation of Tumor Desmoplasia Improves Vascular Perfusion, and the Delivery and Effectiveness of Therapeutics in Tumors.



Yves Boucher, PhD;
Associate Prof., Radiation
Oncology

The rich fibrillar collagen content – associated with tumor desmoplasia – is a significant barrier to drug delivery in tumors. We found that the angiotensin system inhibitor (ASI) losartan produces a dose-dependent reduction in stromal collagen in several tumor models including pancreatic ductal adenocarcinoma (PDAC) in mice. Losartan also improved vascular perfusion, the distribution

and therapeutic efficacy of Doxil and small cytotoxic agents in PDAC and breast cancer models. In a recent retrospective study we found that the chronic use of ASI is independently associated with longer overall survival in non-metastatic PDAC patients. Unbiased gene expression profiling suggested that the improved survival associated with ASI therapy in PDAC patients might be due to inhibition of tumor progression and enhanced anti-tumor immunity. Based on our experimental results, we initiated a clinical trial at Massachusetts General Hospital to determine in patients with locally-advanced PDAC whether losartan improves the efficacy of the drug cocktail FOLFIRINOX. The published results of the FOLFIRINOX-losartan trial indicate that the addition of losartan is associated with a surgical resection rate of 69.4% and R0 resection of 61%. The median OS for all patients was 31.4 months.

The Targeting of Cancer Cells and Tumor Blood Vessels Improves the Spread and Efficacy of Oncolytic Virus.


Phase I/II trials have shown that the intravenous injection (i.v.) of oncolytic viruses (OV) is safe and leads to virus delivery / infections in tumor lesions. Nevertheless, the i.v. delivery of the therapeutic doses of OV remains a challenging task. The relatively large size of viral particles hinders their passage through the wall of tumor vessels, the extracellular matrix and in narrow spaces between cancer cells. We recently tested the hypothesis that the HSP90 inhibitor ganetespib – a potent inducer of apoptosis – would induce endothelial apoptosis, thus increasing the permeability of tumor vessels and the intratumoral distribution and efficacy of OV (Han, submitted). In vitro, ganetespib increased the permeability of endothelial monolayers. However, ganetespib did not induce endothelial cell apoptosis, but increased the phosphorylation of VE-cadherin, which was linked with the disruption of adherens junctions. In breast cancer models ganetespib enhanced the phosphorylation of VE-cadherin – suggesting a disorganization of endothelial adherens junctions in tumor vessels – and increased the intratumoral penetration of nanoparticles and spread of OV. Ganetespib combined with a relatively low dose of OV injected i.v. induced tumor regressions, increased overall survival and produced cures in breast cancer models.

Fibroblast and Cancer Cell Migration and Extracellular Matrix Remodeling. I developed with collaborators a new optical imaging approach to track – for the first time – the

slow *in vivo* movement of tumor-associated fibroblasts (TAFs) and collagen fiber remodeling by TAFs. Using this approach we showed in tumors that integrin $\beta 1$ is required for the close interaction between collagen fibers and TAFs. While MMPs affect cancer cells and TAF migration, the relative stiffness of the tumor matrix can also influence cancer cell migration. We demonstrated that the stiffness of collagen fibers restricts the RhoA-dependent amoeboid movement of cancer cells. In another study we found that TAFs isolated from human breast cancer samples enhance RhoA/ROCK signaling and amoeboid movement. The crosstalk between CAFs and breast cancer cells increased the secretion of insulin growth factor (IGF-1) in CAFs and plasminogen activator inhibitor-1 (PAI-1) activity in cancer cells. Interestingly, both IGF1 and PAI-1 activated RhoA signaling in cancer cells, which promoted cell scattering and invasion. In another project we explored the role of membrane-type 1 matrix metalloproteinase (MT1-MMP) in vascular invasion and metastasis. The down-regulation of MT1-MMP in cancer cells decreased the spontaneous formation of lung metastases from mammary tumors without affecting lymph-node metastasis. This occurs because MT1-MMP down-regulation decreased blood, but not lymphatic, vessel intravasation. In breast cancer biopsies, the expression of MT1-MMP in triple-negative breast cancer correlated with blood vessel invasion. Thus, MT1-MMP expression could be tested as a therapeutic target and biomarker of blood-borne metastasis in TNBC.

Selected Publications

- Perentes JY, McKee TD, Ley CD, Mathiew H, Dawson M, Padera TM, Munn LL, Jain RK, Boucher Y. In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts. *Nature Methods* 2009; 6: 143-145.
- Diop-Frimpong B, Chauhan VP, Boucher Y*, and Jain R.K.* Losartan inhibits collagen I synthesis and improves nanomedicine distribution and efficacy in tumors. *PNAS* 2011; 108: 2909-2914. *Last 2 authors contributed equally to study
- Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, Popovic Z, Huang P, Bawendi M G, Boucher Y, and Jain RK. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. *Nature Communications* 2013; 4: 2516.
- Kumar V, Boucher Y, Liu H, Ferreira D, Hooker J, Catana, C, Jain RK, Guimaraes AR. Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma. *Translational Oncol.* 2016; 9: 431-437.
- Liu, H., Naxerova, K., ... Boucher, Y.,* Jain, R. K.* Use of angiotensin system inhibitors is associated with immune activation and longer survival in non-metastatic pancreatic ductal adenocarcinoma. *Clin. Cancer Res.* 2017; 23: 5959-5969. *Last 2 authors contributed equally to study
- Daubriac J, Han S, Grahovac J, Smith E, Hosein A, Buchanan M, Basik M, Boucher Y. The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1. *Oncotarget* 2018; 9: 10375-10387.
- Murphy, J.E., Boucher, Y., Carlos Castillo, F. Hong, T.S. A phase II study of neoadjuvant FOLFIRINOX in combination with losartan followed by chemoradiotherapy in locally advanced pancreatic cancer: R0 resection rate and clinical outcomes. *JAMA Oncol.* 2019; 5: 1020-1027.



Dan G. Duda, DMD, PhD;
Associate Prof, Radiation
Oncology

New Therapy Approaches for Intractable Hepato-Biliary-Pancreatic (HBP) Malignancies and Metastatic Diseases

The research of Dr. Duda's group is focused

on studies of tumor interaction with its microenvironment, with the

goal of identifying the cellular and molecular mechanisms of: 1) local tumor progression (in liver cancers) and metastatic tumor progression (in other gastrointestinal cancers and in prostate and breast malignancies), and 2) treatment resistance in advanced cancers. The ultimate goal is to identify and validate targets for combination therapy (with radiation and immunotherapy) in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies.

This research is currently supported by grants from the US National Cancer Institute, by The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research, The Neuroendocrine Tumor Research Foundation and by partnerships with the Industry (Bayer, Bristol Myers Squibb, Exelixis, and Leap Tx).

He has authored over 220 publications so far, of which 125 are original reports, including articles in *Nature*, *Nature Genetics*, *Nature Medicine*, *Cell*, *Cancer Cell*, *Cancer Discovery*, *Science Translational Medicine*, *PNAS*, *JNCI*, and *Journal of Clinical Oncology*. He has been invited to present his results at over 200 local, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures. For his work, Dr. Duda received several awards, including from the American Association for Cancer Research, Cancer Research Institute, International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), MGH and the Granara-Skerry Trust for Pancreatic Cancer Research. He is an Honorary Member of the Academy of Medical Sciences of Romania since 2012.


Dr. Duda obtained his DMD from the University of Medicine Iasi, Romania in 1993, and earned a PhD in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001. After graduation, he pursued postdoctoral training with Professor Rakesh K. Jain in the Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School in Boston. He became a Junior Faculty member (Instructor) in 2004, and then rose through the ranks to Full Investigator at MGH Research Institute in 2016 and Associate Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School in 2012. In 2016, he was appointed as the Director of Translational Research in

Gastrointestinal Radiation Oncology at MGH. He has been active internationally and is currently serving as the Head of the Cancer Research Section (since 2013) and Secretary General (since 2015) of IASGO. He is a member of the AASLD Liver Fibrosis Special Interest Group. He has also been serving as a panel member for multiple scientific expert/grant review meetings worldwide since 2009, including as a permanent member of the US NCI DMP, ACS TBG, and Belgium FWO Med4 sections (chair).

Selected Publications

- Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC. *Hepatology* 2019; ePub on Aug 5, 2019 as doi: 10.1002/hep.30889.
- Hong TS, Grassberger C, Yeap B, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eylar C, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma hepatocyte growth factor as biomarker for susceptibility to radiation-induced liver dysfunction in liver cancer patients treated with radiotherapy. *Nature Precision Oncology* 2018; doi:10.1038/s41698-018-0065-y.
- Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Knowles M, Galway A, Afflitto A, Dinicola JF, Maurer JR, Regan E, Jain RK, Mamessier-Birnbaum E, Duda DG*, Zhu AX*. A Phase II and Biomarker Study of Sorafenib Combined with FOLFOX in in Patients with Advanced Hepatocellular Carcinoma. *Clinical Cancer Research* 2018; 25: 80-89. *Co-Senior authors.
- Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. *Sci Rep.* 2017;7:44123. PMID: PMC5343435
- Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG. Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. *Proc Natl Acad Sci USA.* 2015;112(5):1350-5. PMID: PMC4321304
- Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice. *Hepatology.* 2014;61(5):1591-602. PMID: PMC4406806
- Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG. A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed by Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. *Int J Radiat Oncol Biol Phys.* 2014;89(4):830-8. PMID: PMC4791180

Angiogenesis and Tumor Microenvironment



Dai Fukumura, MD, PhD
Associate Professor of
Radiation Oncology

I have three decades of research experience and teaching in the areas of vascular biology and tumor microenvironment (TME). To this end, I have been developing and utilizing state of the art imaging techniques and animal models which led to the discoveries summarize below.

Role of tumor-host interactions in angiogenesis, tumor growth and metastasis

Using genetically engineered mouse and tumor models as well as *in vivo* imaging techniques, we found for the first time that nontransformed stromal cells –including activated fibroblasts, bone marrow derived cells – are a major inducer of tumor angiogenesis and mediate the formation of abnormal microenvironment. Furthermore, various anti-angiogenic or molecularly targeting treatments result in the activation of host stromal cells leading to treatment resistance. We also showed that stromal cells in the primary tumor travel with tumor cells and facilitate survival and growth of metastatic tumors. Controlling tumor-host interaction is a promising approach to facilitate tumor treatment. For example, dual blockade of angiopoietin 2 and vascular endothelial growth factor signaling can normalize tumor vasculature, reprogram immune cells and prolong survival in glioblastoma.

Role of obesity in angiogenesis, tumor growth and treatments.

Obesity is world-wide pandemic causing significant health problems. We first focused on the role of angiogenesis in obesity and discovered provocative reciprocal regulation of adipogenesis and angiogenesis. We then showed that anti-VEGF therapy reduces body weight gain in diet-induced obesity model. Subsequently, we have been studying the underlying mechanisms of obesity-induced aggravation of pancreatic and breast cancers. We found IL-1 β -mediating reciprocal activation among cancer associated adipocytes, fibroblasts and myeloid cells that worsens desmoplasia, hypoxia, immunosuppression, and progression, metastasis and treatment resistance of pancreatic cancers. We also found IL-6 and bFGF mediate anti-VEGF therapy resistance in obesity in both breast cancer preclinical studies and clinical trials of breast cancer patients.

Role of NO in tumor angiogenesis, lymphangiogenesis, microcirculation and radiation therapy

Nitric oxide (NO) is a highly reactive mediator with a variety of physiological and pathological functions. NO increases and/or maintains tumor blood flow, decreases leukocyte-endothelial interactions, and increases vascular permeability. Furthermore, NO mediates angiogenesis and vessel maturation predominantly through endothelial NO synthase. We also found that NO mediates lymphangiogenesis, lymphatic function and metastasis. On the other hand, we also found that tumor cell-derived NO disrupts perivascular NO gradients resulting in abnormal

structure and function of tumor vasculature. Hence, we have been developing novel strategies for tumor vascular normalization by targeting tumor cell NO production to restore perivascular NO gradients and improve immune microenvironment and response to immunotherapy.

Probing tumor microenvironment using nanotechnology

We have been studying the tumor microenvironment and transport properties using nano-probes. We found that relatively large nanoparticles – size of current nanomedicine – can take advantage of enhanced permeability and retention effect for transvascular transport but are unable to penetrate into tumor tissues. We also found superior transvascular transport of rod-shape over spherical nanoparticles. Furthermore, we discovered that neutral charge is the best for interstitial transport. These findings led us to develop multistage nanotherapeutics that shrink upon the entry to the tumor microenvironment in order to facilitate interstitial transport.

Engineering blood vessels

A major limitation of tissue engineering is the lack of functional blood and lymph vessels. We established, for the first time, a model of tissue engineered blood vessels that generates durable functional blood vessels from endothelial cells and perivascular cell precursor cells *in vivo* which last the rest of host animal life. Using this tissue engineered blood vessel model, we further demonstrated successful generation of endothelial cells from human ES cells and cord blood and peripheral blood-derived progenitor cells, perivascular cells from human bone marrow derived mesenchymal stem cells, and functional blood vessels *from* them. Finally, we have established robust protocols deriving endothelial cells and mesenchymal precursor cells from induced pluripotent stem (iPS) cells and successfully generated blood vessels these iPS-derived cells.

Selected Publications

- Fukumura D, – Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. *Nature Reviews Clinical Oncology* 2018;15(5):325-340.
- Incio J, – Fukumura D, Jain RK. Obesity promotes resistance to anti-VEGF therapy in breast cancer by upregulating IL-6 and FGF-2. *Sci Transl Med* 2018;10. pii: eaag0945.
- Jung K, – Fukumura D. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. *JCI* 2017;127:3039-51. [Featured by *JCI Scientific Show Stopper* (<http://www.jci.org/posts/545>)]
- Rahbari NN, – Fukumura D. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. *Sci Transl Med* 2016; 8:360ra135.
- Incio J, – Fukumura D, Jain RK. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. *Cancer Discovery* 2016;6:852-69. [Featured in *Nature* 536: 157-158, 2016; *Cancer Discovery* 6: 821-823, 2016]
- Ager EI, – Fukumura D, Jain RK. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. *JNCI* 2015;107: djv017.
- Goel S, – Fukumura D, Jain RK. Tie-2 Activation by a Vascular-Endothelial Protein Tyrosine Phosphatase Inhibitor Normalizes Breast Cancer Vasculature and Delays Micrometastatic Progression. *JNCI* 2013;105:1188-1201.
- Samuel R – Fukumura D, Jain RK. Generation of functionally competent durable engineered blood vessels from human pluripotent stem cells. *PNAS* 2013;110:12774-9.

Cancer Metastasis



Igor Garkavtsev, MD,
PhD Assistant Professor,
Radiation Oncology

Our research focuses on mechanisms governing the development of brain tumors, with primary emphasis on the identification and characterization of novel tumor suppressor genes. We are particularly interested in understanding how these genes are involved in the

regulation of brain tumor angiogenesis and invasion. A detailed understanding of this regulation may lead to

the rational selection of molecular targets for anti-cancer drug development.


Gliomas are the most common primary tumors of the central nervous system, with nearly 15,000 diagnosed annually in the U.S. and a mortality approaching 80% within the first year after diagnosis. Malignant gliomas are very aggressive, highly invasive, and one of the deadliest of human cancers. Glioblastomas have been linked to the inactivation of the

Cancer Stem Cells

Tumors contain tumorigenic cancer cells, termed "tumor-initiating cells" (TICs), which are capable of both replenishing themselves and giving rise to populations of nontumorigenic cancer cells (non-TICs). The molecular mechanisms responsible for tumor initiation remain poorly understood. We found molecular mechanism that responsible for tumor initiation. We performed chemical screening strategy to identify small molecules that enhance the effect of chemotherapeutic agents on TIC-enriched breast cancer cells. We identified proteins that interact with the lead compound C108, including the stress granule-associated protein, GTPase-activating protein (SH3 domain)-binding protein 2, G3BP2. G3BP2 regulates breast tumor initiation through the stabilization of Squamous cell carcinoma antigen recognized by T cells 3 (SART3) mRNA, which leads to increased expression of the pluripotency transcription factors Octamer-binding protein 4 (Oct-4) and Nanog Homeobox (Nanog). Our findings suggest that G3BP2 is important for the process of breast cancer initiation. Furthermore, these data suggest a possible connection between stress granule formation and tumor initiation in breast cancer cells.

Selected Publications

- Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn LL, Jain RK, Garkavtsev I. Stress granule-associated protein G3BP2 regulates breast tumor initiation. *Proc Natl Acad Sci U S A*. 2017 114:1033-1038 (2017).
- Perentes et al. Cancer cell associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors. *Cancer Research* (2011) 71: 4527-4538.
- Garkavtsev et al. Dehydro- α -lapachone, a plant product with antivasular activity. *Proc Natl Acad Sci U S A* (2011) 108 (28): 11596-11601.
- Garkavtsev et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. *Nature* 2004; 428: 328-332.
- Garkavtsev et al. The candidate tumour suppressor p33 ING1 cooperates with p53 in cell growth control. *Nature* 1998; 391:295-298.
- Helbing et al. A novel candidate tumor suppressor gene, ING1, is involved in the regulation of apoptosis. *Cancer Res* 1997; 57:1255-1258.
- Garkavtsev I, Riabowol K. Extension of the replicative lifespan of human diploid fibroblasts by inhibition of the p33 ING1 candidate tumor suppressor. *Mol Cell Biol* 1997; 17:2014-2019.
- Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. Suppression of the novel growth inhibitor p33 ING1 promotes neoplastic transformation. *Nat Genet* 1996; 14:415-420.



Tumor vasculature and lymphatics imaged using doppler OCT

Spontaneous Tumors and their Isograft Models: Histopathology/Pathophysiology Studies and Applications in Experimental Cancer Therapy



Peigen Huang, MD,
MSc, ;
Assistant Professor,
Radiation Oncology

First, our research focuses on the development of spontaneous tumors in mice and on how the age, genetic background, and immune status of the mice - as well as the presence or absence of specific genes affect the histopathological characteristics of the tumors.

We study the incidence of spontaneous tumors and their pathological pattern in the natural setting of aged mice, which are kept alive for nearly their full normal life span. The animals are raised within a gnotobiotic colony

that is free of life shortening intercurrent infectious diseases. We have found a high incidence of subcutaneous sarcoma in our aging C3Hf/Sed female mice.

In our aging, retired FVB/N breeder mice, tumors are most commonly found in the lungs. The incidence of spontaneous T-cell thymic lymphomas in severe combined immunodeficient (SCID) mice is strikingly high. We have also published the first comprehensive report of spontaneous nonthymic tumors, including 8 myoepitheliomas and 3 rhabdomyosarcomas, from our SCID retired breeders. Our results show that the incidence of spontaneous tumors and their morphological changes are markedly strain dependent, and are immune status as well as age associated. We are also documenting the development, growth, and histopathological characteristics of spontaneous tumors in the GFP transgenic mice with FVB background (such as VEGF-GFP/FVB, and Tie2-GFP/FVB mice). Our goal is to test the hypotheses that (a) the insertion of GFP reporter genes affects the incidence of spontaneous tumors in aging FVB gnotobiotic mice, as well as changes their pathological patterns, and (b) spontaneous tumors developed in FVB-GFP transgenic mice exhibit different biological and molecular biological characteristics, such as different growth and metastatic potential, and different GFP expression in tumors as compared to the tumors in wild-type FVB mice.

Second, we are interested in developing novel tumor lines that are derived from the spontaneous tumors found in our laboratory. These tumor lines are used to study tumor pathophysiology in specific strains of transgenic mice derived from the same genetic background as the spontaneous tumors. One of our tumor lines, Os-P0107, is derived from a spontaneous osteosarcoma in a VEGF-GFP transgenic mouse; each of the cells in an Os-P0107 tumor expresses green fluorescent protein (GFP), which makes them easy to locate and track with intravital

microscopy. Another tumor line, LAP0297, is a lung adenocarcinoma with a high incidence of distant lung metastases. This line, which is ideal for the study of metastasis, is derived from a spontaneous lung tumor in a FVB/N mouse. For pre-clinical studies of antiangiogenesis therapy, we have used spontaneous autochthonous tumors and their isografts, implanted in aged C3Hf/Sed mice, to more accurately simulate the clinical conditions that affect many human cancer patients.

Most recently, we established and characterized two novel in vitro and in vivo tumor models (MCA-M3C and MCA-PSTC) from the spontaneous adenocarcinomas arising in MMTV-PyVT/FVB transgenic mice. MCA-M3C is a high-selected neu-positive metastatic mammary tumor line, which has been considered a very useful model for several new research projects in our laboratory. We have made significant progress in the studies of combining Losartan with radiotherapy for the treatment of MCA-M3C metastatic breast cancer, resulting significantly decreased MCA-M3C MFP-to-lung macro metastases and increased host survival.

Selected Publications

- Li W, Liu Y, Yang W, Han X, Li S, Liu H, Gerweck LE, Fukumura D, Loeffler JS, Yang BB, Jain RK, and Huang P. MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. *J Neuro-Oncol.* 2018; 136: 63-71. DOI:10.1007/s11060-017-2646-y. PMID: 29081036.
- Nia Ht, Datta M, Seano G, Huang P, Munn LL, and Jain RK. Quantifying solid stress and elastic energy from excised or in situ tumors. *Nat Protoc.* 2018; 13: 1091-1105. DOI: 10.1038/nprot.2018.020. PMID: 29674756.
- Jones D, Meijer EFJ, Blatter C, Liao S, Pereira ER, Bouta EM, Jung K, Chin SM, Huang P, Munn LL, Vakoc BJ, Otto M, and Padera TP. Methicillin-resistant *Staphylococcus aureus* causes sustained collecting lymphatic vessel dysfunction. *Sci Transl Med.* 2018 10. eaam7964. DOI: 10.1126/scitranslmed.aam7964. PMID: 29343625.
- Shen S et al.. Gut microbiota is critical to the induction of chemotherapy-induced mechanical hyperalgesia. *Nat Neurosci.* 2017; 20 (9): 1213-1216. DOI: 10.1038/nn.4606. PMID: 28714953.
- Li W, Huang P, Chen DJ, Gerweck LE. Determinates of tumor response to radiation: tumor cells, tumor stroma and permanent local control. *Radiother Oncol.* 2014; 113(1):146-9. PMID: 25284063; PMCID: PMC4280081.
- Gerweck LE, Huang P, Lu HM, Paganetti H, Zhou Y. Lifetime increased cancer risk in mice following exposure to clinical proton beam-generated neutrons. *Int J Radiat Oncol Biol Phys.* 2014; 89(1):161-6. PMID: 24725699; PMCID: PMC4298825.
- Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, Popovic Z, Huang P, Bawendi MG, Boucher Y, Jain RK. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. *Nat Commun.* 2013; 4:2516. PMID: 24084631; PMCID: PMC3806395.
- Huang P, Westmoreland SV, Jain RK, Fukumura D. Spontaneous nonthymic tumors in SCID mice. *Comp Med.* 2011; 61(3):227-34. PMID: 21819692; PMCID: PMC3123755.
- Huang P, Duda DG, Jain RK, Fukumura D. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. *Comp Med* 2008; 58(3):253-63. PMID: 18589867; PMCID: PMC2693079
- Huang P, McKee TD, Jain RK, Fukumura D. Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mouse. *Comp Med* 2005; 55(3):236-43. PMID: 16089171

Tumor Mechanobiology and Vascular Physiology



The Munn Laboratory focuses on mechanobiology of cancer and the vascular systems:

Lymphatic Pumping

Flow of fluid within the lymphatic system is central to many aspects of physiology, including fluid homeostasis and immune

function, and poor lymphatic drainage results in significant morbidity in millions of patients each year. We are investigating the mechanisms of lymphatic pumping, considering the nitric oxide and calcium dynamics driven by mechanobiological mechanisms.

Vascular Anastomosis

To form new, patent blood vessels, angiogenic sprouts must connect. The process by which this happens - anastomosis - is poorly understood, but represents new targets for vascular therapy. Using intravital microscopy and engineered vascular devices, we are following the steps of anastomosis to identify cellular and molecular mechanisms that may eventually be targeted for enhancing wound healing or inhibiting pathological angiogenesis.

Blood Vessel Remodeling

In many normal physiological responses, endothelial cells and the blood vessel networks they form undergo dramatic changes in morphology and function. Examples include angiogenesis in wound healing, vessel dilation/hyperpermeability in inflammation, and endometrial angiogenesis in the female reproductive cycle.

Endothelial cells, in cooperation with other stromal cells, have to accomplish these diverse changes by responding to a limited number of growth factors including VEGF, PIGF and bFGF. We are using a systems biology approach to understand how the various growth factors and cells cooperate to produce these seemingly diverse functions. Because tumor angiogenesis relies on many of these same growth factors and cellular mechanisms (but in an abnormal, poorly controlled way), these studies will allow a better understanding of tumor angiogenesis and anti-angiogenic therapy.

Cancer Cell Invasion

During the initial stage of metastasis, cancer cells must breach the vessel wall and enter the circulation. Despite intense research in this area, the cellular mechanisms by which this occurs are poorly understood. Some tumors seem to metastasize as single rogue cells, while others travel in groups or clusters; some seem to actively migrate into the vessel, while others may be passively pushed. Using gene array analysis and carefully designed coculture systems, we are assessing the mechanical and cellular determinants of the initiation of metastasis.

Angiogenic Sprouting

During angiogenesis, endothelial cells abandon their normal arrangement in the vessel wall to migrate into the extravascular matrix. This process is controlled by multiple signals and is necessary for tissue regeneration and tumor growth. Using in vitro models and microfluidic devices, we are investigating the biochemical and mechanical determinants of this morphogenic transformation.

Mathematical Modeling

With sufficient understanding of the underlying mechanisms, mathematical models can be assembled to validate existing hypotheses and generate new ones.

Selected Publications

- Munn LL, Jain RK. Vascular regulation of anti-tumor immunity. *Science* 365: 544-545, 2019.
- Li H, Mei Y, Maimon N, Padera TP, Baish JW, Munn LL. The effects of valve leaflet mechanics on lymphatic pumping assessed using numerical simulations. *Scientific Reports* 2019; 9(1): 10649.
- Nia HT, Liu H, Seano G, Datta M, Jones D, Rahbari N, Incio J, Chauhan VP, Jung K, Martin JD, Askoxylakis V, Padera TP, Fukumura D, Boucher Y, Hornicek FJ, Grodzinsky AJ, Baish JW, Munn LL, Jain RK. Solid stress and elastic energy: new measures of tumor mechanopathology. *Nature Biomedical Engineering*. 2017; 1:0004.
- Bazou D, Maimon N, Gruionu G, Grahovac J, Seano G, Liu H, Evans CL, Munn LL. Vascular beds maintain pancreatic tumor explants for ex vivo drug screening. *Journal of Tissue Engineering and Regenerative Medicine*. 2017; 1-5.
- Gruionu GG, Bazou D, Maimon N, Onita-Lenco M, Gruionu LG, Huang P, Munn LL. Implantable Tissue Isolation Chambers for Analyzing Tumor Dynamics In Vivo. *Lab Chip*. 2016; 16:1840-51
- Bazou D, Ng MR, Song JW, Chin SM, Maimon N, Munn LL. Flow-induced HDAC1 phosphorylation and nuclear export in angiogenic sprouting. *Scientific Reports*. 2016; 6:34046.
- Bazou D, Maimon N, Gruionu G, Munn LL. Self-assembly of vascularized tissue to support tumor explants in vitro. *Integrative Biology*. 2016; 8:1301-11.
- Song JS, Munn LL Fluid forces control endothelial sprouting *PNAS* 2011; 108(37): 15342-7.
- Cheng G, Liao S, Wong HK, Lacorre DA, di Tomaso E, Au P, Fukumura D, Jain RK, Munn LL Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis. *Blood* 2011; 118:4740-4749.
- Tse, JM, Cheng, G, Tyrrell, JA, Wilcox-Adelman, SA, Boucher, Y, Jain RK, Munn, LL. Mechanical compression drives cancer cells toward invasive phenotype *PNAS* 2011.
- Kunert C, Baish JW, Liao S, Padera TP, Munn LL. Mechanobiological oscillators control lymph flow. *Proc Natl Acad Sci USA*. 2015; 112: 10938-10943
- Kamoun WS, Chae SS, Lacorre DA, Tyrrell JA, Mitre M, Gillissen MA, Fukumura D, Jain RK, Munn LL. Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. *Nat Methods*. 2010; 7:655-60
- Dupin MM, Halliday I, Care CM, Alboul L, Munn LL. Modeling the flow of dense suspensions of deformable particles in three dimensions. *Phys Rev E Stat Nonlin Soft Matter Phys*. 2007; 75:066707
- Bockhorn M, Jain RK, Munn LL. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? *Lancet Oncol* 2007; 8:444-48.

The lymphatic system in disease processes and cancer progression

Lymphatic vessels are responsible for draining interstitial fluid from tissues and for transporting immune cells to lymph nodes to maintain the body's immune surveillance. Thus, lymphatic vessels are important in maintaining both tissue fluid balance and proper function of the immune system.

Predictably, disruptions of the lymphatic system lead to lymphedema and set the conditions for chronic infections. Lymphatic vessels also facilitate the dissemination of cancer cells from a primary tumor to regional lymph nodes. My research group looks to understand the mechanisms behind the growth, maturation and function of lymphatic vessels and how these mechanisms can contribute to the pathogenesis of lymphedema, chronic infections and cancer dissemination. Currently, there are no FDA approved drugs indicated to alter lymphatic function, which presents an important opportunity to develop such drugs for the first curative treatments for lymphedema and other lymphatic related disorders.

In order to study the role of the lymphatic system in a variety of disease states, we have developed novel animal models which mimic certain aspects of human disease. Using intravital microscopy, we have investigated the individual steps of lymphatic metastasis. We can monitor the lymphatic vessels in the tumor margin, observe tumor cells moving in lymphatic vessels, measure lymph flow and quantify the number of tumor cells that arrive in the draining lymph node. Our studies have shown that tumors lack functional intratumor lymphatic vessels due to compressive forces inside tumors that cause their collapse. Our studies have also shown that VEGF-C, which is associated with lymphatic metastasis in patients, increases the size of the tumor margin lymphatic vessels, making them more vulnerable to invasion. Our data suggests that VEGF-C needs to be blocked very early in the metastatic process to be able to reduce VEGF-C enhanced lymphatic metastasis. Furthermore, we have shown that VEGFR targeted agents are not effective in preventing the growth of cancer cells that have seeded the lymph node, questioning the ability of these therapies to be used in the adjuvant setting.

To further study the growth of metastasis in the lymph node, we have developed a novel model that allows chronic imaging of a tumor draining lymph node. Using our model, we have shown that lymph node metastases do not require sprouting angiogenesis in order to grow. Thus, we have shown that lymph node metastases do not respond to anti-angiogenic therapies, identifying one possible mechanism of the lack of efficacy of anti-angiogenic therapy in patients. We have also shown that cancer cells from lymph node metastases can invade lymph node blood vessels, escape the lymph node and colonize distant metastatic sites. Thus, lymph node metastases can be a source of distant metastases.

In addition, we have begun to study the pathogenesis of lymphedema by unraveling the molecular underpinnings of



Timothy P. Padera,
PhD Associate Prof.,
Radiation Oncology


autonomous contraction of collecting lymphatic vessels using a novel animal model. We have shown that the spatial and temporal gradients of nitric oxide, which are disrupted during inflammation, are critical for lymphatics to drive lymph forward. Furthermore, when lymphatic contractions are disrupted, the immune response to a foreign antigen is muted. Thus, disruption of lymphatic function has consequences for the overall immune function. We have also shown the *s. aureus* infections permanently impair lymphatic pumping and flow by destruction of lymphatic muscle cells. We have identified a bacterial regulatory element in *s. aureus* that controls the toxins responsible for this lymphatic muscle cell death. We are now developing drug candidates to protect lymphatic muscle cells in order to preserve lymphatic function during and after infections, which will prevent recurrent infections and lymphedema.

In order to better understand the relationship between lymphatic vessel contraction and lymph flow, we have developed the first method to measure dynamic lymph flow *in vivo* without the need for injected contrast. Our future studies will continue to dissect the physical and molecular determinants of lymphatic vessel function, lymph flow, lymphangiogenesis and lymphatic metastasis. Through the use of our novel imaging technologies and animal models, we will answer timely questions that can lead to the development of treatments for lymphedema, chronic infections and lymphatic metastasis.

Selected Publications

- E.R. Pereira, D. Kedrin, G. Seano, O. Gautier, E.F.J. Meijer, D. Jones, S.M. Chin, S. Kitahara, E.M. Bouta, J. Chang, E. Beech, H.S. Jeong, M.C. Carroll, A.G. Taghian, T.P. Padera. "Lymph node metastases can invade local blood vessels, exit the node and colonize distant organs in mice." *Science*, 2018; 359: 1403-1407.
- D Jones, EFJ Meijer, C Blatter, S Liao, ER Pereira, EM Bouta, K Jung, SM Chin, P Huang, LL Munn, BJ Vakoc, M Otto, TP Padera. "Methicillin-resistant *Staphylococcus aureus* causes sustained collecting lymphatic vessel dysfunction." *Sci. Trans. Med.* 2018; pii: eaam7964
- EFJ Meijer, HS Jeong, ER Pereira, TA Ruggieri, C Blatter, BJ Vakoc, TP Padera. "Murine chronic lymph node window for longitudinal intravital lymph node imaging." *Nature Protocols*, 2017; 12: 1513-20.
- TP Padera, EFJ Meijer, LL Munn. "The lymphatic system in disease processes and cancer progression." *Ann. Rev. in Biomed. Eng.* 2016; 18:125-58.
- Blatter C, Meijer EFJ, Nam AS, Jones D, Bouma BE, Padera TP*, Vakoc BJ*. "In vivo label-free measurement of lymph flow velocity and volumetric flow rates using Doppler optical coherence tomography." *Sci. Rep.* 2016; Jul 5;6:29035. doi: 10.1038/srep29035 .
- Jeong HS*, Jones D*, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP. "Investigation of the lack of angiogenesis in the formation of lymph node metastases." *JNCI.* 2015; 107 (9): djv155 (2015). doi: 10.1093/jnci/djv155.
- Liao S, Cheng G, Conner D, Huang Y, Kucherlapati R, Munn L, Ruddle N, Jain RK, Fukumura D, Padera TP. Impaired lymphatic contraction associated with immunosuppression. *PNAS.* 2011; 108: 18784- 18789..
- Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, Duda DG, Delaney TF, Gaissett HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH. Platelet-derived growth factor receptor-beta in Gorham's disease. *Nat Clin Pract Oncol.* 2006; 3:693-7.
- Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. *Nature.* 2004; 427:695.
- Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. Lymphatic metastasis in the absence of functional intratumor lymphatics. *Science.* 2002; 296:1883-6. Epub 2002 Apr 25.

Tumor-Host Interaction in Tumor Angiogenesis and



Lei Xu, MD, PhD
Assistant Professor,
Radiation Oncology

Metastasis

My areas of expertise are 1) the biology of tumor-host interaction, and 2) the development of novel therapeutic targets for cancer. I aim to translate this knowledge into improved therapies by conducting preclinical and clinical studies in collaboration with MGH clinicians. I'm currently leading the following projects:

Overcoming chemoresistance in human ovarian cancer

One aspect of my research interest is in the role and the molecular mechanism of miRNA in cancer metastasis and chemoresistance. Chemoresistance remains a major obstacle to successful cancer treatment. Chemoresistance may be due to increased drug efflux, dysregulated DNA repair and decreased tumor cell apoptosis. Our exciting preliminary findings show that microRNA-155 (miR-155) directly targets X-linked Inhibitor of Apoptosis Protein (XIAP) and mdr1/P-glycoprotein (P-gp). XIAP inhibits the apoptotic pathway and P-gp exports drugs and decreases their cellular accumulation, both are important mediators contributing to chemoresistance. We propose to investigate if miR-155 increases chemosensitivity via negative regulation of XIAP and P-gp, which increase chemo-induced apoptosis and decreases drug efflux.

Development of new adjunct therapies in NF2 vestibular schwannoma

Over the past few decades, radiation therapy has become a standard treatment for vestibular schwannoma. For patients with sporadic vestibular schwannomas, radiation therapy is associated with long-term tumor control rates exceeding 95%. However, hearing preservation rates after radiation therapy range from 50% to 80%. Thus, hearing loss is the main limitation of radiation therapy for vestibular schwannoma and identifying options that minimize hearing loss are urgently needed. Clinical trial of Anti-VEGF treatment in patients with NF2 vestibular schwannoma patients showed that it inhibited tumor progression and improved hearing. However, not all NF2 patients with hearing loss respond to bevacizumab monotherapy, and for the patients whose hearing improved, the response is transient. Furthermore, some patients are unable to tolerate long-term bevacizumab treatment. Based on these, we proposed to develop new adjunct therapies to radiation and bevacizumab treatment. First, we study the effect of combining radiation with VEGF inhibition for

treatment of NF2-related schwannoma. The results of this study will determine the rationale for combining anti-VEGF treatment and radiation therapy in humans and for the timing of radiation therapy relative to bevacizumab treatment. In addition, the study will provide critical information on biomarkers for the normalization window that may be used in human studies to guide dosing and assess efficacy and toxicity. In parallel, we are studying the effect of targeting the TGF-beta and HGF/cMet pathway in combination with anti-VEGF or radiation therapy in vestibular schwannoma.

Improve the tuberculosis treatment efficacy by modulating the granuloma microenvironment

Anti-VEGF treatment are widely studied and tested in the oncology field, however, whether it can be applied to infectious disease is not known. We studied granulomas lesions from human tuberculosis patients and rabbit models, we found that blood vessels in TB granulomas are very similar to tumor blood vessels in that they are collapsed and structurally abnormal, lacking pericyte coverage of the endothelial layer. This functional abnormality lead to increased hypoxia and may hinder drug delivery. Furthermore, we applied anti-VEGF treatment to rabbit TB model and are examine its effect on drug delivery and efficacy.

Mechanism of evasion from anti-angiogenic treatment

At the same time, I also study the host contribution to tumor progression. In particular, I studied NK cell, an important component of the innate immune system, recruitment and function affected by anti-angiogenic therapy. We found that anti-angiogenic therapy increased NK cell recruitment and enhanced its cytotoxic activity.

Selected Publications

- Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H.T., Zhang, Y., Stylianopoulos, T., Kumar, A.S., Mpekris, F., Datta, M., Sun, Y., Wu, L., Gao, X., Yeku, O., del Carmen, M., Spriggs, D.R., Jain, R.K., and Xu, L. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. *Proceedings of National Academy of Science USA*. (2019); 116(6): 2210-2219.
- Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. *Proceedings of National Academy of Science. USA*. 115(9): E2077-E2084. 2018
- Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L. A cerebellopontine angle mouse model for the investigation of tumour biology, hearing and neurological function in NF2-related vestibular schwannoma. *Nature Protocols*. 2019. 1, 541-555.
- Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. *Proc Natl Acad Sci U S A*. 2015;112(47):14676-81 - PMID: 26554010 - PMCID: PMC4664377

PUBLICATIONS

1991 Publications

Original Articles


1. J. Less, T. Skalak, E.M. Sevick, and R.K. Jain, Microvascular Architecture in a Mammary Carcinoma: Branching Patterns and Dimensions, *Cancer Research*, 51:265-273 (1991).
2. E. M. Sevick and R.K. Jain, Measurement of Capillary Filtration Coefficient in a Solid Tumor, *Cancer Research*, 51:1352-1355 (1991a).
3. C. Ohkubo, D. Bigos and R.K. Jain, IL-2 Induced Leukocyte Adhesion to the Normal and Tumor Microvascular Endothelium *In Vivo* and its Inhibition by Dextran Sulfate: Implications for Vascular-Leak-Syndrome, *Cancer Research*, 51:1561-1563 (1991).
4. E. M. Sevick and R.K. Jain, Effect of RBC Rigidity on Tumor Blood Flow: Increase in Viscous Resistance During Hyperglycemia, *Cancer Research*, 51:2727-2730 (1991b).
5. F. Yuan, L.T. Baxter and R.K. Jain, Pharmacokinetic Analysis of Two-step Approaches Using Bifunctional and Enzyme-conjugated Antibodies, *Cancer Research*, 51:3119-3130 (1991).
6. K.A. Ward, D.J. DiPette, T.N. Held and R.K. Jain, Effect of I.V. Versus I.P. Glucose Injection on Systemic Hemodynamics and Blood Flow Rate in Normal and Tumor Tissues in Rats, *Cancer Research*, 51:3612-3616 (1991).
7. Y. Boucher, J. Kirkwood, D. Opacic, M. Desantis and R.K. Jain, Interstitial Hypertension in Superficial Metastatic Melanomas in Humans, *Cancer Research*, 51:6691-6694 (1991).
8. H.D. Roh, Y. Boucher, S. Kalnicki, R. Buchsbaum, W.D. Bloomer and R.K. Jain, Interstitial Hypertension in Carcinoma of Uterine Cervix in Patients: Possible Correlation with Tumor Oxygenation and Radiation Response, *Cancer Research*, 51:6695-6698 (1991).
9. A. Sasaki, R.J. Melder, T.L. Whiteside, R.B. Herberman, and R.K. Jain, Preferential Localization of Human A-LAK Cells in Tumor Microcirculation: A Novel Mechanism of Adoptive Immunotherapy, *Journal of National Cancer Institute*, 83:433-437 (1991).
10. L.T. Baxter and R.K. Jain, Transport of Fluid and Macromolecules in Tumors. III. Role of Binding and Metabolism, *Microvascular Research*, 41:5-23 (1991a).
11. L.T. Baxter and R.K. Jain, Transport of Fluid and Macromolecules in Tumors. IV. A Microscopic Model of the Perivascular Distribution, *Microvascular Research*, 41:252-272 (1991b).
12. E.N. Kaufman and R.K. Jain, Measurement of Mass Transport and Reaction Parameters in Bulk Solution Using Photobleaching: Reaction Limited Binding Regime, *Biophysical Journal*, 60:596-610 (1991).

Books

13. P. Vaupel and R.K. Jain (editors), *Tumor Blood Supply and Metabolic Microenvironment: Characterization and Therapeutic Implications*, Gustav Fischer Publications, Stuttgart (1991).

Reviews, Commentaries and Book Chapters

14. R.K. Jain, Parameters Governing Tumor Blood Flow, *In: Tumor Blood Supply and Metabolic Microenvironment: Characterization and Therapeutic Implications*, P. Vaupel and R.K. Jain, Eds., Fischer Publications, Stuttgart (1991).
15. L.T. Baxter and R.K. Jain, Vascular and Interstitial Transport in Tumors, *In: Tumor Blood Supply and Metabolic Microenvironment: Characterization and Therapeutic Implications*, P. Vaupel and R.K. Jain, Eds., Fischer Publications, Stuttgart (1991).
16. E.M. Sevick and R.K. Jain, Viscous Resistance to Blood Flow in the Tumor Microcirculation: Clinical Implications, *In: Tumor Blood Supply and Metabolic Microenvironment: Characterization and Therapeutic Implications*, P. Vaupel and R.K. Jain, Eds., Fischer Publications, Stuttgart (1991).
17. K.A. Ward and R.K. Jain, Blood Flow Response to Hyperglycemia, *In: Tumor Blood Supply and Metabolic Microenvironment: Characterization and Therapeutic Implications*, P. Vaupel and R.K. Jain, Eds., Fischer Publications, Stuttgart (1991).
18. R.K. Jain, Hemodynamic and Transport Barriers to the Treatment of Solid Tumors, *International Journal of Radiation Biology*, 60:85-100 (1991).
19. R.K. Jain, Therapeutic Implications of Tumor Physiology, *Current Opinion in Oncology*, 3:1105-1108 (1991).



1992 Publications

Original Articles

20. M. Leunig, A.E. Goetz, M. Dellian, G. Zetterer, F. Gamarra, R.K. Jain and K. Messmer, Interstitial Fluid Pressure in Solid Tumors Following Hyperthermia: Possible Correlation with Therapeutic Response, *Cancer Research*, 52:487-490 (1992a).
21. R. Gutmann, M. Leunig, J. Feyh, A.E. Goetz, K. Messmer, E. Kastenbauer and R.K. Jain, Interstitial Hypertension in Head and Neck Tumors in Patients: Correlation with Tumor Size, *Cancer Research*, 52:1993-1995 (1992).
22. I. Lee, Y. Boucher, and R.K. Jain, Nicotinamide Can Lower Tumor Interstitial Fluid Pressure: Mechanistic and Therapeutic Implications, *Cancer Research*, 52:3237-3240 (1992).
23. E.N. Kaufman and R.K. Jain, Effect of Bivalent Interaction Upon Apparent Antibody Affinity: Experimental Confirmation of Theory Using Fluorescence Photobleaching and Implications for Antibody Binding Assays, *Cancer Research*, 52:4157-4167 (1992a).
24. Y. Boucher and R.K. Jain, Microvascular Pressure Is the Principal Driving Force for Interstitial Hypertension in Solid Tumors: Implications for Vascular Collapse, *Cancer Research*, 52:5110-5114 (1992).
25. L.T. Baxter, F. Yuan, and R.K. Jain, Pharmacokinetic Analysis of the Perivascular Distribution of Bifunctional Antibodies and Haptens, *Cancer Research*, 52:5838-5844 (1992).
26. C.J. Eskey, A.P. Koretsky, M.M. Domach and R.K. Jain, 2H NMR Imaging of Tumor Blood Flow: Spatial and Temporal Heterogeneity in a Tissue-isolated Mammary Adenocarcinoma, *Cancer Research*, 52:6010-6019 (1992).
27. J.R. Less, M.C. Posner, Y. Boucher, D. Borochoviz, N. Wolmark and R.K. Jain, Interstitial Hypertension in Human Breast and Colorectal Tumors, *Cancer Research*, 52:6371-6374 (1992).
28. R. J. Melder and R.K Jain, Kinetics of Interleukin - 2 Induced Changes in Rigidity of Human Natural Killer Cells, *Cell Biophysics*, 20:161-176 (1992).
29. M. Leunig, F. Yuan, M. Menger, Y. Boucher, A. Goetz, K. Messmer and R.K. Jain, Angiogenesis, Microvascular Architecture, Microhemodynamics and Interstitial Fluid Pressure During Early Growth of Human Adenocarcinoma LS174T in SCID Mice, *Cancer Research*, 52:6553-6560 (1992b).
30. E.N. Kaufman and R.K. Jain, In Vitro Measurement and Screening of Monoclonal Antibody Affinity Using Fluorescence Photobleaching, *J. Immunol. Methods*, 155:1-17 (1992b).



1993 Publications

Original Articles

31. C.J. Eskey, A.P. Koretsky, M.M. Domach and R.K. Jain, Role of Oxygen versus Glucose in Energy Metabolism in a Mammary Carcinoma Perfused Ex Vivo: Direct Measurement by 31P NMR, *Proc. Natl. Acad. Sci.*, 90:2646-2650 (1993).
32. F. Yuan, M. Leunig, D. Berk and R.K. Jain, Microvascular Permeability of Albumin, Vascular Surface Area and Vascular Volume Measured in Human Adenocarcinoma LS174T Using Dorsal Chamber in SCID Mice, *Microvascular Research*, 45:269-289 (1993).
33. R. Zlotecki, Y. Boucher, I. Lee, L.T. Baxter and R.K. Jain, Effect of Angiotensin II Induced Hypertension on Tumor Blood Flow and Interstitial Fluid Pressure, *Cancer Research*, 53:2466-2468 (1993).
34. G.R. Martin and R.K. Jain, Fluorescence Ratio Imaging of pH Gradients: Calibration and Application in Normal and Tumor Tissues, *Microvascular Research*, 46:216-230 (1993).
35. D. Berk, F. Yuan, M. Leunig and R.K. Jain, Fluorescence Photobleaching with Spatial Fourier Analysis: Measurement of Diffusion in Light-Scattering Media, *Biophysical Journal*, 65:2428-2436 (1993).
36. P.E.G. Kristjansen, Y. Boucher and R.K. Jain, Dexamethasone Reduces the Interstitial Fluid Pressure in a Human Colon Adenocarcinoma Xenograft, *Cancer Research*, 53:4764-4766 (1993).
37. R.J. Melder, A.L. Brownell, T.M. Shoup, G.L. Brownell and R.K. Jain, Imaging of Activated Natural Killer Cells in Mice by Positron Emission Tomography: Preferential Uptake in Tumors, *Cancer Research*, 53:5867-5871 (1993).

Reviews, Commentaries and Book Chapters

38. R.K. Jain and L.T. Baxter, Extravasation and Interstitial Transport in Tumors, In: *Biological Barriers to Protein Delivery*, K.L. Audus and T.J. Raub, Eds., Chapter 15, pp. 441-465, Plenum Press, New York (1993).
39. R.K. Jain, Physiological Resistance to the Treatment of Solid Tumors, In: *Drug Resistance in Oncology*, B. Teicher, Ed., Chapter 4, pp. 87-105, M. Dekker, New York (1993).
40. R.J. Melder and R.K. Jain, Delivery of Effector Cells to Tumors, In: *'93 Recent Advances in Cancer Research*, J.G. Park, Ed., pp. 202-217, Seoul National University, Seoul, (1993).

1994 Publications

Original Articles

41. I.P. Torres-Filho, M. Leunig, F. Yuan, M. Intaglietta, and R.K. Jain, Non-invasive Measurement of Microvascular and Interstitial pO₂ Profiles in a Human Tumor in SCID Mice, *Proc. Natl. Acad. Sci.*, 91:2081-2085 (1994).
42. M. Leunig, A.E. Goetz, F. Gamarra, G. Zetterer, K. Messmer and R.K. Jain, Photodynamic Therapy-induced Alterations in Interstitial Fluid Pressure, Volume and Water Content of an Amelanotic Melanoma in the Hamster, *British Journal of Cancer*, 69:101-103 (1994a).
43. L.T. Baxter, H. Zhu, D. Mackensen and R.K. Jain, Physiologically Based Pharmacokinetic Model for Specific and Nonspecific Monoclonal Antibodies and Fragments in Human Tumor Xenograft in Nude Mice, *Cancer Research*, 54:1517-1528 (1994).
44. C.J. Eskey, N. Wolmark, C.L. McDowell, M.M. Domach and R.K. Jain, Residence Time Distributions of Various Tracers in Tumors: Implications for Drug Delivery and Blood Flow Measurement, *Journal of the National Cancer Institute*, 86:293-299 (1994).
45. I. Lee, Y. Boucher, T. J. Demhartner and R.K. Jain, Changes in Tumour Blood Flow, Oxygenation and Interstitial Fluid Pressure Induced by Pentoxifylline, *British Journal of Cancer*, 69:492-496 (1994a).
46. F. Yuan, M. Leunig, S.K. Huang, D.A. Berk, D. Papahadjopoulos and R.K. Jain, Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (Stealth) Liposomes in a Human Tumor Xenograft, *Cancer Research*, 54:3352-3356 (1994a).
47. M. Leunig, F. Yuan, D. Berk, L.E. Gerweck and R.K. Jain, Angiogenesis and Growth of Isografted Bone: Quantitative In Vivo Assay in Nude Mice, *Laboratory Investigations*, 71:300-307 (1994b).
48. I. Lee, T.J. Demhartner, Y. Boucher, R.K. Jain and M. Intaglietta, Effect of Hemodilution and Resuscitation on Tumor Interstitial Fluid Pressure, Blood Flow and Oxygenation, *Microvascular Research*, 48:1-12 (1994b).
49. P.E.G. Kristjansen, S. Roberge, I. Lee and R.K. Jain, Tissue-Isolated Human Tumor Xenografts in Athymic Nude Mice, *Microvascular Research*, 48:389-402 (1994).
50. F. Yuan, H.A. Salehi, Y. Boucher, U.S. Vasthare, R.F. Tuma and R.K. Jain, Vascular Permeability and Microcirculation of Gliomas and Mammary Carcinomas Transplanted in Rat and Mouse Cranial Windows, *Cancer Research*, 54:4564-4568 (1994b).
51. A.J. Leu, D.A. Berk, F. Yuan and R.K. Jain, Flow Velocity in the Superficial Lymphatic Network of the Mouse Tail, *American Journal of Physiology*, 267:H1507-H1513 (1994).

Original Articles

52. I.P. Torres-Filho, M. Leunig, F. Yuan, M. Intaglietta, and R.K. Jain, Non-invasive Measurement of Microvascular and Interstitial pO₂ Profiles in a Human Tumor in SCID Mice, *Proc. Natl. Acad. Sci.*, 91:2081-2085 (1994).
53. M. Leunig, A.E. Goetz, F. Gamarra, G. Zetterer, K. Messmer and R.K. Jain, Photodynamic Therapy-induced Alterations in Interstitial Fluid Pressure, Volume and Water Content of an Amelanotic Melanoma in the Hamster, *British Journal of Cancer*, 69:101-103 (1994a).
54. L.T. Baxter, H. Zhu, D. Mackensen and R.K. Jain, Physiologically Based Pharmacokinetic Model for Specific and Nonspecific Monoclonal Antibodies and Fragments in Human Tumor Xenograft in Nude Mice, *Cancer Research*, 54:1517-1528 (1994).
55. C.J. Eskey, N. Wolmark, C.L. McDowell, M.M. Domach and R.K. Jain, Residence Time Distributions of Various Tracers in Tumors: Implications for Drug Delivery and Blood Flow Measurement, *Journal of the National Cancer Institute*, 86:293-299 (1994).
56. I. Lee, Y. Boucher, T. J. Demhartner and R.K. Jain, Changes in Tumour Blood Flow, Oxygenation and Interstitial Fluid Pressure Induced by Pentoxifylline, *British Journal of Cancer*, 69:492-496 (1994a).
57. F. Yuan, M. Leunig, S.K. Huang, D.A. Berk, D. Papahadjopoulos and R.K. Jain, Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (Stealth) Liposomes in a Human Tumor Xenograft, *Cancer Research*, 54:3352-3356 (1994a).
58. M. Leunig, F. Yuan, D. Berk, L.E. Gerweck and R.K. Jain, Angiogenesis and Growth of Isografted Bone: Quantitative In Vivo Assay in Nude Mice, *Laboratory Investigations*, 71:300-307 (1994b).
59. I. Lee, T.J. Demhartner, Y. Boucher, R.K. Jain and M. Intaglietta, Effect of Hemodilution and Resuscitation on Tumor Interstitial Fluid Pressure, Blood Flow and Oxygenation, *Microvascular Research*, 48:1-12 (1994b).
60. P.E.G. Kristjansen, S. Roberge, I. Lee and R.K. Jain, Tissue-Isolated Human Tumor Xenografts in Athymic Nude Mice, *Microvascular Research*, 48:389-402 (1994).
61. F. Yuan, H.A. Salehi, Y. Boucher, U.S. Vasthare, R.F. Tuma and R.K. Jain, Vascular Permeability and Microcirculation of Gliomas and Mammary Carcinomas Transplanted in Rat and Mouse Cranial Windows, *Cancer Research*, 54:4564-4568 (1994b).
62. A.J. Leu, D.A. Berk, F. Yuan and R.K. Jain, Flow Velocity in the Superficial Lymphatic Network of the Mouse Tail, *American Journal of Physiology*, 267:H1507-H1513 (1994).
63. G.R. Martin and R.K. Jain, Noninvasive Measurement of Interstitial pH Profiles in Normal and Neoplastic Tissue Using Fluorescence Ratio Imaging Microscopy, *Cancer Research*, 54:5670-5674 (1994).
64. L. Hamberg, P.E.G. Kristjansen, G.J. Hunter, G.L. Wolf and R.K. Jain, Spatial Heterogeneity in Tumor Perfusion Measured with Functional Computed Tomography at 0.05ml Resolution, *Cancer Research*, 54:6032-6036 (1994).
65. L.L. Munn, R.J. Melder and R.K. Jain, Analysis of Cell Flux in the Parallel Plate Flow Chamber: Implications for Cell Capture Studies,



1994 Publications

Biophysical Journal, 67:889-895 (1994).

66. R.J. Melder and R.K. Jain, Reduction of Rigidity in Human Activated Natural Killer Cells by Thioglycollate Treatment, *Journal of Immunological Methods*, 175:69-77 (1994).
67. R.J. Melder, D. Elmaleh, A. L. Brownell, G. L. Brownell and R.K. Jain, A Method for Labeling Cells for Positron Emission Tomography (PET) Studies, *Journal of Immunological Methods*, 175:79-87 (1994).

Reviews, Commentaries and Book Chapters

68. R.K. Jain, Transport Phenomena in Tumors, *Advances in Chemical Engineering*, 20:129-200 (1994a).
69. R.K. Jain, Tumor Microcirculation: Role in Cancer Diagnosis and Treatment, In: *Progress in Microcirculation Research*, H. Niimi, et al, Eds., pp. 29-36, Pergamon Press, Tarrytown (1994b).
70. R.K. Jain, Barriers to Drug Delivery in Solid Tumors, *Scientific American*, 271:58-65 (1994c).

1995 Publications

Original Articles

71. E.M. Johnson, D.A. Berk, R.K. Jain and W.M. Deen, Diffusion and Partitioning of Proteins in Charged Agarose Gels, *Biophysical Journal*, 68:1561-1568 (1995).
72. R.J. Melder, H.A. Salehi, and R.K. Jain, Interaction of Activated Natural Killer Cells with Normal and Tumor Vessels in Cranial Windows in Mice, *Microvascular Research*, 50:35-44 (1995a).
73. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk V.P. Torchilin and R.K. Jain, Vascular Permeability in a Human Tumor Xenograft: Molecular Size-dependence and Cut-off Size, *Cancer Research*, 55:3752-3756 (1995).
74. Y. Boucher, I. Lee and R.K. Jain, Lack of General Correlation between Interstitial Fluid Pressure and Oxygen Partial Pressure in Solid Tumors, *Microvascular Research*, 50:175-182 (1995).
75. L.L. Munn, G.C. Koenig, R.K. Jain and R.J. Melder, Kinetics of Adhesion Molecule Expression and Spatial Organization Using Targeted Sampling Fluorometry, *BioTechniques*, 19:622-631 (1995).
76. Y. Gazit, D.A. Berk, M. Leunig, L.T. Baxter and R.K. Jain, Scale-Invariant Behavior and Vascular Network Formation in Normal and Tumor Tissue, *Physical Review Letters*, 75:2428-2431 (1995).
77. L.T. Baxter, H. Zhu, D.G. Mackensen, W.F. Butler and R.K. Jain, Biodistribution of Monoclonal Antibodies: Scale-up from Mouse to Human Using a Physiologically Based Pharmacokinetic Model, *Cancer Research*, 55:4611-4622 (1995).
78. D. Fukumura, H. Salehi, B. Witwer, R.F. Tuma, R.J. Melder and R.K. Jain, TNF α -Induced Leukocyte-Adhesion in Normal and Tumor Vessels: Effect of Tumor Type, Transplantation Site and Host, *Cancer Research*, 55:4824-4829 (1995).
79. S. Yamada, T. Mayadas, F. Yuan, D. Wagner, R. Hynes, R. Melder and R.K. Jain, Rolling in P-Selectin Deficient Mice is Reduced but Not Eliminated in the Dorsal Skin, *Blood*, 86:3487-3492 (1995a).
80. R.J. Melder, L.L. Munn, S. Yamada, C. Ohkubo and R.K. Jain, Selectin and Integrin Mediated T Lymphocyte Rolling and Arrest on TNF α -activated Endothelium is Augmented by Erythrocytes, *Biophysical Journal*, 69:2131-2138 (1995b).
81. R.A. Zlotnicki, L.T. Baxter, Y. Boucher and R.K. Jain, Pharmacologic Modification of Tumor Blood Flow and Interstitial Fluid Pressure in a Human Tumor Xenograft: Network Analysis and Mechanistic Interpretation, *Microvascular Research*, 50:429-443 (1995).
82. M. Leunig, F. Yuan, L. E. Gerweck, D.A. Berk and R.K. Jain, Quantitative Analysis of Angiogenesis and Growth of Bone: Consequences of Indomethacin Exposure in a Combined In Vitro - In Vivo Approach, *Res. Exp. Medicine*, 195:275-288 (1995).
83. P.A. Netti, L.T. Baxter, Y. Boucher, R. Skalak and R.K. Jain, Time Dependent Behavior of Interstitial Pressure in Solid Tumors: Implications for Drug Delivery, *Cancer Research*, 55:5451-5458 (1995).
84. S. Yamada, R. J. Melder, M. Leunig, C. Ohkubo and R.K. Jain, Leukocyte-rolling Increases with Age, *Blood*, 86:4707-4708 (1995b).

1996 Publications

Original Articles

85. M.A. Swartz, D.A. Berk and R.K. Jain, Transport in Lymphatic Capillaries: I. Macroscopic Measurements Using Residence Time Distribution Theory, *American Journal of Physiology*, 270:H324-H329 (1996).
86. D.A. Berk, M.A. Swartz, A.J. Leu and R.K. Jain, Transport in Lymphatic Capillaries: II. Microscopic Velocity Measurement with Fluorescence Recovery After Photobleaching, *American Journal of Physiology*, 270:H330-H337 (1996).
87. P.E.G. Kristjansen, T.J. Brown, L.A. Shipley and R.K. Jain, Intratumor Pharmacokinetics, Flow Resistance, and Metabolism During Gemcitabine Infusion in Ex Vivo Perfused Human Small Cell Lung Cancer, *Clinical Cancer Research*, 2:359-367 (1996).
88. C.A. Znati, M. Rosenstein, Y. Boucher, M.W. Epperly, W.D. Bloomer and R.K. Jain, Effect of Radiation on Interstitial Fluid Pressure and Oxygenation in a Human Colon Carcinoma Xenograft, *Cancer Research*, 56:964-968 (1996).
89. L.T. Baxter and R.K. Jain, Pharmacokinetic Analysis of the Microscopic Distribution of Enzyme-conjugated Antibodies and Prodrugs: Comparison with Experimental Data, *British Journal of Cancer*, 73:447-456 (1996).
90. S. Patan, L. Munn and R.K. Jain, Intussusceptive Microvascular Growth in Solid Tumors: A Novel Mechanism of Tumor Angiogenesis, *Microvascular Research*, 51:260-272 (1996).
91. E.M. Johnson, D.A. Berk, R.K. Jain and W.M. Deen, Hindered Diffusion in Agarose Gels: Test of Effective Medium Model, *Biophysical Journal*,

1996 Publications

- 70:1017-1026 (1996a).
92. M. Leunig, F. Yuan, D.A. Berk, L. Gerweck and R.K. Jain, Heating or Freezing Bone: Effects on Angiogenesis Induction and Growth Potential in Mice, *Acta Orthop Scand.*, 67:383-388 (1996).
 93. J.W. Baish, Y. Gazit, D.A. Berk, M. Nozue, L.T. Baxter and R.K. Jain, Role of Tumor Vascular Architecture in Nutrient and Drug Delivery: An Invasion Percolation Model, *Microvascular Research*, 51:327-346 (1996).
 94. M. Dellian, B.P. Witwer, H.A. Salehi, F. Yuan and R.K. Jain, Quantitation and Physiological Characterization of bFGF and VEGF/VPF Induced Vessels in Mice: Effect of Microenvironment on Angiogenesis, *American Journal of Pathology*, 149:59-71 (1996a).
 95. L.L. Munn, R.J. Melder and R.K. Jain, Role of Erythrocytes in Leukocyte-endothelial Interactions: Mathematical Model and Experimental Validation, *Biophysical Journal*, 71:466-478 (1996).
 96. M. Nozue, I. Lee, J.M. Manning, L. R. Manning and R.K. Jain, Oxygenation in Tumors by Modified Hemoglobins, *Journal of Surgical Oncology*, 62:109-114 (1996).
 97. P.A. Netti, S. Roberge, Y. Boucher, L.T. Baxter, and R.K. Jain, Effect of Transvascular Fluid Exchange on Arterio-Venous Pressure Relationship: Implication for Temporal and Spatial Heterogeneities in Tumor Blood Flow, *Microvascular Research*, 52:27-46 (1996).
 98. C.A. Kristensen, M. Nozue, Y. Boucher and R.K. Jain, Reduction of Interstitial Fluid Pressure After TNF- α Treatment of Human Melanoma Xenografts, *British Journal of Cancer*, 74:533-536 (1996).
 99. H. Zhu, R. Melder, L. Baxter and R.K. Jain, Physiologically Based Kinetic Model of Effector Cell Biodistribution in Mammals: Implications for Adoptive Immunotherapy, *Cancer Research*, 56:3771-3781 (1996).
 100. Y. Boucher, M. Leunig and R.K. Jain, Tumor Angiogenesis and Interstitial Hypertension, *Cancer Research*, 56:4264-4266 (1996).
 101. R.J. Melder, G. Koenig, B.P. Witwer, N. Safabakhsh, L.L. Munn and R.K. Jain, During Angiogenesis, Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Regulate Natural Killer Cell Adhesion to Tumor Endothelium, *Nature Medicine*, 2:992-997 (1996).
 102. R. Skalak, S. Zargaryan, P. Netti, R.K. Jain and A. Hoger, Compatibility and the Genesis of Residual Stress by Volumetric Growth, *Journal of Mathematical Biology*, 34:889-914 (1996).
 103. M. Dellian, G. Helmlinger, F. Yuan and R.K. Jain, Fluorescence Ratio Imaging and Optical Sectioning: Effect of Glucose on Spatial and Temporal Gradients, *British Journal of Cancer*, 74:1206-1215 (1996b).
 104. M.E. Johnson, D.A. Berk, D. Blankschtein, D.E. Golan, R.K. Jain and R. Langer, Lateral Diffusion of Small Compounds in Human Stratum Corneum and Model Lipid Bilayer Systems, *Biophysical Journal*, 71:2656-2668 (1996b).
 105. F. Yuan, Y. Chen, M. Dellian, N. Safabakhsh, N. Ferrara and R.K. Jain, Time-dependent Vascular Regression and Permeability Changes in Established Human Tumor Xenografts Induced By an Anti-VEGF/VPF Antibody, *Proceedings of the National Academy of Sciences*, 93:14765-14770 (1996).
 106. H.C. Lichtenbeld, F. Yuan, C.C. Michel and R.K. Jain, Perfusion of Single Tumor Microvessels: Application to Vascular Permeability Measurement, *Microcirculation*, 3:349-357 (1996).

Reviews, Commentaries and Book Chapters

107. R.K. Jain, Delivery of Molecular Medicine to Solid Tumors, *Science*, 271:1079-1080 (1996).
108. W. M. Saltzman and R.K. Jain, Drug Delivery: Barriers to Drug Transport and the Design of Novel Therapeutic Agents, *Molecular Medicine Today*, 1:4 (1996).
109. R.K. Jain, 1995 Whitaker Lecture: Delivery of Molecules, Particles and Cells to Solid Tumors, *Annals of Biomedical Engineering*, 24:457-473 (1996).
110. R.K. Jain, G. Koenig, M. Dellian, D. Fukumura, L.L. Munn and R.J. Melder, Leukocyte-Endothelial Adhesion and Angiogenesis in Tumors, *Cancer and Metastasis Reviews*, 15:195-204 (1996).
111. R.K. Jain, Solid Tumor Barriers to Anticancer Drugs, *Cope*, 12:22-23 (1996).

1997 Publications

Original Articles

112. G. Helmlinger, F. Yuan, M. Dellian and R.K. Jain, Interstitial pH and pO₂ Gradients in Solid Tumors In Vivo: High-Resolution Measurements Reveal a Lack of Correlation, *Nature Medicine*, 3:177-182 (1997a).
113. C.A. Kristensen, S. Roberge and R.K. Jain, Effect of Tumor Necrosis Factor- α on Vascular Resistance, Nitric Oxide Production, Glucose and Oxygen Consumption in Perfused, Tissue-Isolated Human Melanoma Xenografts, *Clinical Cancer Research*, 3:319-324 (1997).
114. D. Fukumura, F. Yuan, M. Endo and R. K. Jain, Role of Nitric Oxide in Tumor Microcirculation: Blood Flow, Vascular Permeability, and Leukocyte-endothelial Interactions, *American Journal of Pathology*, 150:713-725 (1997a).
115. J. R. Less, M.C. Posner, T.C. Skalak, N. Wolmark and R.K. Jain, Geometric Resistance and Microvascular Network Architecture of Human Colorectal Carcinoma, *Microcirculation*, 4:25-33 (1997).
116. Y. Boucher, H. Salehi, B. Witwer, G.R. Harsh, IV and R.K. Jain, Interstitial Fluid Pressure in Intracranial Tumors in Patients and in Rodents, *British Journal of Cancer*, 75:829-836 (1997).
117. P.A. Netti, L.T. Baxter, Y. Boucher, R. Skalak and R.K. Jain, Macro- and Microscopic Fluid Transport in Living Tissues: Application to Solid Tumors, *AIChE Journal*, 43:818-834 (1997).
118. R.J. Melder, G. Koenig, L.L. Munn and R.K. Jain, Adhesion of Activated Natural Killer Cells to TNF- β Treated Endothelium Under Physiological Flow Conditions, *Natural Immunity*, 15:154-163 (1997).
119. H. Zhu, L. Baxter, and R.K. Jain, Potential and Limitations of Radioimmunodetection and Radioimmunotherapy with Monoclonal Antibodies:

1997 Publications

- Evaluation Using a Physiologically-Based Pharmacokinetic Model, *Journal of Nuclear Medicine*, 38:731-741 (1997).
120. D.A. Berk, F. Yuan, M. Leunig and R.K. Jain, Direct in vivo Measurement of Targeted Binding in a Human Tumor Xenograft, *Proceedings National Academy of Sciences USA*, 94:1785-1790 (1997).
 121. J.W. Baish, P.A. Netti and R.K. Jain, Transmural Coupling of Fluid Flow in Microcirculatory Network and Interstitium in Tumors, *Microvascular Research*, 53:128-141 (1997).
 122. M. Jeltsch, A. Kaipainen, V. Joukov, X. Meng, M. Lakso, H. Rauvala, M. Swartz, D. Fukumura, R.K. Jain, and K. Alitalo, Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice, *Science*, 276:1423-1425 (1997).
 123. M. Leunig, F. Yuan, L. Gerweck and R.K. Jain, Effect of bFGF on Angiogenesis and Growth of Isografted Bone: Quantitative in vitro -in vivo Analysis in Mice, *International Journal of Microcirculation*, 17:1-9 (1997).
 124. T. Shioda, L.L. Munn, R.K. Jain and K.J. Isselbacher, Early Events of Metastasis in the Microcirculation Involve Changes in Gene Expression of Cancer Cells, *American Journal of Pathology*, 150:2099-2112 (1997).
 125. G. Helmlinger, P.A. Netti, H.C. Lichtenbeld, R.J. Melder and R.K. Jain, Solid Stress Inhibits the Growth of Multicellular Tumor Spheroids, *Nature Biotechnology*, 15:778-783 (1997b).
 126. D. Fukumura, F. Yuan, W. L. Monsky, Y. Chen and R.K. Jain, Effect of Host Microenvironment on the Microcirculation of Human Colon Adenocarcinoma, *American Journal of Pathology*, 150:679-688 (1997b).
 127. G. Griffon-Etienne, Y. Boucher, R.K. Jain and H.D. Suit, Effects of Needle Insertion in Tumors on Interstitial Fluid Pressure, *Microvascular Research*, 54:174-177 (1997).
 128. M. Nozue, I. Lee, F. Yuan, B. Teicher, D. M. Brizel, M.W. Dewhirst, C. G. Milross, L. Milas, C.W. Song, C.D. Thomas, M. Guichard, S.M. Evans, C.J. Koch, E.M. Lord, R.K. Jain and H.D. Suit, Interlaboratory Variation in Oxygen Tension Measurement by Eppendorf Histogram and Comparison With Hypoxic Marker, *Journal of Surgical Oncology*, 66:30-38 (1997a).
 129. Y. Gazit, J.W. Baish, N. Safabakhsh, M. Leunig, L.T. Baxter and R.K. Jain, Fractal Characteristics of Tumor Vascular Architecture During Tumor Growth and Regression, *Microcirculation*, 4:395-402 (1997).
 130. M. Nozue, I. Lee, A. Hartford, S. Tanda, H.D. Suit and R.K. Jain, pO₂ Measurements in Murine Tumors Using Eppendorf Histogram: Calibration, Reproducibility and Comparison with Diamond-General Device, *International Journal of Oncology*, 9:955-962 (1997b).

Reviews, Commentaries and Book Chapters

131. R.K. Jain, 1996 Landis Award Lecture: Delivery of Molecular and Cellular Medicine to Solid Tumors, *Microcirculation*, 4:1-23 (1997).
132. D.M. Briscoe, P. Ganz, S.I. Alexander, R.J. Melder, R.K. Jain, R.S. Cotran and A.H. Lichtman, The Problem of Chronic Rejection: Influence of Leukocyte-Endothelial Interactions, *Kidney International*, 51:S-22-S-27 (1997).
133. R.K. Jain, Vascular and Interstitial Physiology of Tumours: Role in Cancer Detection and Treatment, In: *Tumor Angiogenesis*, R. Bicknell, C. Lewis and N. Ferrara, Eds., Oxford University Press, Oxford, pp. 45-59 (1997).
134. R.K. Jain, Delivery of Molecular and Cellular Medicine to Solid Tumors, *Advanced Drug Delivery Reviews*, 26:71-90 (1997).
135. R.K. Jain, K. Schlenger, M. Höckel and F. Yuan, Quantitative Angiogenesis Assays: Progress and Problems, *Nature Medicine*, 3:1203-1208 (1997).
136. R.K. Jain, Delivery of Molecular Medicine to Solid Tumors, In: *Microcirculation Annual 1997*, M. Tsuchiya, M. Asano and N. Sato, Eds., Nihon-Igakukan, Tokyo, 13:1-5 (1997).
137. R.K. Jain, Tumor Microcirculation: Role in Drug and Nutrient Delivery, In: *Advances in Blood Substitutes*, Eds., R.M. Winslow, K. D. Vandegriff, and M. Intaglietta, Birkhäuser, Boston, pp. 46-70 (1997).

1998 Publications

Original Articles

138. H. Zhu, R.K. Jain and L.T. Baxter, Tumor Pretargeting for Radioimmunodetection and Radioimmunotherapy: Evaluation Using a Physiologically-Based Pharmacokinetic Model, *Journal of Nuclear Medicine*, 39:65-76 (1998).
139. S. Hobbs, W. Monsky, F. Yuan, G. Roberts, L. Griffiths, V.P. Torchilin and R.K. Jain, Regulation of Transport Pathways in Tumor Vessels: Role of Tumor Type and Microenvironment, *Proceedings National Academy of Sciences USA*, 95:4607-4612 (1998).
140. G.J. Hunter, L.M. Hamberg, N. Choi, R.K. Jain, T. McCloud and A.J. Fischman, Dynamic T1-weighted Magnetic Resonance Imaging and Positron Emission Tomography in Patients with Lung Cancer: Correlating Vascular Physiology with Glucose Metabolism, *Clinical Cancer Research*, 4:949-955 (1998).
141. M. Rosenzweig, M. DeMaria, D. Harper, S. Friedrich, R.K. Jain and R. P. Johnson, Increased Rates of CD4⁺ and CD8⁺ T Lymphocyte Turnover in Simian Immunodeficiency Virus-infected Macaques, *Proceedings National Academy of Sciences USA*, 95:6388-6393 (1998).
142. U. Schoepf, E.M. Marecos, R.J. Melder, R.K. Jain and R. Weissleder, Intracellular Magnetic Labeling of Lymphocytes for in vivo Trafficking Studies, *Biotechniques*, 24:642-651 (1998).
143. M. Detmar, L.F. Brown, M.P. Schön, B.M. Elicker, L. Richard, P. Velasco, D. Fukumura, W. Monsky, K.P. Claffey and R.K. Jain, Increased Microvascular Density and Enhanced Leukocyte Rolling and Adhesion in the Skin of VEGF Transgenic Mice, *Journal of Investigative Dermatology*, 3:1-6 (1998).
144. P. Carmeliet, Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C.J. Koch, P. Ratcliffe, L. Moons, R.K. Jain, D. Collen and Eli Keshet, Role of HIF-1 α Hypoxia-mediated Apoptosis, Cell Proliferation and Tumor Angiogenesis, *Nature*, 394:485-490 (1998).

1998 Publications

145. D. Fukumura, R. Xavier, T. Sugiyama, Y. Chen, E.C. Parks, N. Lu, M. Selig, G. Nielsen, T. Taksir, R.K. Jain and B. Seed, Tumor Induction of VEGF Promoter Activity in Stromal Cells, *Cell*, 94:715-725 (1998).
146. R.K. Jain, N. Safabakhsh, A. Sckell, Y. Chen, L.A. Benjamin, F. Yuan and E. Keshet, Endothelial Cell Death, Angiogenesis, and Microvascular Function Following Castration in an Androgen-dependent Tumor: Role of VEGF, *Proceedings of the National Academy of Sciences USA*, 95:10820-10825 (1998a).
147. D.S. Milstone, D. Fukumura, R.C. Padgett, P.E. O'Donnell, V.M. Davis, O.J. Benavidez, R.J. Melder, R.K. Jain and M.A. Gimbrone, Mice Lacking E-Selectin Show Normal Rolling But Reduced Arrest of Leukocytes on Cytokine-Activated Microvascular Endothelium, *Microcirculation*, 5:153-171 (1998).
148. Y. Boucher, C. Brekken, P.A. Netti, L.T. Baxter and R.K. Jain, Intratumoral Infusion of Fluid: Estimation of Hydraulic Conductivity and Implications for the Delivery of Therapeutic Agents, *British Journal of Cancer*, 78:1442-1448 (1998).
149. A. Sckell, N. Safabakhsh, M. Dellian and R.K. Jain, Primary Tumor Size-Dependent Inhibition of Angiogenesis at a Secondary Site: An Intravital Microscopic Study in Mice, *Cancer Research*, 58:5866-5869 (1998).
150. Review, Commentaries and Book Chapters
151. R.K. Jain, The Next Frontier of Molecular Medicine: Delivery of Therapeutics, *Nature Medicine*, 4:655-657 (1998a).
152. R.K. Jain, Integrative Pathophysiology of Solid Tumors: Role in Detection and Treatment, *The Cancer Journal from Scientific American*, 4:48-57 (1998b).
153. R.K. Jain, Delivery of Molecular and Cellular Medicine to Solid Tumors, *Journal of Controlled Release*, 53:49-67 (1998).
154. D. Fukumura and R.K. Jain, Role of Nitric Oxide in Angiogenesis and Microcirculation in Tumors, *Cancer and Metastasis Reviews*, 17:77-89 (1998).
155. J.W. Baish and R.K. Jain, Cancer, Angiogenesis and Fractals, *Nature Medicine*, 4:984 (1998).
156. R.K. Jain, Tumor Microcirculation: Role in Delivery of Molecular and Cellular Medicine, In: *The Biology of Tumors*, Proceedings of the Ninth Annual Pezcoller Symposium on the Biology of Tumors, Rovereto, Italy, June 4-7, 1997, 319-345 (1998).
157. R.K. Jain, Delivery of Monoclonal Antibodies to the Tumor Cell, In: *Monoclonal Antibody-Based Therapy of Cancer*, M.L. Grossbard, Ed., Marcel Dekker, Inc., New York, pp. 23-52 (1998).
158. R.K. Jain, Microcirculation and Transport Phenomena in Tumours, In: *Connective Tissue Biology: Integration and Reductionism*. R.K. Reed and K. Rubin Eds., Portland Press Ltd., London, 71:269-293 (1998).
159. R.K. Jain, L.L. Munn, D. Fukumura and R.J. Melder, In vitro and In vivo Quantification of Adhesion Between Leukocytes and Vascular Endothelium, In: *Methods in Molecular Medicine - Methods in Tissue Engineering*, J.R. Morgan and M.L. Yarmush, Eds., Humana Press, Totowa, pp. 553-575 (1998b).

1999 Publications

Original Articles

160. P.A. Netti, L.M. Hamberg, J.W. Babich, S. Roberge, D. Kierstead, W. Graham, G.J. Hunter, G.L. Wolf, A. Fischman, Y. Boucher and R.K. Jain, Enhancement of Fluid Filtration Across Tumor Vessels: Implication for Delivery of Macromolecules, *Proceedings of the National Academy of Sciences USA*, 96:3137-3142 (1999).
161. C.A. Kristensen, N. Askenasy, R.K. Jain and A.P. Koretsky, Creatine and Cyclocreatine Treatment of Human Colon Adenocarcinoma Xenografts: 31P and 1H Magnetic Resonance Spectroscopic Studies, *British Journal of Cancer*, 79:278-285 (1999a).
162. S.A. Slavin, A.D. van den Abbeele, A. Losken, M. Swartz and R.K. Jain, Return of Lymphatic Function Following Flap Transfer for Acute Lymphedema, *Annals of Surgery*, 229:421-427 (1999).
163. H.C. Lichtenbeld, N. Ferrara, R.K. Jain and L. L. Munn, Effect of Anti-VEGF Antibody on Tumor Microvessel Permeability, *Microvascular Research*, 57:357-362 (1999).
164. A. Pluen, P.A. Netti, R.K. Jain and D.A. Berk, Diffusion of Macromolecules in Agarose Gels: Comparison of Linear and Globular Configurations, *Biophysical Journal*, 77:542-552 (1999).
165. G. Griffon-Etienne, Y. Boucher, C. Brekken, H.D. Suit and R.K. Jain, Taxane-Induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications, *Cancer Research*, 59:3776-3782 (1999).
166. W.L. Monsky, D. Fukumura, T. Gohongi, M. Ancukiewicz, H.A. Weich, V.P. Torchilin, F. Yuan and R.K. Jain, Augmentation of Transvascular Transport of Macromolecules and Nanoparticles in Tumors Using Vascular Endothelial Growth Factor, *Cancer Research*, 59:4129-4135 (1999).
167. M. Heijn, S. Roberge and R.K. Jain, Cellular Membrane Permeability of Anthracyclines Does Not Affect Their Delivery in a Tissue Isolated Tumor, *Cancer Research*, 59:4458-4463 (1999).
168. M. Endo, R.K. Jain, B. Witwer and D. Brown, Water Channel (Aquaporin 1) Expression and Distribution in Mammary Carcinomas and Glioblastomas, *Microvascular Research*, 58:89-98 (1999).
169. M.A. Swartz, A. Kaipainen, P. Netti, C. Brekken, Y. Boucher, A.J. Grodzinsky and R.K. Jain, Mechanics of Interstitial-Lymphatic Fluid Transport: Theoretical Foundation and Experimental Validation, *Journal of Biomechanics*, 32: 1297-1303 (1999a).
170. M.A. Swartz, C.A. Kristensen, R.J. Melder, S. Roberge, E. Calautti, D. Fukumura, and R.K. Jain, Cells Shed from Tumors Show Reduced Clonogenicity, Resistance to Apoptosis, and in vivo Tumorigenicity, *British Journal of Cancer*, 81:756-759 (1999b).
171. K.S. Moulton, R.J. Melder, V. Dharnidharka, J. Hardin-Young, R.K. Jain, and D.M. Briscoe, Angiogenesis in the huPBL-SCID Model of Human Transplant Rejection, *Transplantation*, 67:1626-1631 (1999).
172. T. Gohongi, D. Fukumura, Y. Boucher, C. Yun, G.A. Soff, C. Compton, T. Todoroki and R.K. Jain, Tumor-host Interactions in the

1999 Publications

- Gallbladder Suppress Distal Angiogenesis and Tumor Growth: Role of TGF β , *Nature Medicine*, 5:1203-1208 (1999).
173. C. A. Kristensen, L. M. Hamberg, G. J. Hunter, S. Roberge, D. Kierstead, G. L. Wolf and R.K. Jain, Changes in Vascularization of Human Breast Cancer Xenografts Responding to Estrogen Withdrawal and Tamoxifen Therapy, *Neoplasia*, 1:518-525 (1999b).
174. P. Somasundaran, S. Simpson, I. Ivanov, R.K. Jain, and D. Sarkar, Thinning and Rupture of Aqueous Surfactant Films on Silica, *Langmuir*, 15:7658-7661 (1999).

Reviews, Commentaries and Book Chapters

175. R.K. Jain, Understanding Barriers to Drug Delivery: High Resolution In vivo Imaging is Key, *Clinical Cancer Research*, 5:1605-1606 (1999).
176. R.K. Jain, Transport of Molecules, Particles, and Cells in Solid Tumors, *Annual Reviews of Biomedical Engineering*, 1:241-263 (1999).

2000 Publications

Original Articles

177. S. Ramanujan, G.C. Koenig, T.P. Padera, B.R. Stoll and R.K. Jain, Local Imbalance of ProAngiogenic and AntiAngiogenic Factors: A Potential Mechanism of Focal Necrosis and Dormancy in Tumors, *Cancer Research*, 60:1442-1448 (2000).
178. R.J. Melder, J. Yuan, L.L. Munn, R.K. Jain, Erythrocytes Enhance Lymphocyte Rolling and Arrest in Vivo, *Microvascular Research*, 59: 316-322 (2000).
179. Y.S. Chang, L.L. Munn, M.V. Hillsley, R. O. Dull, T.W. Gardner, R.K. Jain and J.M. Tarbell, Effect of Vascular Endothelial Growth Factor on Cultured Endothelial Cell Monolayer Transport Properties, *Microvascular Research*, 59:265-277 (2000).
180. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain and D.M. McDonald, Openings Between Defective Endothelial Cells Contribute to Tumor Vessel Leakiness, *American Journal of Pathology*, 156:1363-1380 (2000).
181. M. Dellian, F. Yuan, V.S. Trubetsky, V.P. Torchilin and R.K. Jain, Vascular Permeability in a Human Tumor Xenograft: Molecular Charge Dependence, *British Journal of Cancer*, 82:1513-1518 (2000).
182. A.C. Hartford, T. Gohongi, D. Fukumura and R.K. Jain, Irradiation of a Primary Tumor, Unlike Surgical Removal, Enhances Angiogenesis Suppression at a Distal Site: Potential Role of Host-Tumor Interaction, *Cancer Research*, 60:2128-2131 (2000).
183. P.A. Netti, D.A. Berk, M.A. Swartz, A.J. Grodzinsky and R.K. Jain, Role of Extracellular Matrix Assembly in Interstitial Transport in Solid Tumors, *Cancer Research*, 60:2497-2503 (2000).
184. G. Helmlinger, M. Endo, N. Ferrara, L. Hlatky and R.K. Jain, Formation of Endothelial Cell Networks, *Nature*, 405:139-141 (2000).
185. A. Kaur, C.L. Hale, S. Ramanujan, R.K. Jain and R.P. Johnson, Differential Dynamics of CD4+ and CD8+ T Lymphocyte Proliferation and Activation in acute Simian Immunodeficiency Virus Infection, *Journal of Virology*, 74:8413-8424 (2000).
186. M. Stohrer, Y. Boucher, M. Stangassinger and R.K. Jain, Oncotic Pressure in Solid Tumors is Elevated, *Cancer Research*, 60:4251-4255 (2000).
187. A.J. Leu, D.A. Berk, A. Lymboussaki, K. Alitalo and R.K. Jain, Absence of Functional Lymphatics within a Murine Sarcoma: a Molecular and Functional Evaluation, *Cancer Research*, 60:4324-4327 (2000).
188. N. Hansen-Algenstaedt, B.R. Stoll, T.P. Padera, D.J. Hicklin, D. Fukumura and R.K. Jain, Tumor Oxygenation in Hormone-Dependent Tumors during VEGFR-2 Blockade, Hormone Ablation, and Chemotherapy, *Cancer Research*, 60:4556-4560 (2000).
189. P. Somasundaran, S. Simpson, R.K. Jain, I. Ivanov, V. Raghuraman, Investigation of Thin Aqueous Films on Silica Using a Modified Interferometric Technique, *Journal of Colloid and Interface Science*, 225:243-246 (2000).
190. C.G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K.R. Park, N. Ferrara, R.K. Jain, H.D. Suit and Y. Boucher, Anti-VEGF Treatment Augments Tumor Radiation Response Under Normoxic or Hypoxic Conditions, *Cancer Research*, 60:5565-5570, (2000).
191. Y. Tsuzuki, D. Fukumura, B. Oosthuysen, C. Koike, P. Carmeliet and R.K. Jain. VEGF Modulation by Targeting HIF-1 α →HRE→ VEGF Cascade Differentially Regulates Vascular Response and Growth Rate in Tumors, *Cancer Research*, 60:6248-6252, (2000).
192. Y.S. Chang, E. di Tomaso, D.M. McDonald, R. Jones, R.K. Jain and L.L. Munn. Mosaic Blood Vessels in Tumors: Frequency of Cancer Cells in Contact with Flowing Blood, *Proceedings of the National Academy of Sciences USA*, 97:14608-14613 (2000).

Reviews

193. R.K. Jain and L.L. Munn Leaky vessels? Call Ang! *Nature Medicine*, 6:131-32 (2000).
194. D.M. McDonald, L. Munn and R.K. Jain, Vasculogenic Mimicry: How Convincing, How Novel, and How Significant?, *American Journal of Pathology*, 156: 383-388 (2000).
195. R.K. Jain, Delivery of Biologic Molecules and Cells to Tumors, In: *Biologic Therapy of Cancer: Principles and Practice*, S. Rosenberg, Ed., Lippincott, Williams and Watkins, Philadelphia, pp. 865-874 (2000).
196. J.W. Baish and R.K. Jain, Fractals and Cancer, *Cancer Research*, 60:3683-88 (2000).
197. P. Carmeliet and R.K. Jain, Angiogenesis in Cancer and Other Diseases, *Nature*, 407:249-257 (2000).

2001 Publications

Original Articles

198. D. Fukumura, T. Gohongi, A. Kadambi, J. Ang, C. Yun, D.G. Buerk, P.L. Huang and R.K. Jain, Predominant Role of Endothelial Nitric Oxide Synthase in VEGF-induced Angiogenesis and Vascular Permeability, *PNAS*, 98:2604-2609 (2001).
199. Pluen, Y. Boucher, S. Ramanujan, T.D. McKee, T. Gohongi, E. di Tomaso, E.B. Brown, Y. Izumi, R.B. Campbell, D.A. Berk, and R.K. Jain, Role of Tumor-Host Interactions in Interstitial Diffusion of Macromolecules: Cranial vs. subcutaneous tumors, *PNAS*, 98:4628-4633 (2001).
200. J. Yuan, R.J. Melder, R.K. Jain and L.L. Munn, A Lateral View Flow System for Studies of Cell Adhesion and Deformation under Flow Conditions, *Biotechniques*, 30:388-394 (2001).
201. S.V. Kozin, Y. Boucher, D.J. Hicklin, P. Bohlen, R.K. Jain and H.D. Suit., VEGF Receptor-2 Blocking Antibody Potentiates Radiation-Induced Long Term Control of Human Tumor Xenografts, *Cancer Research*, 61:39-44 (2001).
202. A. Kadambi, C.M. Carreira, C.-O. Yun, T.P. Padera, D.E.J.G.J. Dolmans, P. Carmeliet, D. Fukumura and R.K. Jain. Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment: Role of VEGF-Receptor 2 and Host VEGF-A, *Cancer Research*, 61:2404-2408 (2001).
203. R.O. Dull, J. Yuan, Y.S. Chang, J. Tarbell, R.K. Jain, and L.L. Munn, Kinetics of Placenta Growth Factor/Vascular Endothelial Growth Factor Synergy in Endothelial Hydraulic Conductivity and Proliferation, *Microvascular Research*, 61:203-210 (2001).
204. R.J. Melder, C.A. Kristensen, L.L. Munn, and R.K. Jain, Modulation of A-NK Cell Rigidity: In Vitro Characterization and In Vivo Implications for Cell Delivery, *Biorheology*, 38:151-159 (2001).
205. E.B. Brown, R.B. Campbell, Y. Tsuzuki, L. Xu, P. Carmeliet, D. Fukumura, and R.K. Jain, In vivo Measurement of Gene Expression, Angiogenesis and Physiological Function in Tumors Using Multiphoton Laser Scanning Microscopy, *Nature Medicine*, 7:864-868 (2001).
206. C.L. Davies, R.J. Melder, L.L. Munn, C. Mouta-Carreira, R.K. Jain, and Y. Boucher, Decorin Inhibits Endothelial Migration and Tube-Like Structure Formation: Role of Thrombospondin-1, *Microvascular Research*, 62:26-42 (2001).
207. Losken, M.A. Swartz, A.D. Van Den Abbeele, R.K. Jain, and S.A. Slavin, A Potential Murine Model for Flap-Related Investigations, *Plastic Reconstruction Surgery*, 107:1504-1508 (2001).
208. D. Fukumura, L. Xu, Y. Chen, T. Gohongi, B. Seed, and R.K. Jain, Hypoxia and Acidosis Independently Up-Regulate VEGF Transcription in Brain Tumors In Vivo, *Cancer Research*, 61:6020-6024 (2001).
209. S. Patan, L.L. Munn, S. Tanda, S. Roberge, R.K. Jain, and R.C. Jones, Vascular Morphogenesis and Remodeling in a Model of Tissue Repair: Blood Vessel Formation and Growth in the Ovarian Pedicle after Ovariectomy, *Circulation Research* 89::23-731 (2001).
210. S. Patan, S. Tanda, S. Roberge, R.C. Jones, R.K. Jain and L.L. Munn, Vascular Morphogenesis and Remodeling in a Model of Tissue Repair: Blood Vessel Formation and Growth after Ovariectomy and Tumor Implantation, *Circulation Research* 89:732-739 (2001).
211. Y. Tsuzuki, C.M. Carreira, M. Bockhorn, L. Xu, R.K. Jain, D. Fukumura, Pancreas Microenvironment Promotes VEGF Expression And Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis And Microcirculation, *Lab Investigations* 81:1439-1451 (2001).
212. C. Mouta Carreira, S.M. Nasser, E. diTomaso, T.P. Padera, Y. Boucher, S.I. Tomarev, and R.K. Jain, LYVE-1 is not Restricted to the Lymph Vessels: Expression in Normal Liver Blood Sinusoids and Down-regulation in Human Liver Cancer and Cirrhosis, *Cancer Research*, 61:8079-8084 (2001).

Reviews, Commentaries and Book Chapters

213. R.K. Jain, Clearing the Smoke on Nicotine and Angiogenesis, *Nature Medicine*, 7:775-777 (2001).
214. R.K. Jain. Delivery of Molecular and Cellular Medicine to Solid Tumors, *Adv Drug Deliv Rev*, 46:149-168 (2001).
215. R.K. Jain, L.L. Munn, and D. Fukumura, Transparent Window Models and Intravital Microscopy: Imaging Gene Expression, Physiological Function and Drug Delivery in Tumors, In: *Tumor Models in Cancer Research*, B. Teicher, Ed., Humana Press, Inc., Totowa, NJ, Chapter 34:647-672 (2001).
216. R.K. Jain, Delivery of Molecular Medicine to Solid Tumors: Lessons from In Vivo Imaging of Gene Expression and Function, *J Controlled Release*, 74:7-25 (2001).
217. R.K. Jain, Normalizing Tumor Vasculature with Anti-Angiogenic Therapy: A New Paradigm for Combination Therapy, *Nature Medicine*, 7:987-989 (2001).
218. J.W. Baish and R.K. Jain, Correspondence Regarding Fractals and Cancer, *Cancer Research* 61:8348-8350, (2001).
219. R.K. Jain, In Memoriam: Pietro M. Gullino (1919-2001) *Cancer Research*, 61:930-931 (2001).
220. R.K. Jain and N. Forbes, Can Engineered Bacteria Help Control Cancer?, *PNAS*, 98:14748-14750 (2001).
221. R.K. Jain and P. Carmeliet, Vessels of Death or Life, *Scientific American*, 258:38-45 (2001).



2002 Publications

222. T.P. Padera, B.R. Stoll, P.T.C. So, and R.K. Jain, Conventional and High-Speed Intravital Multiphoton Laser Scanning Microscopy of Microvasculature, Lymphatics, and Leukocyte-Endothelial Interactions, *Molecular Imaging*, 1:9-15 (2002).
223. L. Xu, D. Fukumura, R.K. Jain, Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway. Mechanism of low pH induced VEGF. *J Biol Chem.*, 277:11368-11374 (2002).
224. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, and R.K. Jain, Herceptin Acts as an Anti-angiogenic Cocktail, *Nature*, 416:279-280 (2002).
225. D.E.J.G.J. Dolmans, A. Kadambi, J.S. Hill, C.A. Waters, B.C. Robinson, J.P. Walker, D. Fukumura, and R.K. Jain, Vascular Accumulation of a Novel Photosensitizer, MV6401, Causes Selective Thrombosis in Tumor Vessels following Photodynamic Therapy, *Cancer Research*, 62:2151-2156 (2002).
226. W.L. Monsky, C. Mouta Carreira, Y. Tsuzuki, T. Gohongi, D. Fukumura, and R.K. Jain, Role of Host Microenvironment in Angiogenesis and Microvascular Functions in Human Breast Cancer Xenografts: Mammary Fat Pad vs. Cranial Tumors, *Clinical Cancer Research*, 8:1008-1013 (2002).
227. G. Helmlinger, A. Sckell, M. Dellian, N.S. Forbes, and R.K. Jain, Acid Production in Glycolysis-Impaired Tumors Provides New Insights into Tumor Metabolism, *Clinical Cancer Research*, 8:1284-1291 (2002).
228. S. Morikawa, Peter Baluk, T. Kaidoh, A. Haskell, R.K. Jain, and D.M. McDonald, Abnormalities In Pericytes on Blood Vessels and Endothelial Sprouts In Tumors, *American Journal of Pathology*, 160:985-1000 (2002).
229. R.J. Melder, L.L. Munn, B.R. Stoll, E.M. Marecos, L.T. Baxter, R. Weissleder, and R.K. Jain, Systemic Distribution And Tumor Localization Of Adoptively Transferred Lymphocytes In Mice: Comparison With Physiologically Based Pharmacokinetic Model, *Neoplasia*, 4:3-8 (2002).
230. T.P. Padera, A. Kadambi, E. di Tomaso, C. Mouta Carreira, E.B. Brown, Y. Boucher, N.C. Choi, D. Mathisen, J. Wain, E.J. Mark, L.L. Munn, R.K. Jain, Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics, *Science*, 296:1883-1886 (2002).
231. C. Koike, T.D. McKee, A. Pluen, S. Ramanujan, K. Burton, L.L. Munn, Y. Boucher, and R.K. Jain, Solid Stress Facilitates Spheroid Formation: Potential Involvement of Hyaluronan, *BJC*, 86:947-953 (2002).
232. C. de L. Davies, D.A. Berk, A. Pluen, and R.K. Jain, Comparison of IgG Diffusion and Extracellular Matrix Composition in Rhabdomyosarcomas Grown in Mice Versus In Vitro as Spheroids Reveals the Role of Host Stromal Cells, *BJC*, 86:1639-1644 (2002).
233. D.E.J.G.J. Dolmans, A. Kadambi, J.S. Hill, K. Flores, J. Gerber, J.P. Walker, I.H.M. Borel Rinkes, R.K. Jain, D. Fukumura, Targeting Tumor Vasculature and Cancer Cells in Orthotopic Breast Tumor by Fractionated Photosensitizer Dosing Photodynamic Therapy, *Cancer Research*, 62:4289-4294 (2002).
234. S. Ramanujan, A. Pluen, R.D. McKee, E.B. Brown, Y. Boucher, R.K. Jain, Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium, *Biophysical Journal*, 83:1650-1660 (2002).
235. S.W. Friedrich, S.C. Lin, B.R. Stoll, L.T. Baxter, L.L. Munn and R.K. Jain, Antibody Directed Effector Cell Therapy of Tumors: Analysis and Optimization Using a Physiologically Based Pharmacokinetic Model, *Neoplasia*, 4:449-463 (2002).
236. C. Migliorini, Y.H. Qian, H. Chen, E.B. Brown, R.K. Jain and L.L. Munn, Red Blood Cells Augment Leukocyte Rolling in a Virtual Blood Vessel, *Biophysical Journal*, 83:1834-1841 (2002).
237. R.B. Campbell, D. Fukumura, E.B. Brown, L.M. Mazzola, Y. Izumi, R.K. Jain, V.P. Torchilin, and L.L. Munn, Cationic Charge Determines the Distribution of Liposomes between the Vascular and Extravascular Compartments of Tumors, *Cancer Research*, 62:6831-6836(2002).



Reviews

238. R.K. Jain, L.L. Munn, and D. Fukumura, Dissecting Tumor Pathophysiology using Intravital Microscopy, *Nature Reviews Cancer*, 2:266-276 (2002).
239. R.K. Jain and B.T. Fenton, Intratumoral Lymphatic Vessels: A Case of Mistaken Identity or Malfunction? *JNCI*, 94:417-421 (2002).
240. R.K. Jain and T.P. Padera, Prevention and Treatment of Lymphatic Metastasis by Anti-Lymphangiogenic Therapy, *JNCI*, 94:785-787 (2002).
241. R.K. Jain, Tumor Angiogenesis and Accessibility: Role of Vascular Endothelial Growth Factor, *Seminars in Oncology*, 29:3-9 (2002).
242. R.K. Jain, Angiogenesis and Lymphangiogenesis in Tumors: Insights from Intravital Microscopy, *Cold Spring Harbor Symposia on Quantitative Biology*, 67:239-248 (2002).

2003 Publications

Original Articles

243. H. Schmidt, EB. Brown, B. Schwaller and J. Eilers, Diffusional mobility of parvalbumin in spiny dendrites of cerebellar purkinje neurons quantified by fluorescence recovery after photobleaching. *Biophys. J.*, 84:2599-2608, (2003).
244. Y. Izumi, E. di Tomaso, A. Hooper, P. Huang, J. Huber, DJ Hicklin, D Fukumura, R.K. Jain and H.D. Suit, Responses to Anti-Angiogenesis Treatment of Spontaneous Autochthonous Tumors and Their Isografts, *Cancer Research*, 63:747-751 (2003).
245. F. Mollica, R.K. Jain and P.A. Netti, A Model for Temporal Heterogeneities of Tumor Blood Flow, *Microvascular Research*, 65:56-60 (2003).
246. E. Brown, T. McKee, E. di Tomaso, B. Seed, Y. Boucher and R.K. Jain, Dynamic Imaging of Collagen and its Modulation in Tumors in vivo using Second Harmonic Generation. *Nature Medicine*, 9:796-801 (2003).
247. X. Wei, VG Henke, C Strübing, EB Brown and DE Clapham, Real-time imaging of nuclear permeation by EGFP in single intact cells. *Biophys. J.*, 84:1317-1327, 2003.
248. P.A. Netti, F. Travascio, R.K. Jain, Coupled Macromolecular Transport and Gel Mechanics: Poroviscoelastic Approach, *AIChE Journal*, 49:1580-1596 (2003)
249. B.R. Stoll, C. Migliorini, A. Kadambi, L.L. Munn and R.K. Jain, A Mathematical Model of the Contribution of Endothelial Progenitor Cells to Angiogenesis in Solid Tumors: Implications for Anti-Angiogenic Therapy, *Blood*, 102:2555-2561.
250. N.S. Forbes, L.L. Munn, D. Fukumura and R.K. Jain, Sparse initial entrapment of systemically injected salmonella typhimurium leads to heterogeneous accumulation within tumor necrosis. *Cancer Research*, 63:5188-5193(2003).
251. A. Abdul-Karim, K, Al-Kofahi, E. Brown, R.K. Jain and B. Roysam Automated tracing and change analysis of angiogenic vasculature from in vivo multiphoton image time series. *Microvascular Research*, 66:113-125(2003).
252. C. Sun, C. Migliorini and L.L. Munn, Red blood cells initiate leukocyte rolling in postcapillary expansions: a lattice-Boltzmann analysis. *Biophysical Journal*, 85:208-222(2003).
253. D. Fukumura, A. Ushiyama, D. G. Duda, L. Xu, J. Tam, V. K. K. Chatterjee, I. Garkavtsev, and R.K. Jain. Paracrine Regulation of Angiogenesis and Adipocyte Differentiation during In Vivo Adipogenesis. *Circulation Research*, 93:E88-E97(2003).
254. M. Bockhorn, Tsuzuki Y, Xu L, Frilling A., Broelsch CE, and Fukumura D. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. *Clin Cancer Res*, 9:4221-4226(2003).
255. E.B. Friedrich, A.M. Tager, E. Liu, A. Pettersson, C. Owman, L. Munn, A.D. Luster, R.E. Gerszten. Mechanisms of leukotriene b4-triggered monocyte adhesion. *Arterioscler Thromb Vasc Biol*, 23:1761-1767(2003).
256. T. Roose, P.A. Netti, L.L. Munn, Y. Boucher and R.K. Jain, Solid stress generated by spheroid growth estimated using a linear poroelasticity model. *Microvascular Research*, 66:204-212(2003).
257. C.A. Znati, M. Rosenstein, T.D. Mckee, E. Brown, D. Turner, W.D. Bloomer, S. Watkins, R.K. Jain and Y. Boucher, Irradiation Reduces Interstitial Fluid Transport and Increases the Collagen Content in Tumors. *Clinical Cancer Research*, 9:5508-5513(2003).



Reviews

258. R.K. Jain and T. P. Padera, Lymphatics Make the Break, *Science*, 299:209-210 (2003).
259. D.E.J.G.J. Dolmans, D. Fukumura, R.K. Jain, Photodynamic Therapy for Cancer *Nature Rev. Cancer* 3:380-387 (2003).
260. R.K. Jain, Molecular Regulation of Vessel Maturation, *Nature Medicine*, 9:685-693 (2003).
261. L.L. Munn, Aberrant Vascular Architecture in Tumors and its Importance in Drug-based Therapies. *Drug Discovery Today* 8:396-403 (2003).
262. P.A. Netti and R.K. Jain, Interstitial Transport in Solid Tumors, In: *Cancer Modeling and Simulation* (Editor: L Preziosi) Chapman & Hall, Boca Raton, FL, Chapter 3, pp. 51-74 (2003).
263. R.K. Jain, Molecular Pathophysiology of Tumors, In: *Principles and Practice of Radiation Oncology*, 4th Edition (Editors: C. A. Perez, L. W. Brady, E. C. Halperin, and R. Schmidt-Ullrich), Lippincott, Williams & Wilkins, New York, Chapter 4, pp- 163-179(2003).
264. R.K. Jain and M. F. Booth, What brings pericytes to tumor vessels? *Journal of Clinical Investigation* 112:1134-1136(2003).
265. R.K. Jain and D. G. Duda, Role of bone marrow-derived cells in Tumor Angiogenesis and Treatment, *Cancer Cell* 3:515-516(2003).


2004 Publications

Original Articles

266. C. Willett, Boucher Y, diTomaso E, Duda D, Munn LL, Tong R, Chung D, Sahani D, Kalva S, Kozin S, Mino M, Cohen K, Scadden D, Hartford A, Fischman A, Clark J, Ryan D, Zhu A, Blaszkowsky L, Chen H, Shellito P, Lauwers G, Jain R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, *Nature Medicine*, 10:145-147 (2004).
267. G. Alexandrakis, Brown E, Tong R, McKee T, Campbell R, Boucher Y, Jain R.K. Two-photon correlation spectroscopy reveals the two-phase nature of transport in tumors, *Nature Medicine*, 10:203-207 (2004).
268. T. Padera, Stoll B., Tooredman J., Capen D., diTomaso E., Jain R.K. Cancer cells compress intratumour vessels, *Nature*, 427:625(2004).
269. N. Koike, Fukumura D., Gralla O., Schechner J., Jain R.K. Creation of long-lasting blood vessels *Nature*, 428:138-139(2004).
270. I. Garkavtsev, Kozin, S, Chernova, O, Xu, L, Winkler, F, Brown, E, Barnett G, Jain R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. *Nature*, 428:328-332(2004).
271. T. Gohongi, T. Todoroki, D. Fukumura and R.K. Jain, Influence of the site of human gallbladder xenograft (Mz-ChA-1) on angiogenesis at the distant site *Oncology Reports*, 11:803-807 (2004).
272. M. Bockhorn, S. Roberge, C. Sousa, R.K. Jain and L. L. Munn, Differential Gene Expression in Metastasizing Cells Shed from Kidney Tumors, *Cancer Research*, 64:2469-2473 (2004).
273. E.B. Brown, Y. Boucher, S. Nasser, and R.K. Jain, Measurement of Macromolecular Diffusion Coefficients in Human Tumors, *Microvascular Research*, 67:231-236 (2004).
274. N. Isaka, T. P. Padera, J. Hagendoorn, D. Fukumura, and R.K. Jain, Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function, *Cancer Research*, 64:4400-4404 (2004).
275. R.T. Tong, Y. Boucher, S.V. Kozin, D.J. Hicklin, and R.K. Jain, Vascular normalization by VEGFR2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors, *Cancer Research*, 64:3731-3736 (2004).
276. D.G. Duda, D. Fukumura, L.L. Munn, M.F. Booth, E.B. Brown, P. Huang, B. Seed and R.K. Jain, Differential transplantability of tumor-associated stromal cells, *Cancer Research*, 63:5920-5924(2004).
277. J. Hagendoorn, T.P. Padera, S. Kashiwagi, N. Isaka, F. Noda, M.I. Lin, P.L.Huang, W.C. Sessa, D. Fukumura, and R.K. Jain. Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics, *Circulation Research*, 95:204-209 (2004).
278. L. Xu, P.S. Pathak and D. Fukumura, Hypoxia-induced activation of p38 MAPK and PI3K signaling pathways contributes to expression of interleukin-8 in human ovarian carcinoma cells: Mechanism of hypoxia induced interleukin 8. *Clinical Cancer Research*, 10:701-707 (2004).
279. Y.T. Chan, J.P. Zimmer, M. Stroh, J.S. Steckel, R.K. Jain, & M.G. Bawendi, Incorporation of luminescent nanocrystals into monodisperse core-shell silica microspheres, *Advanced Materials*, 16:23-24 (2004).
280. F. Winkler, S. Kozin, R. Tong, S. Chae, M. Booth, I. Garkavtsev, L. Xu, D. J. Hicklin, D. Fukumura, E. di Tomaso, L.L. Munn, R.K. Jain, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, Angiopoietin-1, and matrix metalloproteinases, *Cancer Cell*, 6:553-562 (2004).

Reviews


281. D.G. Duda, D. Fukumura and R.K. Jain. Role of eNOS in neovascularization: NO for EPCs, *Trends in Molecular Medicine* 10:143-145 (2004).
282. R.K. Jain, Recognition of tumor blood vessel normalization as a new antiangiogenic concept *Nature Medicine* 10:329-330 (2004).
283. C.G. Willett, D.G. Duda, A. Fischman and R.K. Jain, Correspondence: PET concerns in bevacizumab treatment, *Nature Medicine*, 10:561 (2004).
284. R.K. Jain, E.B. Brown, L.L. Munn, and D. Fukumura, Intravital microscopy of normal and diseased tissues in the mouse. In: *Live Cell Imaging: A Laboratory Manual* (Editors: R. D. Goldman and D. L. Spector). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Chapter 24, pp. 435-466 (2004).
285. R.K. Jain *Vascular and Interstitial Biology of Tumors*, In: *Clinical Oncology, 3rd Edition* (Editors: M. Abeleff, J. Armitage, J. Niederhuber, M. Kastan and G. McKenna), Elsevier, Philadelphia, PA, Chapter 9, pp. 153-172 (2004).
286. R.K. Jain, & M. Stroh, Zooming in and out with quantum dots. *Nature Biotechnology*, 22:959-960 (2004).



2005 Publications

Original articles

287. M. Stroh, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK. Quantum Dots spectrally distinguish multiple species within the tumor milieu in vivo. *Nature Medicine*, 11:678-682 (2005).
288. S.S. Shevkopyas, Yoshida T, Munn LL, Bitensky MW. Biomimetic autoseparation of leukocytes from whole blood in a microfluidic device. *Analytical Chemistry*, 77:933-937 (2005).
289. C. Sun, Munn LL. Particulate nature of blood determines macroscopic rheology: a 2-D lattice Boltzmann analysis. *Biophysical Journal*, 88:1635-1645 (2005).
290. Z.N. Demou, M. Awad, T. McKee, J. Y. Perentes, X. Wang, L. L. Munn, R.K. Jain and Y. Boucher, Lack of Telopeptides in Fibrillar Collagen I Promotes the Invasion of a Metastatic Breast Tumor Cell Line. *Cancer Research*, 65:5674-5682 (2005).
291. E. di Tomaso, D. Capen, A. Haskell, J. Hart, D.M. McDonald, R.K. Jain, R.C. Jones and L.L. Munn, Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial markers, *Cancer Research*, 65:5740-5749 (2005).
292. L. Xu, R. Tong, D. M. Cochran and R.K. Jain, Blocking PDGF-D/PDGFR? Signaling Inhibits Human Renal Cell Carcinoma Progression in an Orthotopic Mouse Model, *Cancer Research*, 65:5711-5719 (2005).
293. S. Kashiwagi, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, Munn LL, Jain RK, Fukumura D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels, *Journal of Clinical Investigation*, 115:1816-127 (2005).
294. P. Huang, T. D. McKee, R.K. Jain and D. Fukumura, Green fluorescence protein (GFP)-expressing model derived from a spontaneous osteosarcoma in a VEGF-GFP expressing mouse, *Comparative Medicine*, 55:236-243 (2005).
295. A. Ny, M. Koch, M. Schneider, E. Neven, R.T. Tong, S. Maity, C. Fischer, S. Plaisance, D. Lambrechts, C. Héligon, S. Terclavers, M. Ciesiolka, R. Kälin, W.Y. Man, I. Senn, S. Wyns, L. Marconcini, K. Vleminckx, S. Oliviero, F. Lupu, J. Wood, A. Brändli, D. Collen, E. M. Conway, M. Dewerchin, L. Moons, R.K. Jain and P. Carmeliet, A genetic *Xenopus Laevis* tadpole model to study lymphangiogenesis, *Nature Medicine*, 11:998-1004 (2005).
296. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R. Tong, D. Chung, D. Sahani, S. Kalva, S. Kozin, M. Mino, K. Cohen, D. Scadden, A. Hartford, A. Fischman, J. Clark, D. Ryan, A. Zhu, L. Blaszewski, P. Shellito, G. Lauwers, and R.K. Jain. Surrogate markers for antiangiogenic therapy and dose limiting toxicities for bevacizumab with radio-chemotherapy: Continued experience of a Phase I trial in rectal cancer patients, *Journal of Clinical Oncology*, 31:8136-9 (2005).
297. J. A. Tyrrell, V. Mahadevan, R. T. Tong, E. B. Brown, R.K. Jain and B. Roysam, A 2-D/3-D model-based method to quantify the complexity of microvasculature imaged by in vivo multiphoton microscopy, *Microvascular Research*, 70:165-178 (2005).
298. D.G. Duda, Cohen KS, Kozin SV, JY Perentes, Fukumura D, Scadden DT & Jain RK. Evidence for bone marrow-derived endothelial cells incorporation into perfused blood vessels in tumors. *Blood*, First Edition December 8, p-3210 (2005).
299. T. Acker, T. Diez, J. Aragones, M. Tjwa, K. Brusselmans, D. Fukumura, J. M. Herbert, A. Burger, J. Riedel, G. Elvert, I. Flamme, P. Maxwell, D. Collen, R.K. Jain, K. H. Plate and P. Carmeliet, Genetic evidence for a tumor suppressor Role of HIF-2 α , *Cancer Cell* 8:131-141 (2005).
- Reviews**
300. R.K. Jain. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy of breast cancer. *Science*, 307:58-62 (2005).
301. R.K. Jain, Antiangiogenic therapy of cancer: Current and emerging concepts, *Oncology (Supplement)*, 19:7-16 (2005).
302. D.G. Duda and R.K. Jain Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow, *Journal of Clinical Investigation*, 115:596-598 (2005).
303. R.K. Jain, P. Au, J. Tam, D. G. Duda and D. Fukumura, Engineering vascularized tissue, *Nature Biotechnology*, 23: 821-823 (2005).
304. J. Hagendoorn, Padera T.P., Fukumura D., Jain R.K. Molecular regulation of microlymphatic formation and function: role of nitric oxide. *Trends in Cardiovascular Medicine*, 15:169-173 (2005).
305. E. Brown, A. Majewska, R.K. Jain, FRAP and Multiphoton FRAP. In: Yuste R, Konnerth A. (eds). *Imaging in Neuroscience and Development: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Chapter 56, pages 429-438 (2005).
306. E. Brown, L.L. Munn, D. Fukumura, R.K. Jain. A Practical Guide to in vivo Imaging of Tumors. In: Yuste R, Konnerth A. (eds). *Imaging in Neuroscience and Development: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. Chapter 92,



2005 Publications

pages 695-700 (2005).

307. D. Fukumura. Role of microenvironment on gene expression, angiogenesis and microvascular functions in tumors. In: Meadows GG. editor. Integration/Interaction of Oncologic Growth, Vol. 15. In: Hans Kaiser H. series editor. Cancer Growth And Progression series, Springer Science + Business Media B.V., Dordrecht, the Netherlands Chapter 2, 23-36 (2005).

2006 Publications

Original articles

308. D.G. Duda, Cohen K.S. di Tomaso E., Au P., Klein R.J., Scadden D.T., Willett C.G. & Jain R.K. Differential CD146 expression on circulating versus tissue endothelial cells in cancer patients: Implications for circulating endothelial cells as biomarker for antiangiogenic therapy. *Journal of Clinical Oncology*, 107:2774-2776 (2006).
309. J. Kisucka, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J and Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. *Proceedings of the National Academy of Sciences USA*, 103:855-860 (2006).
310. J. Hagendoorn, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, Xu L, Kucherlapati R, Jain RK. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. *Cancer Research* 66:8065-75 (2006).
311. T. McKee, P Grandi, W Mok, G Alexandrakis, N Insin, JP Zimmer, MG Bawendi, Y Boucher, XO Breakefield and RK Jain, Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic HSV vector, *Cancer Research* 66:3360-3364 (2006).
312. L. Xu, D.M. Cochran, R.T. Tong, F. Winkler, S. Kashiwagi, R.K. Jain and D. Fukumura, PIGF Overexpression Inhibits Tumor Growth, Angiogenesis and Metastasis by Depleting VEGF Homodimers in Orthotopic Mouse Models, *Cancer Research* ,66:3971-3977 (2006).
313. J. Hagendoorn, TP Padera, TI Yock, GP Nielsen, E di Tomaso, TF Delaney, HA Gaijssert, AE Rosenberg, RK Jain and DH Ebb, Platelet-derived growth factor receptor- β in Gorham's disease, *Nature Clinical Practice Oncology*, 3:693-697 (2006).
314. T. Hoshida, N. Isaka, J. Hagendoorn, E. di Tomaso, Y.L. Chen, B. Pytowski, D. Fukumura, T.P. Padera, R.K. Jain, Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications., *Cancer Res.*, 66:8065-75 (2006).
315. L.E. Gerweck, Vijayappa S, and Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. *Molecular Cancer Therapy*, 5:1275-1279 (2006).
316. Y. Saito, Sunamura M, Motoi F, Abe H, Egawa S, Duda DG, Hoshida T, Fukuyama S, Hamada H, Matsuno S. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. *Cancer Gene Therapy*, 13:242-52. (2006).
317. C.H. Sun, Munn LL. Influence of erythrocyte aggregation on leukocyte margination in postcapillary expansions: a lattice-Boltzmann analysis, *Physica A*, 362:191-196 (2006).
318. R. Jones, Capen D, Jacobson M, Munn L. PDGF and microvessel wall remodeling in adult rat lung: Imaging PDGF-AA and PDGF-Ra molecules in progenitor smooth muscle cells developing in experimental pulmonary hypertension. *Cell and Tissue Research*, 16794827 (2006).
319. D.M. Cochran, Fukumura D, Carmeliet P, Jain RK, Evolution of oxygen and glucose concentration profiles in a tissue-mimetic culture system of embryonic stem cells. *Annals of Biomedical Engineering*, 34:1247-1258 (2006).
320. S.T. Reddy, D.A. Berk, R.K. Jain and M.A. Swartz, A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles, *Journal of Applied Physiology*, 101:1162-1169 (2006).

Reviews

321. R.K. Jain, D.G. Duda, J. W. Clark & L.S. Loeffler. Lessons from Phase III clinical trials of anti-VEGF therapy for cancer. *Nature Clinical Practice Oncology*, 3:24-40 (2006).
322. C.G. Willett, Kozin SV, Duda GD, di Tomaso E, Kozak KR, Boucher Y, and Jain RK Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice. *Seminars in Oncology*, 33:S35-S40. (2006).
323. D.G. Duda. Anti-angiogenesis and drug delivery in tumors: Bench to bedside and back. *Cancer Research*, 66:3967-70 (2006).
324. R.K. Jain, Seminal findings and an allergy to black flies. In: Reflections from the Frontiers, Explorations for the Future: Gordon Research Conferences, 1931-2006 (Editors: Arthur A. Daemrlich, Nancy Ryan Gray and Leah Shaper), Gordon Research Conferences and Chemical Heritage Foundation, Philadelphia, pp 70-71 (2006).
325. D.G. Duda. Angiogenesis and vascular targeting agents drug discovery & development. *Investigational Drugs Database (IDdb) and Thomson Pharma*, September (2006).
326. D.S. Hoon, M. Kitago, J. Kim, T. Mori, A. Piris, K. Szyfelbein, M.C. Mihm Jr., S.D. Nathanson, T.P. Padera, A.F. Chambers, S.A. Vantyghem,



2006 Publications

- I.C. MacDonald, S.C. Shivers, M. Alsarraj, D.S. Reintgen, B. Passlick, W. Siene, K. Pantel. Molecular mechanisms of metastasis. *Cancer and Metastasis Reviews*, 25:203-220 (2006).
327. L.L. Munn. Analytical approaches to leukocyte-endothelium interactions. In: Shepro D, editor. *Microvascular Research: Biology and Pathology*, Elsevier Press; Amsterdam, Chapter 117, pp. 791-794.(2006).
328. D. Fukumura. Window Models. In: D. Shepro Editor. *Microvascular Research: Biology and Pathology*, Elsevier Science, San Diego, CA: Chapter 24:151-157 (2006).
329. D. Fukumura, Kashiwagi S, Jain RK. Role of nitric oxide in tumour progression. *Nature Reviews Cancer*, 6:521-534 (2006).

2007 Publications

Original articles


330. T.T. Batchelor, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, *Cancer Cell*, 11:83-95 (2007).
331. D.G. Duda, Cohen KS, Au P, Scadden DT, Willett CG, Jain RK. Detection of circulating endothelial cells: CD146- based magnetic separation enrichment or flow cytometric assay? *Journal of Clinical Oncology*, 25:e3-e5 (2007).
332. C.G. Willett, Duda DG, di Tomaso E, Boucher Y, Czitko BG, Bendell J, Hurwitz HI, Bentley R, Wong TZ, Paulson E, Jain, RK. Complete pathological response in T4 locally advanced rectal cancer after treatment with bevacizumab and standard radio-chemotherapy. *Nature Clinical Practice Oncology*, 4:316-321 (2007).
333. R.K. Jain, Tong R, Munn LL. Effect of vascular normalization by anti-angiogenic therapy on interstitial hypertension, peri-tumor edema and lymphatic metastasis: insights from a mathematical model. *Cancer Research*, 67:2729-2735 (2007).
334. J.A. Tyrrell, E. di Tomaso, D. Fuja, R. Tong, K. Kozak, R.K. Jain and B. Roysam, Robust 3-D modeling of vasculature imagery using superellipsoid, *IEEE Transactions on Medical Imaging*, 26:223-237 (2007).
335. Z.Z. Wang, P. Au, T. Chen, Y. Shao, L. M. Daheron, H. Bai, M. Arzigian, D. Fukumura, R.K. Jain and D. Scadden, Human ES cell-derived endothelial cells form durable functional blood vessels in vivo, *Nature Biotechnology* 25,317-318 (2007).
336. D.G. Duda, K. S. Cohen, D. Scadden and R.K. Jain, A protocol for detection and enumeration of blood circulating endothelial cells and progenitor cells in human blood, *Nature Protocols*, 4:805-810 (2007).
337. L. Xu and R.K. Jain, Downregulation of Placenta Growth Factor by Promoter Hypermethylation in Human Lung and Colon Carcinoma, *Molecular Cancer Research*, 5:873-880 (2007).
338. S.V. Kozin, F. Winkler, I. Garkavtsev, D.J. Hicklin, R.K. Jain, Y. Boucher, Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. *Cancer Research*, 67:5076-82 (2007).
339. C. Sun, R.K. Jain and L.L. Munn, Non-uniform plasma leakage affects local hematocrit and blood flow: Implications for inflammation and tumor perfusion, *Annals of Biomedical Engineering*, 35:2121-29 (2007).
340. C. Sun and L.L. Munn. "Lattice-Boltzmann simulation of blood flow in digitized vessel networks," *Computers & Mathematics with Applications*; 55:1594-1600 (2007).
341. M.M. Dupin, I. Halliday, C.M. Care and L.L. Munn. "Modeling the flow of dense suspensions of deformable particles in three dimensions," *PRE*; 75:066707 (2007).
342. G.M. Nelson, T. P. Padera, I. Garkavtsev, T. Shioda and R.K. Jain, Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells, *Neoplasia*, 9:1038-1045 (2007).
343. W. Mok, Y. Boucher and R.K. Jain, MMP-1 and -8 improve the distribution and efficacy of an oncolytic virus, *Cancer Research*, 67:10664-10668 (2007).
344. B.D. Lawenda, Smith DE, Xu L, Niemierko A, Silverstein JR, Boucher Y, Kashiwagi S, Held KD, Jain RK, Loeffler JS, Eisenberg DM, Blumberg JB. Do the dietary supplements epigallocatechin gallate or vitamin E cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma. *J Soc Integr Oncol.*, 5:11-7 (2007).



2007 Publications

Reviews

345. C.G. Willett, D. G. Duda, R.K. Jain, Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer, *Current Colorectal Cancer Reports*, 3:94-98 (2007).
346. D.G. Duda, T. Batchelor, C.G. Willett and R.K. Jain, The current progress, hurdles and future prospects in anti-VEGF targeted cancer therapy strategies. *Trends in Molecular Medicine*, 13:222-230 (2007).
347. D. Fukumura and R.K. Jain, Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. *Journal of Cellular Biochemistry*, 101:937-949 (2007).
348. R.K. Jain & D.G. Duda, Angiogenesis in Solid Tumors. In: *Antiangiogenic Cancer Therapy* (Editors: James L. Abbruzzese, Darren W. Davis and Roy S. Herbst), CRC Press, Boca Raton, pp. 43-90 (2007).
349. R.K. Jain and D.G. Duda, Normalization of tumor vasculature and microenvironment by antiangiogenic therapy. In: *Angiogenesis: Mechanisms and Cancer Therapy* (Editors: Dieter Marmé and Norbert E. Fusenig), Springer-Verlag, Berlin, pp. 577-92 (2007).
350. R.K. Jain, T. T. Batchelor, D.G. Duda, C.G. Willett, Normalization of tumor vasculature and microenvironment, In: *Antiangiogenic Agents in Cancer Therapy*. (Editors: Beverly Teicher and Lee Ellis), Humana Press, pp. 261-76 (2007).
351. C.G. Willett, D.G. Duda, B.G. Czito, J.C. Bendell, J.W. Clark, R.K. Jain, Targeted therapy in rectal cancer, *Oncology*, 21:1055-65 (2007).
352. D.G. Duda, R.K. Jain, C.G. Willett, Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers, *Journal of Clinical Oncology*, 225:4033-42 (2007).
353. P. Au, J. Tam, D. Fukumura, R.K. Jain, Small blood vessel engineering, *Methods in Molecular Medicine*, 140:183-195 (2007).
354. R.K. Jain and L.L. Munn, Vascular normalization as rationale for combining chemotherapy with antiangiogenic agents, *PPO Updates*, 21:1-7 (2007).
355. R.K. Jain, D. Fukumura, L. Munn and E. Brown, Optical Microscopy in Small Animal Research. In: *Imaging of Vertebrates* (Editors: Tavitian B, Leroy-Willig A & Ntziachristos V). Wiley, London, pp 183-187 (2007).
356. R.K. Jain, D. Fukumura, L. Munn and E. Brown, Tumor Angiogenesis and Blood Flow. In: *Imaging of Vertebrates* (Editors: Tavitian B, Leroy-Willig A & Ntziachristos V). Wiley, London, pp 199-201 (2007).
357. M. Bockhorn, R.K. Jain and L.L. Munn, Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? *Lancet Oncology* 8:444-8 (2007).
358. R.K. Jain, E. diTomaso, D.G. Duda, J.S. Loeffler, A.G. Sorensen and T.T. Batchelor, Angiogenesis in brain tumors, *Nature Reviews Neuroscience*, 8:610-622 (2007).
359. R.K. Jain, A.V. Finn, F.D. Kolodie, H.K. Gold and R. Virmani, Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: A potential strategy for plaque stabilization, *Nature Clinical Practice Cardiovascular Medicine*, 4:491-502 (2007).
360. D.G. Duda, Endothelial cell-based therapy for hematopoiesis, *Blood* 109:2272-3 (2007).
361. D. Fukumura, Jain RK. Novel function of RANKL: eNOS activator. *Blood* 109:1339-1340 (2007).
362. R.K. Jain and L. Xu, α PIGF: A new kid on the antiangiogenic block, *Cell*, 131: 443-445 (2007).
363. E.R. Gerstner, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT. Antiangiogenic agents for the treatment of glioblastoma, *Expert Opin Investig Drugs*, 16:1895-1908 (2007).
364. D. Fukumura and R.K. Jain, Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization, *Microvascular Research*, 74:72-84 (2007).
365. T.P. Padera, M. Ancukiewicz, T. Hoshida, D. Fukumura and R.K. Jain, Data do not support benefits of anti-VEGFR3 therapy, *Cancer Research*, 67:5055 (2007).



2008 Publications

Original articles


366. P. Au, L.M. Daheron, D.G. Duda, K.S. Cohen, J.A. Tyrrell, R.M. Lanning, D. Fukumura, D.T. Scadden, and R.K. Jain, Differential in vivo potential of endothelial progenitor cells from human umbilicalcord blood and adult peripheral blood to form functional long-lasting vessels, *Blood* 111:1302-1305 (2008).
367. P. Au, J. Tam, D. Fukumura and R. K. Jain, "Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature," *Blood* 114: 255- 257 (2008).
368. R. Jones, D. Capen, K. S. Cohen, L. L. Munn, R. K. Jain, D. G. Duda. "A protocol for phenotypic detection and characterization of vascular cells in a lung neovascularization model in rodents," *Nature Protocols*, 3:378-87 (2008).
369. R. Jones, D. Capen, B. Petersen, R. K. Jain, D.G. Duda, "A protocol for a lung neovascularization model in rodents," *Nature Protocols*, 3:388-97 (2008).
370. S. Kashiwagi, K. Tsukada, L. Xu, J. Miyazaki, S. V. Kozin, J. A. Tyrrell, W. C. Sessa, L. E. Gerweck, R. K. Jain and D. Fukumura, "Perivascular

2008 Publications

- nitric oxide gradients normalize tumor vasculature,” *Nature Medicine* 14: 255-257 (2008).
371. P. Huang, D. G. Duda, R. K. Jain and D. Fukumura, “Histopathological findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice,” *Comparative Medicine* 58: 253-263 (2008).
372. S. Nagano, J. Y. Perentes, R. K. Jain and Y. Boucher, “Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors,” *Cancer Research* 68: 3795-802 (2008).
373. T. P. Padera, A. H. Kuo, T. Hoshida, S. Liao, J. Lobo, K. R. Kozak, D. Fukumura and R. K. Jain, “Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and -3 kinase inhibitors cediranib and vandetanib,” *Molecular Cancer Therapeutics* 7: 2272-2279 (2008).
374. L.L. Munn and M.M. Dupin. “Blood cell interactions and segregation in flow,” *Annals of Biomedical Engineering*; 36: 534-544 (2008).
375. M.M. Dupin, I. Halliday, C.M. Care and L.L. Munn, “Lattice Boltzmann modelling of blood cell dynamics,” *International Journal of Computational Fluid Dynamics*; 22: 481-492 (2008).

Reviews

376. R.K. Jain, Taming vessels to treat cancer, *Scientific American*, 298:56-63 (2008).
377. R. K. Jain, “Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer,” *Nature Reviews Cancer* 8:309-316 (2008).
378. R.K. Jain, “Judah Folkman,” *Journal of Clinical Investigation* 118: 823 (2008).
379. E. Brown, A. Majewska and R. K. Jain, “Photobleaching and recovery with nonlinear microscopy.” In: *Handbook of Biomedical Nonlinear Optical Microscopy* (Editors: B. R. Masters and P. T. C. So). Oxford University Press, New York, Chapter 26, pp. 673-688 (2008).
380. R. K. Jain, M. F. Booth, T. P. Padera, L. L. Munn, D. Fukumura and E. Brown, “Applications of nonlinear intravital microscopy in tumor biology.” In: *Handbook of Biomedical Nonlinear Optical Microscopy* (Editors: B. R. Masters and P. T. C. So). Oxford University Press, New York, Chapter 29, pp. 735-756 (2008)
381. R.K. Jain and K. Kozak, “Molecular Pathophysiology of Tumors,” In: *Principles and Practice of Radiation Oncology*, 5th Edition (Editors: E. C. Halperin, C. A. Perez, L. W. Brady), Lippincott, Williams & Wilkins, New York, Chapter 4, pp. 126-141 (2008).
382. R. K. Jain, D. G. Duda, T. T. Batchelor, A. G. Sorensen and C. G. Willett, “Normalization of tumor vasculature and microenvironment,” In: *Angiogenesis: An Integrative Approach from Science to Medicine* (Editors: W. D. Figg and J. Folkman), Springer, pp. 273-282 (2008).
383. D. Fukumura and R. K. Jain, “Imaging angiogenesis and the microenvironment,” *APMIS* 116:695-715 (2008).
384. A. G. Sorensen, T. T. Batchelor, P. Y. Wen, W. T. Zhang and R. K. Jain, “Response criteria for glioma,” *Nature Clinical Practice Oncology* 5:634-44 (2008).
385. E. R. Gerstner, A. G. Sorensen, R. K. Jain and T. T. Batchelor, “Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas,” *Current Opinion in Neurology* 21:728-35 (2008).
386. T. P. Padera and R. K. Jain, “VEGFR3: A new target for anti-angiogenesis therapy?” *Developmental Cell* 15:178-179 (2008).
387. R. K. Jain, J. Lahdenranta and D. Fukumura, “Targeting Platelet-Derived Growth Factor Signaling in Carcinoma-Associated Fibroblasts Controls Cervical Cancer in Mouse Model,” *PLoS Medicine* 5(1): e24 (2008); doi:10.1371/journal.pmed.0050024.



2009 Publications

Original articles


388. J. Tam, D. Fukumura and R. K. Jain, “A mathematical model of murine metabolic regulation by leptin: energy balance and defense of a stable body weight,” *Cell Metabolism* 9:52-63 (2009).
389. J. Y. Perentes, T. D McKee, C. D. Ley, H. Mathiew, M. Dawson, T. P. Padera, L. L. Munn, R. K. Jain and Y. Boucher, “In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts,” *Nature Methods* 6:143-145 (2009).
390. P. Y. Wen, W.K. A. Yung, K. R. Lamborn, A. D. Norden, T. F. Cloughesy, L. M. DeAngelis, H. A. Fine, S. M. Chang, H. I. Robins, K. Fink, L. E. Abrey, A. B. Lassman, M. Mehta, J. Drappatz, E. Di Tomaso, K. Ligon, K. Aldape, Rakesh K. Jain, R. Capdeville, C. Stiles, R. Kaplan, M. J. Egorin, A. J. Murgo, M. D. Prados, “Phase II study of Imatinib Mesylate (Gleevec®) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08),” *Neuro-Oncology* 11:853-860 (2009).
391. G. Cheng, J. Tse, R. K. Jain and L. L. Munn, “Micro-environmental Mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells,” *PLoS One* 4:e4632 (2009).

2009 Publications

392. M. X. Luong, J. T. Q. Lin, J. Hagendoorn, K. J. Moore, T. P. Padera, B. Seed, D. Fukumura, R. Kucherlapati, and R. K. Jain "Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knock out mice," *Journal of Cellular Physiology* 219:430-437 (2009).
393. W. Mok, T. Stylianopoulos, Y. Boucher, R.K. Jain, "Mathematical modeling of herpes simplex virus distribution in solid tumors: Implications for cancer gene therapy," *Clinical Cancer Research* 15:2352-2360 (2009).
394. J. Lahdenranta, J. Hagendoorn, T.P. Padera, T. Hoshida, G. Nelson, S. Kashiwagi, R.K. Jain, D. Fukumura, "Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis," *Cancer Research* 69:2801-8 (2009).
395. E. Chung, H. Yamashita, P. Au, BA Tannous, D. Fukumura, R.K. Jain, "Secreted Gaussia Luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases," *PLoS One* 4:e8316 (2009).
396. A.T.N. Kumar, E. Chung, S.B. Raymond, J.A.J.M. van de Water, K. Shah, D. Fukumura, R.K. Jain, B.J. Bacskai, D.A. Boas, "Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast," *Optics Letters* 34:2066-2068 (2009).
397. R. Jones, D. Capen, M. Jacobson, K.S. Cohen, D.T. Scadden, D.G. Duda, "VEGFR2+PDGFR β + circulating precursor cells participate in lung capillary repair after hyperoxia-induced lung injury (HALI)," *Journal of Cellular and Molecular Medicine* 9b: published online May 6, 2009 as doi:10.1111/j.1582-4934.2009.00785.x. (2009).
398. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhvani V, Blaszewski LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. 2009, "Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study." *Journal of Clinical Oncology*, 27(18):3027-35. PMC2702235
399. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito PC, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. "Efficacy, safety and biomarkers of neoadjuvant bevacizumab, radiation therapy and 5-Fluorouracil in rectal cancer: A multidisciplinary phase II study," *Journal of Clinical Oncology* 27:3020-3026 (2009).
400. P. Au, J. Tam, D. G. Duda, D. Fukumura, R. K. Jain, "Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo," *American Journal of Pathology* 175:294-302 (2009).
401. Sorensen AG, Batchelor TT, Zhang W-T, Chen P-J, Yeo P, Wang M, Jennings D, Wen PY, Ancukiewicz M, Lahdenranta J, di Tomaso E, Duda DG, Jain RK, "A "Vascular Normalization Index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients," *Cancer Research* 69:5296-5300 (2009).
402. Dawson MR, Duda DG, Fukumura D, Jain RK. "VEGFR1-activity-independent metastasis formation," *Nature* 461:E4-E5 (2009).
403. Dawson MR, Duda DG, Chae S-S, Fukumura D, Jain RK, "VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation," *PLoS One* 4:e6525 (2009).
404. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito PC, Czito B, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK, "Direct evidence that bevacizumab, an anti-VEGF antibody, upregulates SDF1 α , CXCR4, CXCL6 and neuropilin 1 in tumors in rectal cancer patients," *Cancer Research* 69: 7905-7910 (2009).
405. J. Tam, D. G. Duda, J. Y. Perentes, R. S. Quadri, D. Fukumura and R. K. Jain, "Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: Role of local versus bone-marrow derived endothelial cells," *PLoS One* 4: e4974 (2009).
406. E. di Tomaso, N. London, D. Fuja, J. Logie, J. A. Tyrrell, W. Kamoun, L. L. Munn and R. K. Jain, "PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment," *PLoS One* 4:e5123 (2009).
407. V. P. Chauhan, R. M. Lanning, B. Diop-Frimpong, W. Mok, E. B. Brown, T. P. Padera, Y. Boucher, and R. K. Jain, "Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo," *Biophysical Journal* 97: 330-336 (2009).
408. W. S. Kamoun, C. D. Ley, C. T. Farrar, A. M. Duyverman, J. Lahdenranta, D. A. Lacorre, T. T. Batchelor, E. di Tomaso, D. G. Duda, L. L. Munn, D. Fukumura, A. G. Sorensen and R. K. Jain, "Edema control by cediranib, a VEGF targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice," *Journal of Clinical Oncology* 27: 2542-2552 (2009).
409. S. R. Plotkin, A. O. Stemmer-Rachamimov, F. G. Barker II, C. Halpin, T. P. Padera, A. Tyrell, A. G. Sorensen, R. K. Jain and E. di Tomaso, "Hearing improvement after bevacizumab in patients with neurofibromatosis 2," *New England Journal of Medicine* 361:358-369 (2009).
410. B. J. Vakoc, R. M. Lanning, J. A. Tyrrell, T. P. Padera, L. A. Bartlett, T. Stylianopoulos, L. L. Munn, G. J. Tearney, D. Fukumura, R. K. Jain and B. E. Bouma, "Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging," *Nature Medicine* 15:1219-1224 (2009).

Reviews

411. R. K. Jain, "A new target for tumor therapy," *New England Journal of Medicine* 360:2669-2671 (2009).
412. J. Y. Perentes, D. G. Duda and R. K. Jain, "Visualizing anti-tumor immune responses in vivo," *Disease Models and Mechanisms* 2:107-110 (2009).
413. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT, "The potential utility of anti-VEGF agents to normalize tumor vasculature and alleviate edema in brain and spinal cord tumor patients," *Nature Clinical Practice Oncology* 6:229-236 (2009).
414. R. K. Jain, J. Tam, P. Au, D. Fukumura, "Angiogenesis in Development, Disease and Regeneration," In: Santin M, editor. *Strategies in Regenerative Medicine: Integrating Biology with Materials Design*. Chapter 6. Springer, New York (2009).



2009 Publications

415. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT, "Anti-vascular endothelial growth factor therapy for malignant glioma," *Current Neurology Neuroscience Report* 9:254-262 (2009).
416. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG, "Biomarkers of response and resistance to antiangiogenic therapy in cancer," *Nature Reviews Clinical Oncology* 6:327-338 (2009).
417. A. S. Chi, A. G. Sorensen, R. K. Jain, T. T. Batchelor, "Angiogenesis as a therapeutic target in malignant gliomas," *Oncologist* 14:621-636 (2009).
418. Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: Rationale, early clinical experience and correlative studies. *Cancer Journal* 2009; 15: 263-8.
419. Duda DG, Ancukiewicz MA, Jain RK. Biomarkers of antiangiogenic therapy: How do we move from candidate biomarkers to valid biomarkers? *Journal of Clinical Oncology* 2009; 28: 183-5.
420. Woodward WA, Bristow RG, Clarke MF, Coppes R, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill R, Jordan CT, Milas L, Pajonk F, Curran W, Dicker A, Chen Y. "Radiation Therapy Oncology Group Translational Research Program Stem Cell Symposium: Incorporating stem cell hypothesis into clinical trials," *International Journal of Radiation Oncology, Biology and Physics* 74: 1580-91 (2009).

2010 Publications

Original articles

421. Kirsch DG, Santiago PM, di Tomasso E, Sullivan JM, Hou W-S, Dayton T, Jeffords LB, Sodha P, Mercer K, Cohen R, Tekeyushi O, Korsmeyer S, Bronson R, Kim CF, Haigis KM, Jain RK, Jacks T. "p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis," *Science*. 327:593-6 (2010).
422. Liu W, Greytak AB, Lee J, Wong CR, Park J, Marshall LF, Jiang W, Curtin PN, Ting AY, Nocera DG, Fukumura D, Jain RK, Bawendi MG. Compact Biocompatible Quantum Dots via RAFT-Mediated Synthesis of Imidazole-Based Random Copolymer Ligand. *J Am Chem Soc*. 132:472-83 (2010).
423. Allen PM, Liu W, Chauhan VP, Lee J, Ting AY, Fukumura D, Jain RK, Bawendi MG. InAs(ZnCdS) Quantum Dots Optimized for Biological Imaging in the Near-Infrared. *J Am Chem Soc*. 132: 470-1 (2010).
424. C. T. Farrar, W. S. Kamoun, C. D. Ley, Y. R. Kim, S. J. Kwon; G. Dai, B. R. Rosen, E. di Tomaso; R. K. Jain, A. G. Sorensen , "In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model," *Neuro-Oncology* 12:341-50 (2010).
425. E. R. Gerstner, P. J. Chen, P. Y. Wen, R. K. Jain, T. T. Batchelor, and G. Sorensen, " Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib," *Neuro-Oncology*, 12:466-72 (2010).
426. H. K. Wong, J. Lahdenranta, W. S. Kamoun, A. W. Chan, A. I. McClatchey, S. R. Plotkin, R. K. Jain and E. di Tomaso, "Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors," *Cancer Research* 70:3483-93 (2010).
427. P. Kim, E. Chung, H. Yamashita, K. E. Hung, A. Mizoguchi, R. Kucherlapati, D. Fukumura, R. K. Jain and S. H. Yun, "In vivo wide-area cellular imaging by side-view endomicroscopy", *Nature Methods* 7:303-5 (2010).
428. T. T. Batchelor, D. G. Duda, E. di Tomaso, M. Ancukiewicz, S. R. Plotkin, E. Gerstner, A. F. Eichler, J. Drappatz, F. H. Hochberg, D. N. Louis, K. S. Cohen, H. Chea, A. Exarhopoulos, M. A. Moses, P. Ivy, A. G. Sorensen, P. Y. Wen and R. K. Jain, "Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma," *Journal of Clinical Oncology*, 28: 2817-23 (2010).
429. Kamoun, W., Chae, S.-S., Lacorre, D., Tyrrell, J., Mitre, M., Gillissen, M., Fukumura, D., Jain, R., and Munn, LL. Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks in vivo. *Nature Methods*, 15:845–851 (2010).
430. Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito PC, Clark JW, Jain RK. Plasma Soluble VEGFR1 is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer. *Oncologist*, 15: 577-83 (2010).
431. Willett CG, Duda DG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito PC, Clark JW, Jain RK. A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared to Standard Chemoradiation in Locally Advanced Rectal Cancer. *Oncologist*, 15:845–851 (2010).
432. Sergey V. Kozin, Walid S. Kamoun, Yuhui Huang, Michelle R. Dawson, Rakesh K. Jain, and Dan G. Duda, "Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation," *Cancer Research* 70: 5679-85 (2010).
433. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK, Fukumura D, "Angiopoietin-2 Interferes with Anti-VEGFR-2- Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas," *Clinical Cancer Research* 16:3618-27 (2010).
434. R. Mounzer, O. Svendsen, P. Baluk, C. Bergman, T. Padera, H. Wiig, R. K. Jain, D. McDonald, N. Ruddle, "Lymphotoxin α contributes to lymphangiogenesis," *Blood* 116:2173-82 (2010).
435. Z. Popović, W. Liu, V. P. Chauhan, J. Lee, C. Wong, A. B. Greytak, N. Insin, D. G. Nocera, D. Fukumura, R. K. Jain and M. G. Bawendi, "A nanoparticle size series for in vivo fluorescence imaging," *Angewandte Chemie Intl Ed Engl*, 49:8649-52 (2010).
436. Stylianopoulos T, Poh M-Z, Insin N, Bawendi MG, Fukumura D, Munn LL, Jain RK, "Diffusion of Particles in the Extracellular Matrix: the Effect of Repulsive Electrostatic Interactions," *Biophysical Journal* 99:1342-9 (2010).
437. T. Stylianopoulos, B. Diop-Frimpong, L. L. Munn and R. K. Jain, "Diffusion anisotropy in collagen gels and tumors: the effect of fiber network orientation," *Biophysical Journal* 99:3119-3128 (2010).
438. D. G. Duda, A. M. M. J. Duyverman, M. Kohno, M. Snuderl, E. J. A. Steller, D. Fukumura and R. K. Jain, "Malignant cells facilitate lung

2010 Publications

metastasis by bringing their own soil," *Proceedings of the National Academy of Science U S A* 107: 21677-21682 (2010).


Reviews

439. D. G. Duda, M. Ancukiewicz, and R. K. Jain, "Biomarkers of antiangiogenic therapy: How do we move from candidate biomarkers to valid biomarkers?" *Journal of Clinical Oncology* 28:183-5 (2010).
440. R. K. Jain, L. L. Munn and D. Fukumura, "Intravital microscopy of normal and diseased tissues in the mouse. In: *Live Cell Imaging: A Laboratory Manual*, 2nd Edition, Chapter 26, pp 475-521 (R. D. Goldman, J. R. Swedlow and D. L. Specter, Eds.), CSH Press, Cold Spring Harbor, NY (2010).
441. A. K. Finn, R. K. Jain, "Coronary plaque neovascularization and hemorrhage: a potential target for plaque stabilization?," *JACC Cardiovasc Imaging*. 3:41-4 (2010).
442. D. Fukumura, D. G. Duda, L. L. Munn and R. K. Jain, "Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models," *Microcirculation* 17:206-25 (2010).
443. Duda DG, Jain RK, "Pre-metastatic lung "niche": Is VEGFR1 activation a requirement?" *Cancer Research* 70: 5670-3 (2010).
444. Brown E, Munn LL, Fukumura D, Jain RK. In vivo imaging of tumors. *Cold Spring Harb Protoc.* 2010 Jul 1; 2010:pdb.prot5452. doi: 10.1101/pdb.prot5452.
445. S. Liao, T. P. Padera and R. K. Jain, "Notch leads lymphatics and connects to blood vessels," *Arteriosclerosis, Thrombosis and Vascular Biology* 30:1682-3 (2010).
446. R. K. Jain and T. Stylianopoulos, "Delivering nanomedicine to solid tumors," *Nature Reviews Clinical Oncology* 7:653-64 (2010).

2011 Publications

Original articles

447. Dawson MR, Chae S-S, Jain RK, Duda DG. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. *American Journal of Cancer Research* 1: 144-54 (2011).
448. di Tomaso E, Snuderl M, Kamoun W, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte T, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape. *Cancer Research* 71: 17-28 (2011).
449. Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation-antigen (Gr-1) positive cells. *Proceedings of the National Academy of Science U S A.* 108: 302-7 (2011).
450. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. *Journal of Neuro-oncology* 103: 325-32 (2011).
451. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad RA, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of sunitinib toxicity in advanced hepatocellular carcinoma: Kinetics and potential biomarker value. *Clinical Cancer Research* 17: 918-27 (2011).
452. Hiratsuka S, Goel S, Kamoun W, Fukumura D, Duda DG, Jain RK. Endothelial focal adhesion kinase mediates cancer cell homing to discrete foci in lungs. *Proceedings of the National Academy of Science U S A* 108: 3725-30 (2011).
453. C. Wong, T. Stylianopoulos, J. Cui, J. Martin, V. P. Chauhan, W. Jiang, Z. Popovic, R. K. Jain, M. G. Bawendi and D. Fukumura, "Multistage nanoparticle delivery system for deep penetration into tumor tissue," *Proceedings of the National Academy of Science U S A*, 108: 2426-2431 (2011).
454. Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner C, Moses MA, Jain RK. Safety, efficacy and biomarker exploration in a phase II study of bevacizumab, oxaliplatin and gemcitabine in recurrent Müllerian carcinoma. *Clin Ovarian Cancer Other Gynecol Malig* 4: 26-33 (2011).
455. J. Baish, T. Stylianopoulos, R. M. Lanning, W. S. Kamoun, D. Fukumura, L. L. Munn, and R. K. Jain, "Scaling rules for diffusive drug delivery in tumor and normal tissues," *Proceedings of the National Academy of Science U S A* 108: 1799-1803 (2011).
456. B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y Boucher, and R. K. Jain, "Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors," *Proceedings of the National Academy of Science U S A*, 108:2909-14 (2011).
457. S. Liao, J. Liu, P. Lin, T. Shi, R. K. Jain and Lei Xu, "TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma model," *Clinical Cancer Research*, 17:1415-24 (2011).
458. I. Garkavtsev, V. Chauhan, H. K. Wong, A. Mukhopadhyay, M. Glicksman, R. Peterson and R. K. Jain, "Dehydro- α -lapachone, a plant product with antivascular activity," *Proceedings of the National Academy of Science U S A* 108: 11596-601 (2011).
459. Yoon SS, Duda DG, Karl DL, Kim T-M, Kambadakone AR, Chen Y-L, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon



2011 Publications

- DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, DeLaney DF. Phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas. *International Journal of Radiation Oncology, Biology and Physics* 81: 1081-90 (2011).
460. J. Liu, S. Liao, Y. Huang, R. Samuel, T. Shi, K. Naxerova, P. Huang, W. Kamoun, R. K. Jain, D. Fukumura and L. Xu, "PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer," *Clinical Cancer Research* 17: 3638-48 (2011).
461. C. T. Farrar, W. S. Kamoun, C. D. Ley, Y. R. Kim, C. Catana, S. J. Kwon, B. R. Rosen, R. K. Jain, A. G. Sorensen, "Sensitivity of MRI Tumor Biomarkers to VEGFR Inhibitor Therapy in an Orthotopic Mouse Glioma Model." *PLoS One* 6(3): e17228 (2011).
462. H. Kim, C. Catana, E. M. Ratai, O. C. Andronesi, D. Jennings, T. T. Batchelor, R. K. Jain, A. G. Sorensen, "Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma," *Cancer Research* 71:3745-52 (2011).
463. K. E. Emblem, A. Bjornerud, K. Mouridsen, R. J. Borra, T. T. Batchelor, R. K. Jain, A. G. Sorensen, "T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: Part II predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients," *J Cereb Blood Flow Metab.* 31(10): 2054-64 (2011).
464. J.Y. Perentes, N. Kirkpatrick, S. Nagano, E. Y. Smith, C. M. Shaver, D. Sgroi, I. Garkavstev, L. L. Munn, R. K. Jain and Y. Boucher, "Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors," *Cancer Research* 71: 4527-38 (2011).
465. Zhao W, Schafer S, Choi J, Yamanaka YJ, Lombardi ML, Bose S, Carlson AL, Phillips JA, Teo W, Droujinine IA, Cui CH, Jain RK, Lammerding J, Love JC, Lin CP, Sarkar D, Karnik R, Karp JM, "Cell-surface sensors for real-time probing of cellular environments," *Nat Nanotechnol.* 6:524-31 (2011).
466. G. Cheng, S. Liao, H. K. Wong, D. A. Lacorre, E. di Tomaso, P. Au, D. Fukumura, R. K. Jain and L. L. Munn, "Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis." *Blood* 118:4740-9 (2011).
467. Liao S, Cheng G, Conner DA, Huang Y, Kucherlapati RS, Munn LL, Ruddle NH, Jain RK, Fukumura D and Padera TP, "Impaired lymphatic contraction associated with immunosuppression." *Proceedings of the National Academy of Science U S A* 108:18784-9 (2011).
468. Chauhan VP, Popović Z, Chen O, Cui J, Fukumura D, Bawendi MG, Jain RK, "Fluorescent Nanorods and Nanospheres for Real-Time In Vivo Probing of Nanoparticle Shape-Dependent Tumor Penetration," *Angew Chem Int Ed Engl.* 50:11417-11420 (2011).
469. Jain A, Munn LL Biomimetic postcapillary expansions for enhancing rare blood cell separation on a microfluidic chip. *Lab Chip* 11(17): 2941-7 (2011).
470. Song JS, Munn LL Fluid forces control endothelial sprouting. *Proceedings of the National Academy of Science U S A* 2011; 108(37): 15342-7.
471. Faber A, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes C, Gómez H, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA. BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors. *Cancer Discov.* 1(4): 352-365 (2011).
472. P. Huang, S. V. Westmoreland, R. K. Jain and D. Fukumura, "Spontaneous Nonthymic Tumors in SCID Mice." *Comp Medicine* 61:227-34 (2011).
- Reviews**
473. Y. Huang, M. Snuderl, and R. K. Jain, "Polarization of tumor-associated macrophages: A novel strategy for vascular normalization and antitumor immunity," *Cancer Cell* 19: 1-2 (2011).
474. E. Van Cutsem, D. Lambrechts, H. Prenen, R. K. Jain and P. Carmeliet. Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next? *J Clin Oncol*, 29:1-4 (2011).
475. D. G. Duda, S. V. Kozin, N. D. Kirkpatrick, L. Xu, D. Fukumura, and R. K. Jain. CXCL12 (SDF1a) – CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anti-Cancer Therapies? *Clinical Cancer Research* 17:2074-2080 (2011).
476. A. X. Zhu, D. G. Duda, D. V. Sahani and R. K. Jain, "HCC and angiogenesis: possible targets and future directions," *Nature Reviews Clinical Oncology* 8: 292-301 (2011).
477. P. Carmeliet and R. K. Jain, "Molecular mechanisms and clinical applications of angiogenesis," *Nature* 473: 298-307 (2011).
478. P. Carmeliet and R. K. Jain, "Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases," *Nature Reviews Drug Discovery* 10:417-27 (2011).
479. S. Goel, D. G. Duda, L. Xu, L.L. Munn, Y. Boucher, D. Fukumura and R. K. Jain. Normalization of the vasculature for treatment of cancer and other diseases. *Physiological Reviews* 91: 1071–121 (2011).
480. A. F. Eichler, E. Chung, D. P. Kodack, J. S. Loeffler, D. Fukumura and R. K. Jain. The biology of brain metastases—translation to new therapies. *Nature Reviews Clinical Oncology* 8: 344-56 (2011).
481. Duda DG. Targeting Tumor Angiogenesis: Biomarkers of Angiogenesis and Antiangiogenic Therapy in Cancer. e-publication, Angiogenesis Foundation, CME, August 30, 2011 (2011).
482. V. P. Chauhan, T. Stylianopoulos, Y. Boucher and R. K. Jain. Delivery of molecular and nanoscale medicine to tumors: Transport barriers and



2011 Publications

- strategies. *Annual Review of Chemical and Biomolecular Engineering* 2: 281–98 (2011).
483. Kozin SV, Duda DG, Munn LL, Jain RK. Is vasculogenesis crucial for the regrowth of irradiated tumours? *Nat Rev Cancer* 11(7): 532 (2011).


2012 Publications

Original articles

484. Tse, JM, Cheng, G, Tyrrell, JA, Wilcox-Adelman, SA, Boucher, Y, Jain RK, Munn, LL. Mechanical compression drives cancer cells toward invasive phenotype. *Proceedings of the National Academy of Science U S A* 109(3): 911-6 (2012).
485. Saylor PJ, Kozak RK, Smith MR, Ancukiewicz M, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. *Oncologist* 17(2): 212-9 (2012).
486. Duyverman AMMJ, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK. Studying stromal cell involvement in cancer metastasis using an isolated tumor perfusion model in mice. *Nature Protocols* 7(4): 749-55 (2012).
487. Duyverman AMMJ, Steller JA, Fukumura D, Jain RK, Duda DG. Studying carcinoma-associated fibroblast involvement in cancer metastasis in mice. *Nature Protocols* 7(4): 756-62 (2012).
488. Duyverman AMMJ, Kohno M, Duda DG, Jain RK, Fukumura D. Studying stromal cell involvement in cancer metastasis in mice using skin transplantation by transient parabiosis. *Nature Protocols* 7(4): 763-70 (2012).
489. Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI Protocol 6948). *PLoS One* 7(2): e26331 (2012).
490. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. *Cancer Res.* 72(2): 402-7 (2012).
491. Wong HK, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AW, di Tomaso E, Klagsbrun M, Jain RK. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. *Neoplasia* 14(2): 84-94 (2012).
492. ND. Kirkpatrick, E Chung, DC.Cook, XHan, G Gruionu, S Liao, LL Munn, TP Padera, D Fukumura and RK Jain, Video-rate resonant scanning multiphoton microscopy: An emerging technique for intravital imaging of the tumor microenvironment. *IntraVital*, 1: 60-68 (2012)..
493. Stylianopoulos T, Wong C, Bawendi MG, Jain RK, Fukumura D. Multistage nanoparticles for improved delivery into tumor tissue. *Methods Enzymol.* 508: 109-30 (2012).
494. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. *Nat Nanotechnol.* Epub on Apr 8, 2012 as doi: 10.1038/nnano.2012.45 (2012).
495. Plotkin SR, Bredella MA, Cai W, Kassarian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. *PLoS One* 7(4): e35711 (2012).
496. Duyverman AMMJ, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK. Studying stromal cell involvement in cancer metastasis using an isolated tumor perfusion model in mice. *Nature Protocols* 7:749-55 (2012).
497. Duyverman AMMJ, Steller JA, Fukumura D, Jain RK, Duda DG. Studying carcinoma-associated fibroblast involvement in cancer metastasis in mice. *Nature Protocols* 7:756-62 (2012).
498. Duyverman AMMJ, Kohno M, Duda DG, Jain RK, Fukumura D. Studying stromal cell involvement in cancer metastasis in mice using skin transplantation by transient parabiosis. *Nature Protocols* 7:763-70 (2012).
499. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, and Jain RK. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size dependent manner. *Nature Nanotechnology* 7: 383-8 (2012).
500. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, Smith BL, Ferrone CR, Hornicek FJ, Boucher Y, Munn LL and Jain RK. Causes, consequences and remedies for growth-induced solid stress in murine and human tumors. *PNAS* 109:15101-8 (2012)

Reviews

501. Vacok B, Fukumura D, Jain RK and Bouma B. Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. *Nature Reviews Cancer* 12:363-8 (2012).
502. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastatic colorectal cancer. *PLoS One* (In press).
503. Somers RC, Lanning RM, Snee PT, Greytak AB, Jain RK, Bawendi MG and Nocera DG. A Nanocrystal-based Ratiometric pH Sensor for Natural pH Ranges. *Chemical Science* (2012).
504. Stylianopoulos T, Soteriou K, Fukumura D, and Jain RK. Cationic nanoparticles have superior transvascular flux into solid tumors: Insights from a mathematical model. *Annals of Biomedical Engineering* 41:68-77 (2012).
505. Liu J, et al. TGF- β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.



2012 Publications

- PNAS 109:16618-23 (2012).
506. Huang Y, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. PNAS, 109:17561-6 (2012).
507. Kodack DP, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. PNAS, 109: E3119–E3127 (2012).
508. Jain RK, Munn LL, Fukumura D. Measuring Interstitial pH and pO₂ in Mouse Tumors. Cold Spring Harb Protoc. 2013;2013(7):675-7 - PMID: 23818669
509. Jain RK, Munn LL, Fukumura D. Measuring interstitial diffusion, convection, and binding parameters in mouse tumors. Cold Spring Harb Protoc. 2013;2013(7):678-80 - PMID: 23818670
510. Jain RK, Munn LL, Fukumura D. Measuring leukocyte-endothelial interactions in mice. Cold Spring Harb Protoc. 2013;2013(6):561-3 - PMID: 23734020
511. Jain RK, Munn LL, Fukumura D. Measuring vascular permeability in mice. Cold Spring Harb Protoc. 2013;2013(5):444-6 - PMID: 23637370
512. Jain RK, Munn LL, Fukumura D. Measuring angiogenesis and hemodynamics in mice. Cold Spring Harb Protoc. 2013;2013(4):354-8 - PMID: 23547161
513. Jain RK, Munn LL, Fukumura D. Lung window preparation in mice. Cold Spring Harb Protoc. 2013;2013(1):ePub - PMID: 23282642
514. Jain RK, Munn LL, Fukumura D. Pancreatic tumor preparation in mice. Cold Spring Harb Protoc. 2012;2012(12):ePub - PMID: 23209145
515. Jain RK, Munn LL, Fukumura D. Liver tumor preparation in mice. Cold Spring Harb Protoc. 2012;2012(12):ePub - PMID: 23209146
516. Jain RK, Munn LL, Fukumura D. Lymphangiography of the mouse tail. Cold Spring Harb Protoc. 2012;2012(11):1177-8 - PMID: 23118364
517. Jain RK, Munn LL, Fukumura D. Lymphangiography of the mouse ear. Cold Spring Harb Protoc. 2012;2012(11):1179-80 - PMID: 23118365
518. Jain RK, Munn LL, Fukumura D. Mammary fat pad chamber preparation in mice. Cold Spring Harb Protoc. 2012;2012(10):1113-4 - PMID: 23028075
519. Jain RK, Munn LL, Fukumura D. Mammary fat pad tumor preparation in mice. Cold Spring Harb Protoc. 2012;2012(10):1115-6 - PMID: 23028076
520. Jain RK, Munn LL, Fukumura D. Corneal pocket assay in rabbits. Cold Spring Harb Protoc. 2012;2012(9):1017-8 - PMID: 22949714
521. Jain RK, Munn LL, Fukumura D. Rabbit ear chambers. Cold Spring Harb Protoc. 2012;2012(7):813-14 - PMID: 22753607
522. Jain R.K. and Duda DG. Molecular Pathophysiology of Tumors. In: Principles and Practice of Radiation Oncology, 6th Edition (Editors: E. C. Halperin, C. A. Perez, L. W. Brady), Lippincott, Williams & Wilkins, New York, Chapter 4; in press (2012).
523. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2(3): a006486 (2012).
524. Goel S, Fukumura D, Jain RK. Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology. Proc Natl Acad Sci U S A. Epub on May 1, 2012 (2012).
525. Kozin SV, Duda DG, Munn LL and Jain RK. Neovascularization after irradiation: What is the source of newly formed vessels in recurring tumors? JNCI, 104: 899-905 (2012).
526. Jain RK, Carmeliet P. SnapShot: Tumor Angiogenesis. Cell, 149:1408-1408.e1 (2012).

2013 Publications


Original articles

527. H-S Han, JD Martin, J Lee, DK. Harris, D Fukumura, RK. Jain, and M Bawendi, Spatial Charge Configuration Regulates Nanoparticle Transport and Binding Behavior In Vivo. Angew Chem Int Ed Engl. 52:1414-9 (2013).
528. M Snuderl, A Batista, ND Kirkpatrick, CR de Almodovar, L Riedemann, EC Walsh, R Anolik, Y Huang, JD Martin, W Kamoun, E Knevels, T Schmidt, CT Farrar, BJ Vakoc, N Mohan, E Chung, S Roberge, T Peterson, C Bais, BH Zhelyazkova, S Yip, M Hasselblatt, C Rossig, E Niemeyer; N Ferrara, M Klagsburn, DG Duda, D Fukumura, L Xu, P Carmeliet and RK Jain. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell, 152: 1065–1076 (2013). [Highlighted in Nature Reviews Cancer, Cancer Discovery, The New England Journal of Medicine].
529. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, Jackson McCleary N, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study. Clin Cancer Res. 19: 1557-66 (2013).
530. O Chen, J Zhao, VP Chauhan, J Cui, C Wong, DK Harris, H Wei, H-S Han, D Fukumura, RK Jain & MG Bawendi. Compact high-quality “CdS core” shell nanocrystals with narrow emission linewidths and suppressed blinking. Nature Materials. 12: 445-51 (2013).
531. Y Huang, S Goel, DG Duda, D Fukumura and RK Jain. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Research 73: 2943-2948 (2013).
532. T Stylianopoulos, JD Martin, M Snuderl, F Mpekris, SR Jain and RK Jain. Co-evolution of solid stress and interstitial fluid pressure in tumors during progression: Implications for vascular collapse. Cancer Research 73: 3833-3841 (2013).



2013 Publications

533. C Lu-Emerson, M Snuderl, ND Kirkpatrick, J Goveia, C Davidson, Y Huang, L Riedemann, J Taylor, P Ivy, DG Duda, M Ancukiewicz, SR Plotkin, AS Chi, ER Gerstner, AF Eichler, J Dietrich, AO Stemmer-Rachamimov, TT Batchelor and RK Jain. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival in recurrent glioblastoma patients. *Neuro-Oncology* 15:1079-87, 2013.
534. R Samuel, L Daheron, S Liao, T Vardam, WS Kamoun, A Batista, C Buecker, R Schäfer, X Han, P Au, DT Scadden, DG Duda, D Fukumura and RK Jain. Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. *PNAS* 110:12774-9, 2013.
535. T Batchelor, P Mulholland, B Neyns, L Nabors, M Campone, A Wick, W Mason, T Mikkelsen, S Phuphanich, L Ashby, J DeGroot, R Gattamaneni, L Cher, M Rosenthal, F Payer, J Jurgensmeier, RK Jain, GA Sorensen, J Xu, Q Liu and M van den Bent. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. *Journal of Clinical Oncology* 31(26):3212-3218 (2013).
536. DV Sahani, T Jiang, K Hayano, DG Duda, OA Catalano, M Ancukiewicz, RK Jain and AX Zhu. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: Association with response and circulating biomarkers after sunitinib therapy. *Journal of Hematology & Oncology* July 10, 2013. [Epub ahead of print].
537. S Goel, N Gupta, BP Walcott, M Snuderl, CT Kesler, ND Kirkpatrick, T Heishi, Y Huang, JD Martin, E Ager, R Samuel, S Wang, J Yazbek, BJ Vakoc, RT Peterson, TP Padera, DG Duda, D Fukumura, and RK Jain. Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. *JNCI* 105 (16): 1188-1201 (2013). [See accompanying editorial: doi: 10.1093/jnci/djt199].
538. M Thunemann, L Wen, M Hillenbrand, IA Vachaviolos, S Feil, T Ott, X Han, D Fukumura, RK Jain, M Russwurm, C de Wit and R Feil. Transgenic Mice for cGMP Imaging. *Circulation Research* 113:365-71 (2013).
539. KE Emblem, K Mouridsen, A Bjornerud, CT Farrar, D Jennings, RJ H. Borra, PY Wen, P Ivy, TT Batchelor, BR Rosen, RK Jain and AG Sorensen. Vascular architecture imaging identifies patient responders to anti-angiogenic therapy. *Nature Medicine* 19:1178-1183 (2013).
540. VP Chauhan, JD Martin, H Liu, DA Lacorre, SR Jain, SV Kozin, T Stylianopoulos, AS Mousa, X Han, P Adstamongkonkul, Z Popović, P Huang, MG Bawendi, Y Boucher and RK Jain. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels. *Nature Communications* 4: 2516 (2013).
541. Chen Y, Huang P, Reiberger T, Duyverman AM, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1 α /CXCR4 axis and Gr-1+ myeloid cell infiltration in mice. *Hepatology*; doi: 10.1002/hep.26790 (2013).
542. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. A phase II and biomarker study of ramucirumab, a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, as first-line monotherapy in patients with advanced hepatocellular carcinoma. *Clinical Cancer Research* (in press).
543. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho M, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Bo-Moon C, lafrate AJ, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved perfusion and oxygenation due to vascular normalization improves survival in glioblastoma patients treated with cediranib and chemoradiation. *Proceedings of the National Academy of Science USA* (in press).
544. T Stylianopoulos and RK Jain. Combining two strategies to improve perfusion and drug delivery in solid tumors. *Proceedings of the National Academy of Science USA* (in press).
545. Kesler CT, Kuo AH, Wong H-K, Masuck DJ, Shah JL, Kozak KR, Held KD, Padera TP. Vascular endothelial growth factor-C enhances radiosensitivity of lymphatic endothelial cells. *Angiogenesis*, In Press.
546. Qazi H, Palomino R, Shi Z-D, Munn LL, Tarbell JM. Cancer Cell Glycocalyx Mediates Mechanotransduction and Flow-Regulated Invasion. *Integr. Biol.*, 2013, DOI: 10.1039/C3IB40057C.
547. Munn LL. Dynamics of tissue topology during cancer invasion and metastasis. *Physical Biology* 2013, 10(6):065003 (13pp).



Reviews

548. U Prabhakar, H Maeda, RK Jain, EM Sevick-Muraca, W Zamboni, OC Farokhzad, ST Barry, A Gabizon, P Grodzinski and DC Blakey. Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology. *Cancer Research* 73: 2412-2417 (2013).
549. RK Jain. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. *J Clinical Oncology* 31:2205-18 (2013).
550. DG Duda, LL Munn and RK Jain. Can we identify predictive biomarkers for anti-angiogenic therapy of cancer using mathematical modeling? *JNCI* 105:762-5 (2013).
551. Munn LL, Kunert C, Tyrrell JA, Modeling Tumor Blood Vessel Dynamics, in *Mathematical Methods and Models in Biomedicine-- Lecture Notes on Mathematical Modelling in the Life Sciences*, Urszula Ledzewicz, Heinz Schättler, Avner Friedman, Eugene Kashdan ed. (2013), pp 117-147
552. Kesler CT, Liao S, Munn LL, Padera TP Lymphatic vessels in health and disease. *Wiley Interdisciplinary Reviews: Systems Biology and*

2013 Publications

- Medicine, (2013).
553. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. *Cancer Research* 73: 2943-8 (2013).
554. Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK. [Letter] Benefits of vascular normalization are dose- and time-dependent. Re: Bevacizumab Hampers Antibody Uptake. *Cancer Research* doi:10.1158/0008-5472.CAN-13-1989 (2013).
555. Jain RK, Fukumura D, Duda DG. Modes of neovascularization in tumors and clinical translation of antiangiogenic therapy. In: *Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms*. First Edition, Elsevier Inc. McManus LM and Mitchell RN, editors. 12:958-962 (2013).
556. Liao S, Padera TP. Lymphatic function and immune regulation in health and disease. *Lymphatic Research and Biology*, 11(3):136-143 (2013). PMC3780287.
557. Jain RK, Chauhan V, Duda DG. Vascular and interstitial biology of tumors. In: *Clinical Oncology Fifth Edition*, Elsevier, Philadelphia. Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG, editors. 2013; in press.
558. VP Chauhan and RK Jain. Size matters in cancer nanomedicine. *Nature Materials* (in press).
559. Hagendoorn J, Yock TI, Borel Rinkes IHM, Padera TP, Ebb DH. Novel molecular pathways in Gorham's disease: implications for treatment. *Pediatric Blood and Cancer*, In Press.

2014 Publications

Original articles

560. Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA. mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL inhibition by Suppressing MCL-1. *Cancer Discovery* 4:42-52 (2014).
561. Kesler CT*, Kuo AH*, Wong H-K, Masuck DJ, Shah JL, Kozak KR, Held KD, Padera TP. "Vascular endothelial growth factor-C enhances radiosensitivity of lymphatic endothelial cells." *Angiogenesis*, 17(2):419-27 (2014)
562. MC Pinho, P Polaskova, J Kalpathy-Kramer, D Jennings, K Emblem, RK Jain, BR Rosen, PY Wen, AG Sorensen, TT Batchelor and ER Gerstner. Anti-VEGF therapy suppresses GBM pseudoprogression. *Oncologist* 19:75-81 (2014).
563. CM Lemon, PN Curtin, RC Somers, AB Greytak, RM Lanning, RK Jain, MG Bawendi and DG Nocera. Metabolic Tumor Profiling with pH, Oxygen, and Glucose Chemosensors on a Quantum Dot Scaffold. *Inorg Chem*. 53:1900-15 (2014).
564. RK Jain. An indirect way to tame cancer. *Scientific American* 310: 46-53 (2014). [Link to the podcast about this article, posted on January 27, 2014
565. Naxerova K, Brachtel E, Salk JJ, Seese AM, Power K, Abbasi B, Snuderl M, Chiang S, Kasif S, and Jain RK. Hypermutable DNA chronicles the evolution of human colon cancer. *PNAS* 111(18): E1889-98 (2014).
566. Liao S, Jones D, Cheng G, Padera TP. "Method for the quantitative measurement of collecting lymphatic vessel contraction in mice." *Journal of Biological Methods*, 1(2):e6 1-9. (2014)
567. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG. A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. *Int J Radiat Oncol Biol Phys*. 89:830-8 (2014).
568. G Seano, G Chiaverina, PA Gagliardi, L di Blasio, A Puliafito, C Bouvard, R Sessa, G Tarone, L Sorokin, D Helley, RK Jain, G Serini, F Bussolino and L Primo. Endothelial podosome rosettes regulate vascular branching in tumor angiogenesis. *Nature Cell Biology* 16:931-941 (2014).
569. O Chen, L Riedemann, F Etoc, H Herrmann, M Coppey, M Barch, C Farrar, J Zhao, O Bruns, H Wei, P Guo, J Cui, R Jensen, Y Chen, D Harris, J Cordero, Z Wang, A Jasanoff, D Fukumura, R Reimer, M Dahan, RK Jain, and M Bawendi. Magneto-fluorescent core-shell suprananoparticles. *Nature Communications* 5:5093 (2014). doi: 10.1038/ncomms6093.

Reviews

570. Hagendoorn J, Yock TI, Borel Rinkes IHM, Padera TP, Ebb DH. "Novel molecular pathways in Gorham's disease: implications for treatment." *Pediatric Blood and Cancer*, 61:401-6 (2014).
571. VP Chauhan, Y Boucher, CR Ferrone, S Roberge, JD Martin, T Stylianopoulos, N Bardeesy, RA DePinho, TP Padera, LL Munn, and RK Jain. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. *Cancer Cell* 26:14-15 (2014).
572. DG Duda, M Ancukiewicz, SJ Isakoff, IE Krop, RK Jain. Seeds and soil: How does local tumor stroma mediate distant metastasis? *JNCI* 106(8) pii: dju187 (2014).
573. Munn LL, Padera TP. "Imaging the lymphatic system." *Microvascular Research*, 96:55-63 (2014).
574. RK Jain, JD Martin and T Stylianopoulos. The role of physical forces in tumor growth and therapy. *Annual Reviews of Biomedical Engineering* 16: 321-46 (2014).
575. K Emblem, C Farrar, E Gerstner, T Batchelor, R Borra, B Rosen, AG Sorensen, and RK Jain. Vessel caliber - a potential MRI biomarker of tumour response in clinical trials. *Nature Reviews Clinical Oncology*. 11:566-584 (2014).
576. E Chung, C Yeon, RK Jain and D Fukumura. Uncovering tumor biology by intravital microscopy. In: *Comprehensive Biomedical Physics*,


2014 Publications

- Volume: IV “Optical molecular imaging” (Editor: Kiessling Alves & Anders Brahme). Elsevier Press (In press).
577. Jain RK, Netti PA. Letter to the editor regarding recent article by Wu et Al. [journal of Theoretical Biology, 355, 194-207 (2014)].
578. RK Jain, D Fukumura and DG Duda. Modes of neovascularization in tumors and clinical translation of antiangiogenic therapy. In: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (Editor: LM McManus & RN Mitchell). Elsevier Press, San Diego, p. 2926-2957 (2014).
579. Jain RK. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. *Cancer Cell* 26: 605–622 (2014).

2015 Publications

Original articles

580. Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG. Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. *PNAS* 112(5): 1350-5 (2015).
581. Ladra MM, Mandeville HC, Niemierko A, Padera TP, Friedmann AM, MacDonald SM, Ebb DH, Chen YL, Tarbell NJ, Yock TI. “Local failure in parameningeal rhabdomyosarcoma correlates with poor response to induction chemotherapy.” *Int J Radiat Oncol Biol Phys*, Apr 8. pii: S0360-3016(15)00155-8. doi: 10.1016/j.ijrobp.2015.01.049 (2015)
582. Kuo AH, Ancukiewicz M, Kozak KR, Yock TI, Padera TP. “Cardiac and inflammatory biomarkers do not correlate with volume of heart or lung receiving radiation.” *Radiation Oncology*, 10:5 1-5 (2015)
583. Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. *PNAS* 112(5): 1547-52 (2015).
584. Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, Weiner DM, Schimel D, England K, Martin JD, Gao X, Xu L, Barry CE III, and Jain RK. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. *PNAS* 112(6): 1827-32 (2015).
585. Cho JK, Hyun SH, Choi N, Kim MJ, Padera TP, Choi JY, Jeong HS. “Significance of lymph node metastasis in cancer dissemination of head and neck cancer.” *Translational Oncology*, 8:119-25 (2015).
586. Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D and Jain RK. Emerging strategies for treating brain metastases from breast cancer. *Cancer Cell* 27: 163–175 (2015).
587. Kesler CT, Pereira ER, Cui CH, Nelson GM, Masuck DJ, Baish JW, Padera TP. “Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation.” *FASEB Journal*, 29:3668-77 (2015)..
588. Ager EI, Kozin S, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein D, Dransfield DT, Devy L, Boucher Y, Fukumura D, Jain RK. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. *JNCI* 107(4). pii: djv017. doi: 10.1093/jnci/djv017 (2015).
589. Stylianopoulos T, Economides E-A, Baish JW, Fukumura D and Jain RK. Towards optimal design of cancer nanomedicines: Multi-stage nanoparticles for the treatment of solid tumors. *Annals of Biomedical Engineering* 43: 2291-2300 (2015).
590. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. *Hepatology* 61(5): 1591-602 (2015).
591. H-S Jeong, D Jones, S Liao, DA Wattson, C Cui, DG Duda, CG Willett, RK Jain and TP Padera. Investigation of the lack of angiogenesis in the formation of lymph node metastases. *JNCI* 2015;107(9) pii: djv155. doi: 10.1093/jnci/djv155.
592. Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow B, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon SH, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor T, Ligon KL, Wen PY. A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly-diagnosed glioblastoma patients. *Clin Cancer Res*. 21(16): 3610-8 (2015).
593. Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. *Neuro Oncol*. 17:1386-92 (2015).
594. Reiberger T, Chen Y, Ramjiawan RK, Hat T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX, Bardeesy N, Jain RK, Duda DG. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. *Nature Protocols* 10:1264-1274 (2015).
595. Jain, RK, Duda DG and Fukumura, D. Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years Journey. *Cancer J*. 21: 235-236 (2015).
596. Batista A, Riedemann L, Vardam T, and Jain, RK. Targeting the Tumor Microenvironment to Enhance Pediatric Brain Cancer Treatment. *Cancer J*. 21: 307-313 (2015).



2015 Publications

597. Lemon CM, Karnas E, Han X, Bruns OT, Kempa TJ, Fukumura D, Bawendi MG, Jain RK, Duda DG, Nocera DG. Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors. *J Am Chem Soc.* 137:9832-42 (2015).
598. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T. PF-06463922, an ALK/ROSI Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. *Cancer Cell* 28:70-81 (2015).
599. R Samuel, DG Duda, D Fukumura and RK Jain. Vascular diseases await translation of blood vessels engineered from stem cells. *Science Translational Medicine* 7, 309rv6 (2015). doi: 10.1126/scitranslmed.aaa1805
600. Stylianopoulos T and Jain RK. Design considerations for nanotherapeutics in oncology. *Nanomedicine: Nanotechnology, Biology and Medicine* 11: 1893-1907 (2015).
601. Datta M, Via LE, Chen W, Baish JW, Xu L, Barry CE, and Jain RK. Mathematical Model of Oxygen Transport in Tuberculosis Granulomas. *Annals of Biomedical Engineering* (in press).
602. Sara M. Tolaney Yves Boucher, Dan G. Duda, John D. Martin, Giorgio Seano, Marek Ancukiewicz, William T. Barry, Shom Goel, Johanna Lahdenrata, Steven J. Isakoff, Eren Yeh, Saloni R. Jain, Mehra Golshan, Jane Brock, Matija Snuderl, Eric P. Winer, Ian E. Krop, Rakesh K. Jain. Potential Role of Vascular Density and Vascular Normalization in Response to Neoadjuvant Bevacizumab and Chemotherapy in Breast Cancer Patients. *PNAS*, 112: 14325-14330 (2015).
603. X Gao, Y Zhao, AO Stemmer-Rachamimov, H Liu, Peigen Huang, SM China, M Selig, S Plotkin, RK Jain and L Xu. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. *PNAS*, 112: 14676-81 (2015).
604. Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig M, Brachtel E, Duda DG, Huang P, Fukumura D, Engelman JA and Jain RK. Preclinical efficacy of ado-trastuzumab emtansine in the brain microenvironment. *JNCI* Nov 7; 108(2). pii: djv313. Print 2016 Feb.
605. Kunert C, Baish JW, Liao S, Padera TP, Munn LL. Mechanobiological oscillators control lymph flow, *PNAS* 2015. doi:10.1073/pnas.
606. J Incio, P Suboj, SM Chin, T Vardam-Kaur, H Liu, T Hato, S Babykutty, I Chen, V Deshpande, RK Jain, and D Fukumura. Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. *PLoS One* 10(12): e0141392 (2015). doi: 10.1371/journal.pone.0141392.
607. Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, Lee CL, Snuderl M, Blazer III DG, Hwang SE, Greenup RA, Mosca PJ, Mito JK, Cuneo KC, Larrier NA, O'Reilly EK, Riedel RF, Eward WC, Strasfeld DB, Fukumura D, Jain RK, Lee WD, Griffith LG, Bawendi MG, Kirsch DG, and Brigman BE. A Mouse-human Phase I co-clinical trial of a protease-activated fluorescent probe for imaging cancer. *Science Translational Medicine* (In Press)
608. PK Singhal, S Sassia, L Lana, P Au, SC Halvorsena, D Fukumura, RK Jain, and B Seed. Mouse Embryonic Fibroblasts Exhibit Extensive Developmental and Phenotypic Diversity. *PNAS*, 113:122-7 (2016). doi/10.1073/pnas.1522401112.
609. J Incio, P Suboj, SM Chin, T Vardam-Kaur, H Liu, T Hato, S Babykutty, I Chen, V Deshpande, RK Jain, and D Fukumura. Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. *PLoS One* 10(12): e0141392 (2015). doi: 10.1371/journal.pone.0141392.
- Reviews**
610. Naxerova K, Jain RK Using tumour phylogenetics to identify the roots of metastasis in humans. *Nat Rev Clin Oncol.* 12: 258-272 (2015).
611. Pereira ER, Jones D, Jung K, Padera TP. "The lymph node microenvironment and its role in the progression of metastatic cancer." *Seminars in Cell and Developmental Biology*, 38:98-105 (2015).
612. C Lu-Emerson, DG Duda, KE Emblem, JW Taylor, ER Gerstner, JS Loeffler, TT Batchelor, and RK Jain. Lessons from Anti-VEGF/VEGFR Trials in Glioblastoma Patients. *Journal of Clinical Oncology* 33:1197-1213. (2015).
613. Song JW, Bazou D, Munn LL. Microfluidic Model of Angiogenic Sprouting. In *Vascular Morphogenesis*, Springer, NY. (2015) pp 243-254.
614. Munn LL. Mechanobiology of lymphatic contractions. *Seminars in Cell & Developmental Biology* (2015), 38:67-74.
615. Jain RK, Fukumura D, Duda DG. Lessons From 30 Years of Teaching About the Microenvironment of Tumors. *Cancer J.* 21:137 (2015)
616. Duda DG, Heist RS, Sahani DV, Stylianopoulos T, Engelman JA, Jain RK. Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. *PNAS* 112(27): E3454 (2015).

2016 Publications

Original articles

617. Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig M, Brachtel E, Duda DG, Huang P, Fukumura D, Engelman JA and Jain RK. Preclinical efficacy of ado-trastuzumab emtansine in the brain microenvironment. *JNCI* Nov 7; 108(2). pii: djv313. Print 2016 Feb.
618. PK Singhal, S Sasia, L Lana, P Au, SC Halvorsena, D Fukumura, RK Jain, and B Seed. Mouse Embryonic Fibroblasts Exhibit Extensive Developmental and Phenotypic Diversity. *PNAS*, 113:122-7 (2016). doi/10.1073/pnas.1522401112.
619. Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, Lee CL, Snuderl M, Blazer III DG, Hwang SE, Greenup RA, Mosca PJ, Mito JK, Cuneo KC, Larrier NA, O'Reilly EK, Riedel RF, Eward WC, Strasfeld DB, Fukumura D, Jain RK, Lee WD, Griffith LG, Bawendi MG, Kirsch DG, and Brigman BE. A Mouse-human Phase I co-clinical trial of a protease-activated fluorescent probe for imaging cancer. *Science Translational Medicine*, 8(320):320ra4 (2016).
620. Park KR, Monsky WL, Lee CG, Song CH, Kim DH, Jain RK, Fukumura D. Mast Cells Contribute to Radiation-Induced Vascular Hyperpermeability. *Radiat Res.* 185:182-9 (2016).
621. D Fukumura, J Incio, R Shankaraiah, RK Jain, Obesity and cancer: an angiogenic and inflammatory link. *Microcirculation* 23:191-206 (2016).
622. Datta M, Via LE, Chen W, Baish JW, Xu L, Barry CE, and Jain RK. Mathematical Model of Oxygen Transport in Tuberculosis Granulomas. *Annals of Biomedical Engineering* 44: 863-872 (2016).
623. Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. *PNAS* 113:4470-5 (2016).
624. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. *PNAS* 113:4476-81 (2016).
625. Blatter C, Meijer EFJ, Nam AS, Jones D, Bouma BE, Padera TP*, Vakoc BJ*. "In vivo label-free measurement of lymph flow velocity and volumetric flow rates using Doppler optical coherence tomography." *Scientific Reports*, Jul 5;6:29035. doi: 10.1038/srep29035 (2016). *Equal contribution corresponding authors. PMC4932526.
626. Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam TD, Batista A, Babykutty S, Jung K, Khachatryan A, Hato T, Ligibel J, Krop IE, Puchner SB, Schlett CL, Hoffmann U, Ancukiewicz M, Shibuya M, Carmeliet P, Soares R, Duda DG, Jain RK, Fukumura D. PIGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. *Clinical Cancer Research* 22: 2993-3004 (2016).
627. Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. *J Clin Oncol.* 34:1669-75 (2016).
628. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D & Jain RK. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. *Cancer Discovery* 6: 852-869 (2016). [Commentaries by V Bronte and G Tortora, *Cancer Discovery* 6: 821-3 (2016); MC Arkan, *Nature* 536:157-8 (2016).]
629. Nia HT, Liu H, Seano G, Datta M, Jones D, Rahbari N, Incio J, Chauhan VP, Jung K, Martin JD, Askoxylakis V, Padera TP, Fukumura D, Boucher Y, Hornicek FJ, Grodzinsky AJ, Baish JW, Munn LL and Jain RK. Solid stress and elastic energy as measures of tumour mechanopathology. *Nature Biomedical Engineering* 1: 4 (2016). doi:10.1038/s41551-016-0004. [Accompanying News & Views by Daniele M. Gilkes and Denis Wirtz - 'Tumour mechanopathology: Cutting the stress out' doi: 10.1038/s41551-016-0012; Peter Sidaway, Solid stress indicates tumour pathology, *Nature Reviews Clinical Oncology* (2016) doi:10.1038/nrclinonc.2016.209].
630. Hajjarian Z, Nia HT, Ahn S, Grodzinsky AL, Jain RK, and Nadkarni S. Laser Speckle Rheology for evaluating the viscoelastic properties of hydrogel scaffolds. *Scientific Reports* 6:37949 (2016). doi: 10.1038/srep37949.
631. Emblem KE and Jain RK. Improving Treatment of Liver Metastases by Targeting Non-angiogenic Mechanisms. *Nature Medicine* 22: 1209-1210 (2016).
632. Menter AR, Carroll NM, Sakoda LC, Delate T, Hornbrook MC, Jain RK, Kushi LH, Quinn VP and Ritzwoller DP. Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small Cell Lung Cancer. *Clinical Lung Cancer* 2016, Aug 20. pii: S1525-7304(16)30188-7. doi: 10.1016/j.clcc.2016.07.008.



2016 Publications

633. Meijer EFJ, Baish JW, Padera TP, Fukumura D. "Measuring vascular permeability *in vivo*." *Methods in Molecular Biology*, 1458:71-85 (2016).
634. Rahbari N, Kedrin D, Incio J, Liu H, Nia HT, Edrich C, Dubroix J, Chen I, Heishi T, Martin JD, Huang Y, Grodzinsky AJ, Duda DG, Jain RK & Fukumura D. Extracellular matrix remodeling after anti-VEGF therapy contributes to therapeutic resistance in colorectal cancer liver metastases. *Science Translational Medicine* 8: 360ra135 (2016). doi:10.1126/scitranslmed.aaf5219. [Highlighted in *Cancer Discovery*, *Nature Reviews Cancer*, *Nature Reviews Gastroenterology*].
635. Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. *J Neurooncol*. 2016 Nov 16.
636. Baish JW, Kunert C, Padera TP, Munn LL. Synchronization and random triggering of lymphatic vessel contractions. *PLOS Computational Biology*. 2016; 12: e1005231. doi: 10.1371/journal.pcbi.1005231.
637. Gruionu GG, Bazou D, Maimon N, Onita-Lenco M, Gruionu LG, Huang P, Munn LL. Implantable Tissue Isolation Chambers for Analyzing Tumor Dynamics *In Vivo*. *Lab Chip*. 2016; 16:1840-51.
638. Qazi H, Shi ZD, Song JW, Cancel LM, Huang P, Zeng Y, Roberge S, Munn LL*, Tarbell JM.* Heparan Sulfate Proteoglycans Mediate Renal Carcinoma Metastasis. *International Journal of Cancer*. 2016; 139:2791-2801. *Equal contributions.
639. Bazou D, Ng MR, Song JW, Chin SM, Maimon N, Munn LL. Flow-induced HDAC1 phosphorylation and nuclear export in angiogenic sprouting. *Nature Scientific Reports*. 2016; 6:34046.
640. Bazou D, Maimon N, Gruionu G, Munn LL. Self-assembly of vascularized tissue to support tumor explants *in vitro*. *Integrative Biology*. 2016; 8:1301-11.
641. Nia HT, Liu H, Seano G, Datta M, Jones D, Rahbari N, Incio J, Chauhan VP, Jung K, Martin JD, Askoxylakis V, Padera TP, Fukumura D, Boucher Y, Hornicek FJ, Grodzinsky AJ, Baish JW, Munn LL, Jain RK. "Solid stress and elastic energy as measures of tumour mechanopathology." *Nature Biomedical Engineering*, 1: 0004 (2016)
642. Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak E, Lauwers GY. A protein and mRNA expression based classification of gastric cancer. *Modern Pathology* 2016; 29: 772-84.
643. Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor- β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. *Neuro-Oncology* 2016; Epub ahead of print on Sept 23, 2016 as doi: 10.1093/neuonc/now185.
644. Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer's armor. *Oncogene* 2016;35:4957-4972. PMID: PMC5457742

Reviews


645. Munn LL and Jain, RK. The forces of cancer. *The Scientist* 30: 52-57 (2016).
646. Ferraro GB, Kodack DP, Askoxylakis V and Jain RK. Closing the gap between astrocytes and brain metastases. *Cell Research* 26: 973-4 (2016).
647. Martin JD, Fukumura D, Duda DG, Boucher Y, Jain RK Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity. *Cold Spring Harbor Perspectives in Medicine* 6:a027094 (2016). doi: 10.1101/cshperspect.a027094
648. Kumar V, Boucher Y, Liu H, Ferreira D, Hooker J, Catana C, Jain RK and Guimaraes AR. Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma. *Translational Oncology* 9:431-437 (2016).
649. Ng RM and Jain RK. Hypoxia-induced DNA hypermethylation: Another reason to normalize tumor vessels. *Translational Cancer Research* 5(Suppl 7):S1358-S1362 (2016). doi: 10.21037/tcr.2016.12.72.
650. Munn LL. Cancer and Inflammation. *WIREs Systems Biology and Medicine*. 2016; doi:10.1002/wsbm.1370.
651. Padera TP, Meijer EFJ, Munn LL. "The lymphatic system in disease processes and cancer progression." *Annual Reviews in Biomedical Engineering*, 18:125-58 (2016).
652. Gupta N, Duda DG. Role of Stromal Cell-Derived Factor 1 α Pathway in Bone Metastatic Prostate Cancer. *Journal of Biomedical Research* 2016; 30: 181-185.
653. Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. *Immunotherapy* 2016; 8: 299-313.
654. Popp I, Niedermann G, Grosu AL, Duda DG. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. *Radiotherapy and Oncology* 2016; 120: 185-94.
655. Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabash K, Shaked Y, Saulnier Sholler G, Sterba J, Waxman D, Banavali S. Next Generation Metronomic Chemotherapy – Report from the 5th Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6th – 8th May 2016, Mumbai. *eCancer* 2016; 10: 689.
656. Meijer EFJ, Baish JW, Padera TP, Fukumura D. Measuring vascular permeability *in vivo*. *Methods in Molecular Biology*. Springer press. 2016, Chapter 6. p. 71-85. PMID: PMC5435480



2017 Publications

Original articles

657. Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WR, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP and Duda DG. Phase 2 and biomarker study of cabozantinib for metastatic triple-negative breast cancer patients. *Oncologist* 2017; 22: 25-32
658. Andronesi O, Esmaili M, Borra R, Emblem K, Gerstner E, Pinho M, Plotkin S, Chi A, Eichler A, Dietrich J, Ivy P, Wen PY, Duda DG, Jain RK, Rosen B, Sorensen AG, Batchelor TT. Early changes in glioblastoma metabolism measured by MR Spectroscopic Imaging during combination of antiangiogenic cediranib and chemoradiation therapy are associated with survival. *Nature Precision Oncology* 2017 (in press).
659. Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. *United European Gastroenterol J.* 2017;5(7):987-996
660. Rowlands CJ, Park D, Bruns OT, Piatkevich KD, Fukumura D, Jain RK, Bawendi MG, Boyden ES, So PT. Wide-field three-photon excitation in biological samples. *Light Sci Appl.* 2017;6:e16255.
661. Bruns OT, Bischof TS, Harris DK, Franke D, Shi Y, Riedemann L, Bartelt A, Jaworski FB, Carr JA, Rowlands CJ, Wilson MWB, Chen O, Wei H, Hwang GW, Montana DM, Coropceanu I, Achorn OB, Kloepper J, Heeren J, So PTC, Fukumura D, Jensen KF, Jain RK, Bawendi MG. Next-generation in vivo optical imaging with short-wave infrared quantum dots. *Nat Biomed Eng.* 2017;1.
662. Li W, Yang W, Liu Y, Chen S, Chin S, Qi X, Zhao Y, Liu H, Wang J, Mei X, Huang P, Xu D. MicroRNA-378 enhances inhibitory effect of curcumin on glioblastoma. *Oncotarget.* 2017;8(43):73938-73946.
663. Li S, Kumar T P, Joshee S, Kirschstein T, Subburaju S, Khalili JS, Kloepper J, Du C, Elkhali A, Szabó G, Jain RK, Köhling R, Vasudevan A. Endothelial cell-derived GABA signaling modulates neuronal migration and postnatal behavior. *Cell Res.* 2017;;ePub - PMID: 29086765
664. Li W, Liu Y, Yang W, Han X, Li S, Liu H, Gerweck LE, Fukumura D, Loeffler JS, Yang BB, Jain RK, Huang P. MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. *J Neurooncol.* 2017;;ePub - PMID: 29081036
665. Askoxylakis V, Badeaux M, Roberge S, Batista A, Kirkpatrick N, Snuderl M, Amoozgar Z, Seano G, Ferraro GB, Chatterjee S, Xu L, Fukumura D, Duda DG, Jain RK. A cerebellar window for intravital imaging of normal and disease states in mice. *Nat Protoc.* 2017;12(11):2251-2262 .
666. Zhang N, Chen J, Ferraro G, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachamimov A, Xu L. Anti-VEGF treatment improves neurological function in tumors of the nervous system. *Exp Neurol.* 2017;;ePub - PMID: 28911884
667. Jung K, Heishi T, Incio J, Huang Y, Beech EY, Pinter M, Ho WW, Kawaguchi K, Rahbari NN, Chung E, Kim JK, Clark JW, Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D. Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer. *Proc Natl Acad Sci U S A.* 2017;114(39):10455-10460.
668. Wang X, Freire Valls A, Schermann G, Shen Y, Moya IM, Castro L, Urban S, Solecki GM, Winkler F, Riedemann L, Jain RK, Mazzone M, Schmidt T, Fischer T, Halder G, Ruiz de Almodóvar C. YAP/TAZ Orchestrate VEGF Signaling during Developmental Angiogenesis. *Dev Cell.* 2017;42(5):462-478.e7.
669. Blatter C, Meijer EFJ, Padera TP, Vakoc BJ. Simultaneous measurements of lymphatic vessel contraction, flow and valve dynamics in multiple lymphangions using optical coherence tomography. *J Biophotonics.* 2017;;ePub - PMID: 28700145
670. Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, Chung E, Clark JW, Willett CG, Luster AD, Yun SH, Langer R, Anderson DG, Padera TP, Jain RK, Fukumura D. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. *J Clin Invest.* 2017;127(8):3039-3051.
671. Naxerova K, Reiter JG, Brachtel E, Lennerz JK, van de Wetering M, Rowan A, Cai T, Clevers H, Swanton C, Nowak MA, Elledge SJ, Jain RK. Origins of lymphatic and distant metastases in human colorectal cancer. *Science.* 2017;357(6346):55-60.
672. Meijer EFJ, Jeong HS, Pereira ER, Ruggieri TA, Blatter C, Vakoc BJ, Padera TP. Murine chronic lymph node window for longitudinal intravital lymph node imaging. *Nat Protoc.* 2017;12(8):1513-1520.
673. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PKH, Chung AYF, Ooi LLPJ, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov L, Gordan R, Rozen SG, Shibata T, Pairajkul C, Teh BT, Tan P. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. *Cancer Discov.* 2017;7(10):1116-1135.
674. Levin VA, Chan J, Datta M, Yee JL, Jain RK. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. *J Neurooncol.* 2017;;ePub - PMID: 28631191
675. Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A,



2017 Publications

- Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemo KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK. Use of Angiotensin System Inhibitors is Associated with Immune Activation and Longer Survival in Non-Metastatic Pancreatic Ductal Adenocarcinoma. *Clin Cancer Res.* 2017;23(19):5959-5969 .
676. Li W, Yang W, Liu Y, Chen S, Chin S, Qi X, Zhao Y, Liu H, Wang J, Mei X, Huang P, Xu D. MicroRNA-378 enhances inhibitory effect of curcumin on glioblastoma. *Oncotarget.* 2017;;ePub - PMID: 28575858
677. Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. *Sci Transl Med.* 2017;9(391): eaa4682
678. Meijer EF, Blatter C, Chen IX, Bouta E, Jones D, Pereira ER, Jung K, Vakoc BJ, Baish JW, Padera TP. Lymph node effective vascular permeability and chemotherapy uptake. *Microcirculation.* 2017;;ePub - PMID: 28510992
679. Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, Dima S, Duda DG, Teh BT, Popescu I, Lim TK. Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors. *Am J Cancer Res.* 2017;7(3):484-502.
680. Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. *Sci Rep.* 2017;7:44123.
681. Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. *Cancer.* 2017;123(11):1979-1988.
682. Mpekris F, Baish JW, Stylianopoulos T, Jain RK. Role of vascular normalization in benefit from metronomic chemotherapy. *Proc Natl Acad Sci U S A.* 2017;114(8):1994-1999.
683. Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn LL, Jain RK, Garkavtsev I. Stress granule-associated protein G3BP2 regulates breast tumor initiation. *Proc Natl Acad Sci U S A.* 2017;114(5):1033-1038.
684. N Lippok, M Villiger, A Albanese, EFJ Meijer, K Chung, TP Padera, SN Bhatia, BE Bouma. Depolarization signatures map gold nanorods within biological tissue. *Nature Photonics*, July 31, 2017 doi:10.1038/nphoton.2017.128.
685. Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. *United European Gastroenterol Journal:* 5(7): 987-996 (2017).
686. Kozin SV, Maimon N, Wang R, Gupta N, Munn LL, Jain RK, Garkavtsev I. Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers. *Oncotarget.* 2017; 8(65): 108292–108302.
687. DA Reardon, A Lassman, D Schiff, Shakeeb Yunus; Elizabeth Gerstner; Timothy Cloughesy; Eudocia Quant Lee; Sarah C. Gaffey; Jennifer Barrs; Jennifer Bruno; Alona Muzikansky, Dan G. Duda; Rakesh K. Jain; Patrick Y. Wen. Phase II and biomarker study of trebananib, an angiopoietin blocking peptidobody, with and without bevacizumab for recurrent glioblastoma patients. *Cancer* 2017; 124: 1438–48.

Reviews

688. Aoki S, Cobbold M, Zhu AX, Duda DG. Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? *Hepatology.* 2017;;ePub - PMID: 29077214
689. Mitchell MJ, Jain RK, Langer R. Engineering and physical sciences in oncology: challenges and opportunities. *Nat Rev Cancer.* 2017;17(11):659-675.
690. Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. *Sci Transl Med.* 2017;9(410):ePub - PMID: 28978752.
691. Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? *Onco Targets Ther.* 2017;10:1403-1412
692. Askoxylakis V, Arvanitis CD, Wong CSF, Ferraro GB, Jain RK. Emerging Strategies for Delivering Antiangiogenic Therapies to Primary and Metastatic Brain Tumors. *Adv Drug Deliv Rev.* 2017;119:159-174.
693. Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? *Angiogenesis.* 2017;20(2):185-204.
694. Zhang N, Gao X, Zhao Y, Datta M, Liu P, Xu L. Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma. *J Rare Dis Res Treat.* 2017;1(2):51-55.
695. Askoxylakis V, Kodack DP, Ferraro GB, Jain RK. Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB? *Breast Cancer Res Treat.* 2017;165(2):467-468.
696. De Palma M, Jain RK. CD4(+) T Cell Activation and Vascular Normalization: Two Sides of the Same Coin? *Immunity.* 2017;46(5):773-775.
697. Wang N, Jain RK, Batchelor TT. New Directions in Anti-Angiogenic Therapy for Glioblastoma. *Neurotherapeutics.* 2017;14(2):321-332.
698. Munn LL. Cancer and Inflammation. *WIREs Systems Biology and Medicine.* (2017) 9:e1370 doi:10.1002/wsbm.1370.

2018 Publications

Original articles

699. Sung Y-C, Liu Y-C, Chao P-H, Chang C-C, Lin T-T, Lin J-A, Cheng H-T, Wang J, Lai CP, Chen L-H, Jin P, Wu AY, Chiang T, Gao D-Y, Duda DG, Chen Y. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. *Theranostics* 2018; 8: 894–904.
700. Bouta EM, Blatter C, Ruggieri TA, Meijer EFJ, Munn LL, Vakoc BJ, Padera TP. Lymphatic function measurements influenced by contrast agent volume and body position. 2018; *JCI Insight*. 3(2):e96591. J
701. Jones D, Meijer EFJ, Blatter C, Liao S, Pereira ER, Bouta EM, Jung K, Chin SM, Huang P, Munn LL, Vakoc BJ, Otto M, Padera TP. Methicillin-resistant *Staphylococcus aureus* causes sustained collecting lymphatic vessel dysfunction. 2018; *Science Translational Medicine*. 10(424), eaam7964. [doi:10.1126/scitranslmed.aam7964](https://doi.org/10.1126/scitranslmed.aam7964).
702. Bazou D, Maimon N, Gruionu G, Grahovac J, Seano G, Liu H, Evans CL, Munn LL. Vascular beds maintain pancreatic tumor explants for ex vivo drug screening. *Journal of Tissue Engineering and Regenerative Medicine*. 2018; 12(1): e318-e322.
703. E.R. Pereira, D. Kedrin, G. Seano, O. Gautier, E.F.J. Meijer, D. Jones, S.M. Chin, S. Kitahara, E.M. Bouta, J. Chang, E. Beech, H.S. Jeong, M.C. Carroll, A.G. Taghian, T.P. Padera. “Lymph node metastases can invade local blood vessels, exit the node and colonize distant organs in mice.” *Science*, 359: 1403-1407 (2018).
704. A. Bourquard, A.P. Trinidad, I. Butterworth, Á. Sánchez-Ferro, C.C. Canales, K. Humala, M.F. Urdiola, C. del Rio, B. Valles, J.M. Tucker-Schwartz, E.S. Lee, B.J. Vakoc, T.P. Padera, M.J. Ledesma-Carbayo, Y.-B. Chen, E.P. Hochberg, M.L. Gray, C. Castro-González “Non-invasive detection of severe neutropenia in chemotherapy patients by optical imaging of nailfold microcirculation.” *Scientific Reports*, Mar 28;8(1):5301. [doi: 10.1038/s41598-018-23591-0](https://doi.org/10.1038/s41598-018-23591-0). (2018).
705. K Dixon, M Schorer, J Nevin, Y Etminan, Z Amoozgar, T Kondo, S Kurtulus, N Kassam, RA Sobel, D Fukumura, RK Jain, AC Anderson, VK Kuchroo, N Joller. Functional anti-TIGIT antibodies regulate development of autoimmunity and anti-tumor immunity. *Journal of Immunology*. 200: 3000-3007 (2018).
706. D.J. Firl, S.E. Degn, T. Padera, M.C. Carroll. “Capturing change in clonal composition amongst single mouse germinal centers.” *eLife*, Aug 1;7: pii: e33051. [doi: 10.7554/eLife.33051](https://doi.org/10.7554/eLife.33051) (2018).
707. S Li, P Kumar T, S Joshee, T Kirschstein, S Subburaju, J Khalili, J Kloepper, C Du, A Elkhali, G Szabo, RK Jain, R Koehling and A Vasudevan. Endothelial Cell Derived GABA Signaling Modulates Neuronal Migration and Postnatal Behavior. *Cell Research*, 28:221-248 (2018).
708. MJ Khandekar and RK Jain. Smooth sailing for immunotherapy for unresectable stage III Non-small cell lung cancer: The PACIFIC study. *Translational Cancer Research* 7: S16-S20 (2018).
709. DA Reardon, A Lassman, D Schiff, Shakeeb Yunus; Elizabeth Gerstner; Timothy Cloughesy; Eudocia Quant Lee; Sarah C. Gaffey; Jennifer Barrs; Jennifer Bruno; Alona Muzikansky, Dan G. Duda; Rakesh K. Jain; Patrick Y. Wen. Phase II and biomarker study of trebananib, an angiopoietin blocking peptibody, with and without bevacizumab for recurrent glioblastoma patients. *Cancer* (Online on December 19, 2017). [doi: 10.1002/cncr.31172](https://doi.org/10.1002/cncr.31172). 124:1438-1448 (2018).
710. W Li, Y Liu, W Yang, X Han, S Li, H Liu, LE Gerweck, D Fukumura, JS Loeffler, BB Yang, RK Jain and P Huang. MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. *Journal of Neuro-Oncology* 136: 63-71 (2018).
711. Y Zhao, P Liu, N Zhang, J Chen, LD Landegger, L Wu, F Zhao, Y Zhang, J Zhang, T Fujita, A Stemmer-Rachamimov, GB Ferraro, H Liu, A Muzikansky, SR Plotkin, KM Stankovic, RK Jain and L Xu. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. *PNAS* (online on Feb 9, 2018) 115: E2077-E2084 (2018).
712. J Incio, JA Ligibel, DT McManus, P Suboj, K Jung, K Kawaguchi, M Pinter, S Babykutty, SM Chin, TD Vardam, Y Huang, NN Rahbari, S Roberge, D Wang, IL Gomes-Santos, SB Puchner, CL Schlett, U Hoffmann, M Ancukiewicz, SM Toloney, IE Krop, DG Duda, Y Boucher, D Fukumura and RK Jain. Obesity promotes resistance to anti-VEGF therapy in breast cancer by upregulating IL-6 and potentially FGF-2. *Science Translational Medicine*, 10: eaag0945. Published online on March 14, 2018.
713. JA Carr, D Franke, JR Carama, CF Perkinson, V Askoxylakis, M Datta, D Fukumura, RK Jain, MG Bawendi and OT Bruns. Shortwave Infrared Fluorescence Imaging with the Clinically Accessible Near-Infrared Dye Indocyanine Green. *PNAS* 115:4465-4470 (2018).
714. HT Nia, M Datta, G Seano, P Huang, LL Munn, and RK Jain. Quantifying solid stress and elastic energy from excised or in situ tumors. *Nature Protocols* 13(5):1091-1105 (2018). <https://rdcu.be/LZEV>
715. A Griveau, G Seano, SJ Shelton R Kupp, A Jahangiri, K Obernier, S Krishnan, OR Lindberg, TJ Yuen, A-C Tien, JK Sabo, N Wang, I Chen, J Kloepper, L Larrouquere, M Ghosh, It Tirosh, E Huillard, A Alvarez-Buylla, MC Oldham, AI Persson, WA Weiss, TT Batchelor, A Stemmer-Rachamimov, ML Suva, JJ Phillips, M Aghi, S Mehta, RK Jain and DH Rowitch. A glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment. *Cancer Cell* 33 (5): 874-889 (2018).
716. M Binnewies, E Roberts, V Chan, K Kersten, DF Fearon, M Merad, LM Coussens, D Gabrilovich, S Ostrand-Rosenberg, CC Hedrick, RH Vonderheide, M Pittet, RK Jain, W Zou, K Howcroft, E Woodhouse, The TiME Working Group, R Weinberg, M Krummel. The Tumor Immune Microenvironment (TIME): The Future of Understanding Tumor-Tissue Biology for Key Insights and Cures. *Nature Medicine* 24(5): 541-550 (2018).
717. Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyer CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX and Duda DG. Differential Association Between Circulating Lymphocyte Populations with Outcome after Radiation Therapy in Subtypes of Liver Cancer. *Int J Radiat Oncol Biol Phys*. 101(5):1222-1225 (2018).
718. EQ Lee, DG Duda, A Muzikansky, ER Gerstner, JG Kuhn, DA Reardon, L Nayak, AD Norden, L Doherty, J Stefanik, D LaFrankie, J Armitage, T Vardam, D Stokes, KH Smith, C McCluskey, S Gaffey, TT Batchelor, RK Jain and, PY Wen. Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma. *Clinical Cancer Research* 24(19):4643-4649 (2018).
719. CD Arvanitis, V Askoxylakis, Y Guo, M Datta, J Kloepper, GK Ferraro, MO Bernabeu, D Fukumura, N McDannold and RK Jain. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced transient blood-tumor barrier disruption. *PNAS* 115(37):

2018 Publications

- E8717-E8726 (2018).
720. Ina Ly K, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. *Science Reports* 8(1):17062 (2018).
721. S Li, W Li, C-H Leung, S Kitahara, Y Liu, S Klein, D Fukumura, JS Loeffler, RK Jain, DG Duda, and P Huang. Combining Angiotensin Receptor Blocker Losartan and the CXCR4 Inhibitor AMD3100 Increases the Efficacy of Radiotherapy in a Metastatic Osteosarcoma Mouse Model. *J Cancer Sci Ther* 10: 351-365 (2018). doi: 10.4172/1948-5956.1000570.
722. S.D. Nathanson, D. Krag, H.M. Kuerer, L.A. Newman, M. Brown, D. Kerjaschki, E.R. Pereira, T.P. Padera. "Breast cancer metastasis through the lympho-vascular system." *Clinical and Experimental Metastasis*, May 13, 2018 <https://doi.org/10.1007/s10585-018-9902-1>

Reviews

723. D Fukumura, J Kloepper, Z Amoozgar, DG Duda and RK Jain. Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges. *Nature Reviews Clinical Oncology*. 15: 325-340 (2018).
724. RK Jain and A. Batista. A physical view of cancer. *Trends in Cancer* 4: 257 (2018).
725. T Stylianopoulos, LL Munn and RK Jain. Reengineering the tumor vasculature: Improving drug delivery and efficacy. *Trends in Cancer* 4: 258-259 (2018).
726. T Stylianopoulos, LL Munn and RK Jain. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: From math modeling to bench to bedside. *Trends in Cancer* 4: 292-319 (2018).
727. M Pinter, WJ Kwanten and RK Jain. Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events. *Clinical Cancer Research* 24: 3803-12 (2018).
728. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. *Angiogenesis*. 2018; ePub - PMID: 29766399 - DOI: 10.1007/s10456-018-9613-x
729. Munn LL, Garkavtsev I. SLPI: a new target for stopping metastasis. *Aging*. 2018;10(1): 13–14.
730. D. Jones, E.R. Pereira, T.P. Padera. "Growth and immune evasion of lymph node metastasis." *Frontiers in Oncology*, Feb 21;8:36. doi: 10.3389/fonc.2018.00036. (2018).

2019 Publications

Original articles


731. Li H, Mei Y, Maimon N, Padera TP, Baish JW, Munn LL. The effects of valve leaflet mechanics on lymphatic pumping assessed using numerical simulations. *Scientific Reports* 2019; 9(1): 10649.
732. L Goyal, H Zheng, T Abrams, R Mihsad, A Bullock, J Allen, M Yurgelun, J Clark, A Muzikansky, M Knowles, A Galway, A Afflitto, C Dinicola, E Regan, T Hato, E Mamessier, K Shigeta, RK Jain, DG Duda, and A Zhu. A Phase II and Biomarker Study of Sorafenib Combined with FOLFOLX in Patients with Advanced Hepatocellular Carcinoma. *Clinical Cancer Research* 25: 80-89 (2019).
733. I Keklikoglou, C Cianciaruso, E Güç, M L Squadrito, S Tazzyman, L Lambein, A Poissonnier, GB Ferraro, C Baer, A Cassará, A Guichard, ML Iruela-Arispe, CE Lewis, LM Coussens, A Bardia, LM Spring, RK Jain, JW Pollard and M DePalma. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. *Nature Cell Biology* 21(2):190-202 (2019). <https://rdcu.be/be4fa>
734. S Liao, EM Bouta, LM Morris, D Jones, RK Jain and TP Padera. Inducible nitric oxide synthase and CD11b+Gr1+ cells impair lymphatic contraction of tumor draining lymphatic vessels. *Lymphatic Research and Biology* 17: 294-300 (2019).
735. G Seano, HT Nia, KE Emblem, M Datta, J Ren, J Kloepper, S Krishnan, M Ghosh, MC Pinho, V Askoxylakis, GB Ferraro, L Riedemann, ER Gerstner, TT Batchelor, PY Wen, NU Lin, AJ Grodzinsky, D Fukumura, P Huang, JW Baish, TP Padera, LL Munn and RK Jain. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. *Nature Biomedical Engineering* 3: 230-245 (2019). <https://rdcu.be/bfjBl>
736. J Chen, L Landegger, Y Sun, J Ren, N Maimon, L Wu, M Ng, J Chen, N Zhang, Y Zhao, X Gao, T Fujita, S Roberge, P Huang, RK Jain, S Plotkin, K Stankovic and L Xu. A cerebellopontine angle mouse model for the investigation of tumour biology, hearing and neurological function in NF2-related vestibular schwannoma. *Nature Protocols* 14(2):541-555 (2019).
737. V Askoxylakis, GB Ferraro, M Badeaux, DP Kodack, I Kirst, RC Shankaraiah, CSF Wong, DG Duda, D Fukumura and RK Jain. Dual endothelin receptor inhibition enhances T-DMI efficacy in brain metastases from HER2-positive breast cancer. *NPJ Breast Cancer* 5: 4 (2019). <https://rdcu.be/bgVG5>
738. Y Zhao, J Cao, A Melamed, M Worley, A Gockley, D Jones, HT Nia, Y Zhang, T Stylianopoulos, AS Kumar, F Mpekris, M Datta, Y Sun, L Wu, X Gao, O Yeku, MG del Carmen, DR Spriggs, RK Jain and L Xu. Losartan treatment enhances chemotherapy efficacy and

2019 Publications

- reduces ascites in ovarian cancer models by normalizing the tumor stroma. *PNAS* 116: 2210-2219 (2019) <https://doi.org/10.1073/pnas.1818357116>
739. C Voutouri, ND Kirkpatrick, E Chung, F Mpekris, JW Baish, LL Munn, D Fukumura, T Stylianopoulos and RK Jain. Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies. *PNAS* 116: 2662-2671 (2019) doi:10.1073/pnas.1818322116
740. IX Chen, VP Cauhan, J Posada, MR Ng, MW Wu, P Adstamongkonkul, P Huang, N Lindeman, R Langer and RK Jain. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. *PNAS* 116 (10) 4558-4566 (2019) www.pnas.org/cgi/doi/10.1073/pnas.1815515116 [Accompanying Commentary by George Sledge 116 (11) 4769-4771 (2019) <https://doi.org/10.1073/pnas.1900368116>] [NCI Blog: <https://www.cancer.gov/news-events/cancer-currents-blog/2019/transplant-drug-immunotherapy-metastatic-breast-cancer>]
741. VP Chauhan, IX Chen, R Tong, MR Ng, JD Martin, K Naxerova, MW Wu, Y Boucher, DS Kohane, R Langer and RK Jain. Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. *PNAS* 116: 10674-10680 (2019).
742. JE Murphy, JY Wo, DP Ryan, JW Clark, W Jiang, BY Yeap, LC Drapek, LS Blazskowsky, CR Ferrone, M Qadan, D Berger, A Parikh, CD Weekes, R Nipp, EL Kwak, JN Allen, RB Corcoran, DT Ting, JE Faris, AX. Zhu, L Goyal, KD Lillemoe, RK Jain, TF DeLaney, DG Duda, Y Boucher, C Fernandez-del Castillo and TS Hong. Total Neoadjuvant Therapy with Folfirinox in Combination with Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase II Clinical Trial. *JAMA Oncology* 5(7):1020-1027 (2019). Doi: 10.1001/jamaoncol.2019.0892.
743. JM Cleary, NK Horick, NJ McCleary, TA Abrams, MB Yurgelun, CG Azzoli, DA Rubinson, G Brooks, JA Chan, LS Blazskowsky, JW Clark, L Goyal, JA Meyerhardt, K Ng, D Schrag, DMF Savarese, C Graham, KA Gibb, Y Boucher, DG Duda, RK Jain, CS Fuchs, and PC Enzinger. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma (ZAMEGA): a double blind randomized multi-center phase 2 trial. *Cancer* 125: 2213-2221 (2019). <https://doi.org/10.1002/cncr.32029>
744. CJ Rowland, OT Bruns, D Franke, D Fukumura, RK Jain, MG Bawendi and PTC So. Increasing the penetration depth of temporal focusing multiphoton microscopy for neurobiological applications. *Journal of Physics D: Applied Physics* (in press, 2019).
745. K Shigeta, M Datta, Tai Hato, S Kitahara, I Chen, A Matsui, H Kikuchi, E Mamessier, S Aoki, P Huang, M Cobbold, AX Zhu, RK Jain and DG Duda. Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC. *Hepatology* Published online on Aug 5, 2019. doi: 10.1002/hep.30889.
746. C Fernandez-Martos, C Pericay, F Losa, R García-Carbonero, L Layos, N Rodríguez-Salas, M Martin-Richard, V Alonso, R Vera, J Gallego, J Capdevila, A Salud, M Nogué, J Maurel, I Guash, C Montagut, C Lopez, I Macias RK Jain, and X Garcia-Albeniz. Effect of Adding Aflibercept to Induction Chemotherapy Followed by Chemoradiotherapy and Surgery in High-Risk Rectal Cancer. GEMCAD 1402 Study. A Randomized Clinical Trial. *JAMA Oncology*. Published online August 29, 2019. doi:10.1001/jamaoncol.2019.2294
747. JP Leone, DG Duda, J Hu, WT Barry, L Trippa, ER Gerstner, RK Jain, STan, E Lawler, EP Winer, NU Lin, and SM Tolaney. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. *Breast Cancer Research and Treatment*. <https://doi.org/10.1007/s10549-019-05445-z>
748. E Gerstner, K Emblem, K Chang, B Vakulenko-Lagun, Y-F Yen, A Beers, J Dietrich, S Plotkin, C Catana, J Hooker, D Duda, B Rosen, J Kalpathy-Cramer, RK Jain, and TB Batchelor. Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. *Clinical Cancer Research* DOI: 10.1158/1078-0432.CCR-19-1739

Reviews

749. JD Martin, G Seano and RK Jain. Normalizing Function of Tumor Vessels: Progress, Prospects and Challenges. *Annual Reviews of Physiology* 81: 505-534 (2019). <https://doi.org/10.1146/annurev-physiol-020518-114700>
750. H Nia, LL Munn and RK Jain. Mapping physical tumor microenvironment and drug delivery. *Clinical Cancer Research* 25: 2024-6 (2019). <http://clincancerres.aacrjournals.org/content/25/7/2024.full>
751. Z Amoozgar, RK Jain and D Duda. Role of apelin in glioblastoma vascularization and invasion after anti-VEGF therapy: What is the impact on the immune system? *Cancer Research* 79: 2104-2106 (2019).
752. M Datta, LM Coussens, H Nishikawa, FS Hodi and RK Jain. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. *Am Soc Clin Oncol Educ Book*. 39:165-174 (2019). doi: 10.1200/EDBK_237987.
753. LL Munn and RK Jain. Vascular regulation of anti-tumor immunity. *Science* 365: 544-545 (2019). DOI: 10.1126/science.aaw7875.
754. JD Martin, H Cabral, T Stylianopoulos and RK Jain. Improving cancer immunotherapy using nanomedicine: Progress, opportunities and challenges. *Nature Reviews Clinical Oncology* (in press).
755. CD Arvanitis, GB Ferraro and RK Jain. The blood-brain barrier and blood-tumor barrier in brain tumors and metastases. *Nature Reviews Cancer* (in press).
756. G. Seano and RK Jain. Vessel co-option in glioblastoma: emerging insights and opportunities. *Angiogenesis* (in press).



PATENTS

R.K. Jain, Y. Boucher, A. Stacey-Clear, R. Moore and D. Kopans, "Method for Locating Tumors Prior to Needle Biopsy," U.S. Patent Number 5, 396, 897, March 14, 1995.

P. Netti and R.K. Jain, "Method of Enhancing Delivery of a Pharmaceutical Formulation," U.S. Patent Number 5, 888, 530, March 30, 1999.

R.K. Jain, R.J. Melder, G.C. Koenig, and L.L. Munn. "Therapeutic Use of bFGF to Treat Conditions Involving Adhesion of Cytotoxic White Cells to Endothelium," U.S. Patent Number 6, 101, 712, January 4, 2000.

G. Helmlinger, P. Netti, R.J. Melder, H. Lichtenbeld-Dubois, and R.K. Jain. "Modulation of Multicellular Aggregates by Pressure from Growth in a Matrix," U.S. Patent Number 6,368,858, April 9, 2002.

R. B. Campbell and R. K. Jain, "Drug Delivery Formulations and Targeting," U.S. Patent Number 6,860,068, January 20, 2004.

B. Seed and R. K. Jain. "Methods to Potentiate Cancer Therapies", Patent number US 6,719,977, April 13, 2004.

R.K. Jain, S. Kozin, D. Fukumura, D.G. Duda. "Anti-CXCR4 As A Sensitizer to Cancer Therapeutics" US Patent No. 9,155,723, Oct 13, 2015

Duda D.G., Lauwers G. Y. "A Protein and mRNA Expression Based Classification of Gastric Cancers" Application MGH23815 filed on 2/09/16 with the USPTO.

Duda D.G., Tolaney S. "Triple Negative Breast Cancer Treatment Method". Application DFCI2289 filed on 11/30/16 with the USPTO.

R. K. Jain, V. Chauhan, B. Diop-Frimpong, Y. Boucher, S. M. Krane and A. L. Crane. "Novel Composition and Uses of Anti-hypertension agents for Cancer Therapy." Foreign Patent No. 030258-069094-AU, April 13, 2017.

C. R. Wong, M. G. Bawendi, D. Fukumura, and R. K. Jain. "Multistage nanoparticle drug delivery system for the treatment of solid tumors," U.S. Patent No. 9,919,059, March 20, 2018.


RESEARCH TEAM

Professor	Rakesh K. Jain
Associate Professors	Yves Boucher Dai Fukumura Dan G. Duda Lance L. Munn Tim Padera
Assistant Professors	Peigen Huang Igor Garkavtsev Lei Xu
Fellows	Patrik Andersson Zohreh Amoozger Jiang Chen Sampurna Chaterjee Yoon Sun Choi Meenal Datta Gino Ferraro Lei Gao Koetsu Inoue Kazumichi Kawakubo Hiroto Kikuchi Sergey Kozin Shanmugarajan Krishnan Pinji Lei Huabing Li Chong Liu Aya Matsui Bhushan Patel Ethel Perreira Jessica Posada Nick (Xiaoling) Qi Jun Ren

Fellows	Kangsan Roh Yao Sun Limeng Wu Wei Yang Weining Yang Changli Yue Yanxia Zhao
Graduate Students	Ashwin Kumar Jun Ren William Ho Jan Willem vanWijnbergen Mohammad Nikmaneshi
	Aurea Aguasvivas
Technical Assistants	Mark Duquette Ya Li (Sandy) Guan Julia Kahn Anna Khachatryan Brigido Lopez YanFang Lu Nghia Pham Sylvie Roberge Carolyn Smith TSION Tale Penny Woo Rikcy Yun
Administrative support	Zeina Chaptini Elizabeth Garzon

RESEARCH TEAM

In September 1991, we started with a small team of six people, and we have since grown to approximately 65 members, and have developed a **leading, multidisciplinary research and education** program in the integrative biology of cancer. We have trained more than 200 graduate and post-graduate students - several of them have become leaders in academia, government and industry.



ALUMNI

Assistant Professors

Robert J. Melder	1989 - 98
Fan Yuan	1990 - 96
Laurence T. Baxter	1991 - 98
David Berk	1992 - 98
E. diTomaso	1998 - 09

Instructors

Intae Lee	1991 - 94
Hera Lichtenbeld	1994, 1997 - 99
Ping Jiang	1997 - 98
Kevin Burton	1999 - 2001

Fellows

Cindy Znati	1990 - 95
Michael Leunig	1991 - 93
Robert Zlotnicki	1992 - 93
Paul Kristjansen	1992 - 94
Anders Leu	1993 - 94
Manfred Stohrer	1993 - 94
Shige Yamada	1993 - 94
Marc Dellian	1993 - 95
Mutsumi Nozue	1993 - 95
Shigeru Tanda	1994 - 96
Mit Endo	1994 - 97
Gabriel Helmlinger	1994 - 97
Paolo Netti	1994 - 97
Sybil Patan	1994 - 99
Stuart Freidrich	1996 - 97
Axel Sckell	1996 - 97
Lance Wilsey	1996 - 97
Genevieve Griffon	1996 - 98
Wayne Monsky	1996 - 98
Takeshi Gohongi	1997 - 00
Alain Pluen	1997 - 00
Jin Yuan	1997 - 00
Nils Hansen	1997 - 98
Keiichi Ohtaka	1997 - 98
Marc Heijn	1997 - 99
Chang Geol Lee	1997 - 99
Kyung Ran Park	1997 - 99
Saroja Ramanujan	1998 - 00
Yoshikazu Tsuzuki	1998 - 01
Chieko Koike	1998 - 00
Ananth Kadambi	1998 - 01
Yong Chang	1998 - 00
Chae - Ok Yun	1998 - 00
Randal Dull	1998 - 99
Sergey Kozin	1998 - 15
Yotaro Izumi	1999 - 02
Vincent Moutardier	1999 - 00

Carla Mouta - Carreira	1999 - 01
Robert Campbell	1999 - 02
Edward Brown	1999 - 05
Brenda Fenton	2000 - 01
Oliver Gralla	2000 - 01
Cristiano Migliorini	2000 - 01
Akira Ushiyama	2000 - 01
Xaioye Wang	2000 - 01
Maximilian Bockhorn	2000 - 02
Dennis Dolmans	2000 - 02
Neil Forbes	2000 - 02
Tiina Roose	2001 - 02
Naoto Koike	2001 - 03
George Alexandrakis	2001 - 04
Zoe Demou	2001 - 04
Naohide Isaka	2002 - 04
Mark Stroh	2002 - 04
Chenghai Sun	2002 - 05
Patrick Au	2002 - 09
Frank Winkler	2003 - 04
Jeroen Hagendoorn	2003 - 05
Mitsutomo Kohno	2003 - 05
Michael Booth	2003 - 06
Tohru Hoshida	2003 - 06
Satoshi Kashiwagi	2003 - 06
Mai Luong	2003 - 07
Aaron Mulivor	2003 - 07
Sung Suk Chae	2004 - 10
Junichi Miyazaki	2004 - 05
Michael Dupin	2004 - 07
Aaron Mulivor	2004 - 07
Greg Nelson	2004 - 07
Jean Yannis Perentes	2004 - 07
Satoshi Nagano	2004 - 09
Cimona Hinton	2005
Carsten Ley	2005
Delphine Lacorre	2005 - 11
Kevin Kozak	2005 - 07
Carsten Ley	2005 - 07
Michelle Dawson	2005 - 08
Johanna Lahdrenranta	2005 - 08
Mai Luong	2005 - 08
Gang Cheng	2005 - 09
Walid Kamoun	2006 - 11
Annique Pieters	2006 - 10
Kevin Kozak	2006 - 07
J. Alex Tyrrell	2006 - 08
Angera Kuo	2006 - 09
Euiheon Chung	2007 - 10
Sachie Nakamura	2007 - 10

Hiroshi Yamashita	2007 - 10
Kosuke Tsukada	2007 - 09
Andus Wong	2007 - 09
Shan Liao	2007 - 13
Rekha Samuel	2008 - 11
T. Stylianopoulos	2008 - 10
Ned Kirkpatrick	2008 - 13
Matija Snuderl	2008 - 12
Jonathan Song	2008-14
Han - Sing Jeong	2009 - 11
Temitope Sondunke	2009 - 10
Jayeeta Bhaumik	2010 - 11
Christian Kunert	2010-15
David Kodack	2010-14
Christina Kesler	
Becky Chen	2010 - 13
Christine Lu-Emerson	2010 - 12
Janet Tse	2010 - 11
Ana Batista	2010 - 15
Robin Amelung	
Lars Riedemann	2011-15
Eleanor Ager	2011- 13
Despina Bazou	2011- 16
Tatiana Demidova-Rice	2011 - 13
Nuh Rahbari	2011- 13
Gabriel Gruionu	2011-15
Julien Daubriac	
Rouxu Dou	
Vikash Chauhan	2012-15
Nir Maimon	2012 -19
Mark Badeaux	2012 -17
Dennis Jones	2012- 18
Echoe Bouta	2012- 17
Jennie Taylor	2012 -14
Trupti Vardam	2012-15
Vera Verbuggen	
Xiaoxing Han	2012 -15
Jonas Kloepper	2012 -16
Daniel Schanne	2013- 17
Tai Hato	2013- 16
Giorgio Seano	2013 -18
Rosa Ng	2013 -18
Shuang Yan	2014 -15
Shuji Kitahara	2014- 17
Sen Li	2014- 16
Hadi Nia	2014 -18
Louis Larrouquere	2015 - 17
Yingchao Zhao	2015-16
Eelco Meijer	2015- 17
Yuhui Zhao	2015 -17

Matthias Pinter	2015 -17
Ivy Chen	2015-19
Mitrajit Ghosh	2016 -17
Emilie Mamessier	2016- 17
Christina Wong	2016 -18
Kohei Shigeta	2016 - 18
Kosuke Kawaguchu	2016 - 18
Shuichi Aoki	2016 - 19
Nojiri Takashi	2017 - 18
Som Nath Pandey	2019
Medical Students	
Thomas Demhartner	1992
Hassan Salehi	1993 - 94
Brian Witwer	1994 - 95
Daniel Greif	1995
Albert Loskin	1995 - 96
Nina Safabakhsh	1995 - 96
Jennifer Ang	1998 - 99
Aloke Finn	2005 - 06
Michael Awad	2001 - 03
Toshiya Miyauchi	2013 - 14
Sebastian Klein	2014 - 15
Takuya Suematsu	2014 - 15
Glenn Geidel	2015 - 16
Kevin Koch	2016 - 17
Mie Yamanaka	2017 -
Technical Assistants	
Houng Pham	-
Beatrice Sonntag	1991 - 93
Yi Chen	1994 - 99
Daniel Ross	1992 - 93
Feng Zhou	1999 - 2000
Chelsea Swandal	2000 - 04
Amy Alt	2000 - 01


Naran Bao	2001 - 02
Yenong Zhou	2001 - 19
Peter Vitello	2002 - 04
James Logie	2003 - 04
Jessica Tooredman	2002 - 04
Chris Van Wart	2002 - 03
Damon Hobson	2003 - 05
Lucine Petit	2004 - 06
Melanie Fortier	2004 - 06
Michelle Riley	2003 - 06
Song Xu	2006 - 07
PeiChun Lin	2006 - 08
MaryGrace Gorospe	2006 - 08
MingTau Lee	2006 -
Marlana Yee	2008 - 09
Dan Nguyen	2008 - 09
Kathryn Kinzel	2008 - 11
Dannie Wang	2009 - 11
Christina Koppel	2009 - 13
Graduate Students	
Cliff Eskey	1992
Hui Zhu	1992 - 96
Yuval Gazit	1993 - 96
Sue Hobbs	1993 - 98
Cecilia Capello	1994
G. Ray Martin	1994
Christian Brekken	1994 - 95, 1997
Melody Swartz	1994 - 98
Brian Stoll	1998 - 2003
Trevor McKee	2000 - 05
David Cochran	2001 - 05
Ricky Tong	2001 - 05
Wilson Mok	2002 - 07

Josh Tam	2002 - 08
Ryan Lanning	2003 - 09
Irene Chen	2008
Vikash Chauhan	2006 - 12
Benjamin Diop-Frimpong	2007 - 10
Ming - Zer Poh	2007 - 09
Janet Tse	2007 - 11
Abhishek Jain	2008 - 12
Yuhui Huang	2008-13
Shom Goel	2009 - 12
Jieqion (Jane) Liu	2009 - 12
Chun Li	2009
John Martin	2009-15
Kamila Naxerova	2009 -13
Teresa Peterson	2009 -15
Joao Incio	2010 -16
Elisabeth Niemeyer	2010 – 11
Koen Marijt	
Rakesh Ramjiawan	2012-18
Nisha Gupta	2012-17
Li Chong	2012 -15
Meenal Datta	2013 -18
Research Assistants	
Eric Kaufman	1988 - 92
Patrick Yoon	1993
Peter Khalifah	1993 - 93
Luke Wang	1995
Valerie Verdier	1995 - 96
Visiting Scholars	
James Baish	1994, 2013, 2017
Catharina Davies	1997 - 98
John Tarbell	1997 - 98
Donald Buerk	1998 - 99
Robert Feil	2012 - 13

RESOURCES AND ENVIRONMENT

The Steele Laboratories are located at two different sites. A facility for defined flora and immunodeficient rodents and about 1500 ft² of laboratory space, including two microscopy suites and multipurpose bench area and offices, are located at the Massachusetts General Hospital (MGH). Additional laboratory space (approximately 5,000 ft²) which includes a microscopy suite, tissue culture facility, surgical area, clinical research studies, multipurpose bench space and offices, is located at the MGH-East facility in Charlestown. Investigators divide their time between these sites via a shuttle system.

Facility	Use
Intravital fluorescence microscopy laboratory #1	In vivo quantitative fluorescence microscopy measurement of hemodynamics and transport in tissues
Intravital fluorescence microscopy laboratory #2	In vivo quantitative fluorescence microscopy, including fluorescence photobleaching
Intravital fluorescence microscopy laboratory #3	In vivo quantitative fluorescence microscopy, on-line digitization of images and digital image analysis, and optical measurement of pH, pO ₂ , etc.
Intravital fluorescence microscopy laboratory #4	In vivo quantitative fluorescence microscopy for single vessel perfusion
Intravital fluorescence microscopy laboratory #5	In vivo two-photon laser scanning microscopy/ Animal colony
Intravital fluorescence microscopy laboratory #6	Video rate multiphoton microscopy
Intravital fluorescence microscopy laboratory #7	Multiphoton microscopy with oxygen sensing and permeability measurement capabilities
Optical frequency domain microscope suite	Imaging of tissue and blood vessels with high depth penetration base on doppler optical frequency domain technology; high frequency ultrasound imaging.
Histology facility	Serial sections, immunohistology, etc.
Pathophysiology laboratory	In vivo and ex vivo perfusion of isolated tumors and measurement of blood flow, blood pressure, interstitial fluid pressure, pO ₂ , etc.
Cellular biophysics laboratory	Measurement of cell deformability and dynamic adhesion; Time-lapse live cell imaging
Molecular biology laboratory	Molecular techniques
Cell culture facility	Mammalian cell culture
Tumor metabolism	Measurement of blood flow, pO ₂ , pH
Computing facilities	Various computer workstations, desktop and portable computers; 32 node cluster for parallel computation
Cox Animal facility	Gnotobiotic mice (33 strains)
Clinical research laboratory	Measurement in cancer patients of blood and urine markers, interstitial fluid pressure, pO ₂ , immunohistology, molecular and cellular studies etc



Edwin L. Steele Laboratories for Tumor Biology
Massachusetts General Hospital
Department of Radiation Oncology
100 Blossom Street, Cox-734
Boston, MA 02114

<http://steele.mgh.harvard.edu>